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Summary 
The global incidence of Type 2 Diabetes Mellitus (T2DM) is increasing rapidly. Many 
people with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) will 
however not progress to T2DM but appear to spontaneous revert to normal glucose 
homeostasis, others however will progress slowly and in some cases rapidly progress 
towards diabetes. Therapeutic interventions will reduce the risk, or at least the pace, of 
deterioration from IFG and IGT to T2DM. However, in order to target interventions 
appropriately, to prevent progression in those at greatest risk further information as to 
which individuals are most likely to progress is needed. There is a variable rate of 
progression from either IFG, IGT or combined IFG and IGT to T2DM and in general, 
progression rates are lowest in the general population and highest in target “at-risk” 
group. Age, body mass index (BMI), fasting and 2 hour plasma glucose concentrations, 
elevated fasting pro-insulin, low 2-hour insulin and fasting triglyceride levels are known 
to be associated with a greater risk of progression and in order to maintain 
normoglycemia, adequate quantitative and qualitative moment-by-moment pancreatic 
beta-cell secretion and action is essential. A marker of deteriorating carbohydrate 
homeostasis would be increased fluctuations in blood glucose levels and continuous 
glucose monitoring (CGM) is an ideal method to look at just this. The use of CGM to 
quantify the fluctuations was proposed to assess whether CGM can help identify people 
with abnormal glucose tolerance that progress to T2DM. In this study, CGM profiles 
inspected by eye for variability appeared to correlate well with mathematically devised 
CGM parameters based on CGM data, both at baseline and at Year 1. However, neither 
the subject CGM profiles nor the CGM parameters at baseline were significant in 
predicting progression to diabetes (T2DM) at Year 1 or Year 3 from a pre diabetic state 
at baseline. However, when one looked at progression from pre diabetes to diabetes, 
with regard to CGM profiles and CGM parameters, the interval period between study 
baseline and Year 1 appeared to be when most variation in glucose levels occurred; this 
was especially the case for those subjects with IFG, compared to subjects with IGT or 
IFG+IGT mix, respectively. This effect was diluted at Year 3 and not observed. In 
conclusion, this study demonstrated that CGM did not predict progression from pre 
diabetes to diabetes (T2DM), but did however, correlate well by eye with mathematical 
assessments models of the same CGM data and identify an at risk IFG group that could 
be targeted at baseline with more intensive therapy. 
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1.0 Introduction 
The term diabetes mellitus (DM) describes a metabolic disorder with heterogeneous 
aetiologies which is characterized by chronic hyperglycaemia and disturbances of 
carbohydrate, fat and protein metabolism. It consists of an array of Type 2 Diabetes 
Mellitus: Practice Essentials, Background, Pathophysiology [Internet]. [cited 2016 Apr 
7]) (1). Bearing in mind this study was initiated in 2009, the outcome indicator in this 
study was Type 2 diabetes mellitus (T2DM), which was diagnosed using the criteria set 
by the World Health Organisation (WHO) (2006) (2). In this document, the WHO 
published its guidelines on definition and diagnosis of diabetes mellitus and 
intermediate hyperglycaemia. In this guideline document, T2DM is diagnosed when a 
person is found to have symptoms of diabetes (polyuria, polydipsia and unexplained 
weight loss for Type 1 Diabetes (T1DM)) plus a fasting plasma glucose concentration 
of ≥7.0 mmol/l or a random venous plasma glucose concentration ≥11.1 mmol/l, as 
described by Alberti et al (1998) (3) or two hour plasma glucose concentration> 11.1 
mmol/l two hours after 75g anhydrous glucose in an oral glucose tolerance test (OGTT). 
These values are based on evidence which suggests the risk of complications increases 
significantly amongst people with plasma glucose levels consistently above these levels, 
as described by Gabir et al (2000) (4). Fasting and post-prandial (or random) plasma 
glucose levels broadly follow a normal distribution in the general population, as 
described by Lim et al (2000) (5) and the pre-diabetes categories of impaired fasting 
glycaemia (IFG)/ impaired glucose tolerance (IGT) stated below are an attempt to 
recognise this. 
 
IFG:   fasting glucose >6.1 mmol/l 
IGT:  fasting glucose <7 mmol/l; 2 hour post-challenge 7.8-11.1 mmol/l 
 
IFG and IGT are not clinical entities in their own right, but rather risk categories for 
cardiovascular disease and/or future diabetes. IFG has been introduced to classify 
individuals who have fasting glucose values above the normal range but below those 
diagnostic of diabetes while IGT is a stage of impaired glucose regulation. IFG and IGT 
define individuals who may develop progressive deterioration in glucose homeostasis, 
leading to frank T2DM, as described by Alberti et al (1996) (6). Many people with IFG 
or IGT will not progress to T2DM but appear to spontaneous revert to normal, as 
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described by Riccardi et al (1985) (7). Others may progress only very slowly, whereas 
in some cases the progression may be rapid, as described by Ferrannini et al (2004) (8). 
 
1.1 Pathophysiology 
T2DM is characterized by the combination of peripheral insulin resistance and 
inadequate insulin secretion by pancreatic beta cells. Insulin resistance, which has been 
attributed to elevated levels of free fatty acids and pro-inflammatory cytokines in 
plasma leads to decreased glucose transport into muscle cells, elevated hepatic glucose 
production and increased fat breakdown. In T2DM, the reciprocal relationship between 
the glucagon- secreting alpha cell and the insulin- secreting beta cell is lost, resulting in 
hyperglucagonemia and consequentially hyperglycaemia, as described by Unger and 
Orchi (2010) (9). Beta cell dysfunction is a major factor across the spectrum of pre-
diabetes to diabetes, with beta cell dysfunction happening early in the pathological 
process and not necessarily following the stage of insulin resistance. In the progression 
from normal glucose tolerance to abnormal glucose tolerance, postprandial blood 
glucose levels increase first; eventually, fasting hyperglycemia develops as suppression 
of hepatic gluconeogenesis fails. During the induction of insulin resistance, such as is 
seen after high-calorie diet, increased glucagon levels and increased glucose-dependent 
insulinotropic polypeptide (GIP) levels accompany glucose intolerance; however, 
postprandial glucagon like peptide-1 (GLP-1) response is unaltered, as described by 
Hansen et al (2011) (10). Genome wide association studies of single- nucleotide 
polymorphisms (SNPs) have also identified a number of genetic variants that are 
associated with beta-cell function and insulin resistance. Some of these SNPs have been 
shown to increase the risk for T2DM, as described by Billings and Florez (2010) (11). 
As patients with T2DM retain the ability to secrete some endogenous insulin, they are 
not absolutely dependent upon insulin for life, however many patients with T2DM will 
ultimately require insulin (Figure 1). 
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Figure 1: Pathophysiology of T2DM 
-The pathophysiology of T2DM is illustrated in the above diagram. It is characterised by a combination of peripheral 
insulin resistance and inadequate insulin secretion by pancreatic beta cells. 
 
1.2 Aetiology 
T2DM develops when a diabetogenic lifestyle (i.e. excessive caloric intake, inadequate 
caloric expenditure, obesity) is superimposed upon a susceptible genotype, as described 
in Type 2 Diabetes Mellitus: Practice Essentials, Background, Pathophysiology 
[Internet]. [cited 2016 Apr 7] (1). When testing for T2DM and pre-diabetes in 
asymptomatic individuals, T2DM screening should be performed in adults of any age 
who are overweight or obese, and who have one or more diabetic risk factors. The 
major risk factors for T2DM are the following, as described in the American Diabetes 
Association (ADA) Guidelines (2016) (12): 
 
 Age greater than 45 years. 
 Physical inactivity. 
 Family history of T2DM in a first-degree relative (eg, parent or sibling). 
  High risk race or ethnicity: African-American, Latino, Native American, Asian-
American, Pacific Islander descent. 
 History of previous IGT or IFG. 
 Hypertension (>140/90 mm Hg) or on treatment. 
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 Dyslipidemia (high-density lipoprotein [HDL-C] cholesterol level < 35 mg/dL 
and / or a triglyceride level > 250 mg/dL). 
 History of gestational diabetes mellitus (GDM) or of delivering a baby with a 
birth weight of >9 lb. 
 Conditions associated with insulin resistance i.e polycystic ovarian syndrome 
(PCOS), a weight greater than 120% of desirable body weight (severe obesity) 
or acanthosis nigricans. 
 A HbA1c ≥5.7%. 
 A history of cardiovascular disease. 
In addition, the body mass index (BMI) at which excess weight increases risk for 
diabetes varies with different racial groups, as described by Barnes (2015) (13). 
Hypertension and pre-hypertension are also associated with greater risk of developing 
diabetes in whites compared with African-Americans, as described by Wei et al (2011) 
(14). 
 
1.3 Epidemiology 
The global incidence of T2DM is increasing rapidly. At least 250 million people 
currently have diabetes and this figure is likely to more than double to 366 million by 
2030 unless appropriate action is taken, as described in Type 2 Diabetes Mellitus: 
Practice Essentials, Background, Pathophysiology [Internet]. [cited 2016 Apr 7] (1). 
The top 10 countries, in numbers of people with diabetes, are currently India, China, the 
United States, Indonesia, Japan, Pakistan, Russia, Brazil, Italy and Bangladesh. It is 
anticipated that the greatest percentage increase in rates of diabetes will occur in Africa 
over the next 20 years, as people adopt Western lifestyles, gain weight. In 2011, the 
Centers for Disease Control and Prevention (CDC) estimated that nearly 26 million 
Americans of all ages have diabetes (90-95% being Type 2), a quarter of which are 
unaware of this fact, as described in the Statistics Report (2014) (15). It is also 
estimated that 79 million Americans have pre-diabetes, affecting 35% of adults aged 20 
years and older. In 2014, the CDC reported that about 40% of USA adults will develop 
diabetes, primarily T2DM in their lifetime and more than 50% of ethnic minorities will 
be affected. These figures are higher than previous estimates and are due to the increase 
in obesity, as described by Gregg et al (2014) and Lipscombe (2014) (16) (17). 
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The prevalence of T2DM varies widely among various racial and ethnic groups. It is 
more prevalent among Hispanics, Native Americans, African-Americans and Asians/ 
Pacific Islanders than in non Hispanic whites, as described in Type 2 Diabetes Mellitus: 
Practice Essentials, Background, Pathophysiology [Internet]. [cited 2016 Apr 7] (1). 
With regard to age, T2DM occurs most commonly in adults aged 40 years or older, the 
prevalence of the disease increasing with advancing age, as described in Type 2 
Diabetes Mellitus: Practice Essentials, Background, Pathophysiology [Internet]. [cited 
2016 Apr 7] (1). However, more recently T2DM has also been observed to be 
increasing in younger persons, particularly in highly susceptible racial and ethnic 
groups and the obese, as described in Type 2 Diabetes Mellitus: Practice Essentials, 
Background, Pathophysiology [Internet]. [cited 2016 Apr 7] (1). 
1.4 Morbidity and Mortality 
Diabetes mellitus (DM) is one of the leading causes of world morbidity and mortality 
because of its role in the development of cardiovascular, renal, neuropathic, and retinal 
disease. In patients with T2DM, the United Kingdom Prospective Diabetes Study 
(UKPDS) demonstrated an association with a raised microvascular risk, as described by 
UKPDS (1998) (18), with other studies reporting an increased macrovascular risk, as 
described by Gabir et al (2000) and Lim et al (2000) (4) (5). This has an effect on 
morbidity and premature mortality of patients with DM, with the prognosis being 
strongly influenced by the degree of disease control and risk factor management. To 
date, some studies have demonstrated an early multifactorial intensive management 
approach is key to managing patients with T2DM, in order to reduce the incidence of 
microvascular, as described by UKPDS (1998) (18) and macrovascular events, as 
described by Group: The Action to Control Cardiovascular Risk in Diabetes Study 
(2008) (19). 
 
Both IFG and IGT are considered to be a pre-diabetic state, associated with insulin 
resistance, increased risk of cardiovascular pathology and increased mortality (although 
IGT is of lesser risk than IGT). Over 10 years, there is a 50% risk of IFG patients 
progressing to overt diabetes. However, some newly identified IFG patients progress to 
T2DM in less than three years and IGT may precede T2DM by many years, as 
discussed by Barr et al (2007) (20). Results from studies by De Fronzo et al (2010) 
(21), using frequently sampled intravenous glucose tolerance test (FSIVGTT), strongly 
suggested that progressive β cell failure is the main determinant of progression of NGT 
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to IGT; Suzuki et al (2003) (22) also supported this view. Accordingly, targeted 
pathophysiologic therapy based on oral OGTT-derived measures of insulin sensitivity 
and β-cell function can be implemented in medical practice, which is associated with 
marked improvement in glucose tolerance and reversion of pre-diabetes to normal 
glucose tolerance in more than 50% of patients Armato et al (2012) (23). In 2007, 
Gillies et al (2007) (24) performed a systemic review and meta-analysis, of randomised 
controlled trials that evaluated interventions to delay or prevent T2DM in individuals 
with IGT. The conclusion from this analysis was that lifestyle and pharmacological 
interventions reduce the rate of progression to T2DM in people with IGT. Da Qing IGT 
and Diabetes Study also investigated subjects with IGT who were randomised to a 
control group or one of three active treatment groups: diet only, exercise only or diet 
plus exercise. After a 6 year follow up period, results demonstrated that all interventions 
were associated with a reduction in risk of developing diabetes by 31%, 46% and 42%, 
respectively (Li et al 2008) (25). The Finnish Diabetes Prevention Study (DPS) also 
showed that it was possible to achieve primary prevention of T2DM by changing 
lifestyle (diet and exercise) in subjects with IGT (Tuomilehto et al 2001) (26). When 
The Diabetes Prevention Program (DPP) Research Group randomized over 3000 
individuals with IFG and IGT, to placebo, metformin or a lifestyle intervention 
program, after 2.8 years, the incidence of T2DM was 11.0, 7.8 and 4.8 cases per 100 
person-years, respectively (Knowler et al 2002) (27); the DPP reduced the development 
of T2DM by 31% and has been recommended by the ADA for treating high risk 
individual with IGT. The WHO recommendation on physical exercise for adults in this 
context is at least 150 minutes per week of moderate- intensity aerobic physical activity, 
or 75 minutes per week of vigorous- intensity aerobic physical activity, or an equivalent 
combination of moderate and vigorous- intensity activity (WHO 2010) (28). These 
studies demonstrate the potential to prevent T2DM in high risk individuals, reducing the 
conversion rate of IGT to T2DM, through lifestyle intervention, focusing on 
achievement and maintenance of weight reduction by having a healthy diet and 
increasing physical activity. In order to achieve this, it is important to tailor lifestyle 
interventions within distinct populations and with each health care encounter, patients 
should be educated and encouraged to follow an appropriate management plan. IFG, 
IGT and diabetes can now be found in almost every population in the world and 
therapeutic interventions have been shown to reduce the risk, or at least the pace, of 
deterioration from IFG and IGT to T2DM, as described by the Statistics Report (2014) 
(15), Gregg et al (2014) (16) and Lipscombe (2014) (17). 
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Epidemiological evidence suggests that without effective prevention and the control 
programmes discussed above, the burden of diabetes is likely to continue to increase 
globally, as described by Griffin et al (2011) (31) and Alberti et al (2007) (32). The 
consequence of this is an escalating financial healthcare burden with allocation of 
healthcare resources becoming increasingly difficult, as described by Ferrannini et al 
(2004) (8), which will be a challenge in the current economic climate. Therefore early 
identification of individuals at increased risk of developing T2DM is crucial. If 
individuals at increased risk of developing T2DM can be identified early on, healthcare 
interventions or lifestyle changes can be targeted appropriately, as discussed above. In 
order to target interventions to prevent progression in those at greatest risk, further 
information as to which individuals are most likely to progress is needed. There is a 
variable rate of progression from IFG and IGT to T2DM and in general, progression 
rates are lowest in the general population and highest in target “at-risk” groups, as 
described by Group: The Action to Control Cardiovascular Risk in Diabetes Study 
(2008) (19), Barr et al (2007) (20), De Fronzo et al (2010) (21) and Suzuki et al (2003) 
(22). Age, BMI, fasting and 2 hour plasma glucose concentrations, elevated fasting pro-
insulin, low 2-hour insulin and fasting triglyceride levels are associated with a greater 
risk of progression, as described by Alberti et al (1996) and Group: The Action to 
Control Cardiovascular Risk in Diabetes Study (2008) (6) (19). Adequate moment-by-
moment insulin secretion and action being essential for glycaemic control. 
 
1.5 Diagnostic Testing for Diabetes Mellitus 
As discussed in section 1.0, T2DM is diagnosed in clinical practice, as per the WHO 
definition (2006) (bearing in mind the start date of the study) when a person is found to 
have a fasting plasma glucose ≥7.0 mmol/l or a random glucose ≥11.1 mmol/l, as 
described by Albeti et al (1998) (3). Pre-diabetes or intermediate diabetes is diagnosed 
when IFG (fasting glucose >6.1 mmol/l) or IGT (fasting glucose <7 mmol/l; 2 hour 
post-challenge 7.8-11.1 mmol/l) occurs. As a basic screening test, OGTT is cheap and 
fairly straightforward to perform, however it is performed during a single two hour 
period, it is a non-physiological stimulus and individuals show day to day variability in 
glucose tolerance. 
In 2011, The World Health Organisation (WHO) published a report (37), which was an 
addendum to the diagnostic criteria published in by WHO (2006) (2) and Alberti et al 
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(1998) (3) and addressed the use of glycated haemoglobin (HbA1c) in diagnosing 
diabetes mellitus. The WHO Consultation accepted that HbA1c can be used as a 
diagnostic test for diabetes. A HbA1c = ≥48 mmol/mol is recommended as the cut off 
point for diagnosing T2DM, but a value of less than that does not exclude diabetes 
diagnosed using glucose tests. A HbA1c = 42-47 mmol/mol can also indicate people 
with pre-diabetes, with a HbA1c = < 42 mmol/mol being classed as normal. The use of 
HbA1c can be used as a diagnostic test for diabetes on condition that stringent quality 
assurance tests are in place and assays are standardised to criteria aligned to the 
international reference values, with no conditions present which preclude its accurate 
measurement. In patients without symptoms of diabetes the laboratory venous HbA1c 
should be repeated. If the second sample is <48mmol/mol the person should be treated 
as at high risk of diabetes and the test should be repeated in 6 months or sooner if 
symptoms develop. The benefits of using HbA1c for the diagnosis of DM are that it is a 
simple test that can be performed at any time of the day, reflects average plasma glucose 
over the previous eight to 12 weeks, as described by Nathan et al (2007) (38), has less 
biological variability and does not require any special preparation such as fasting. These 
advantages have implications for early identification and treatment which have been 
strongly advocated in recent years. These properties have made it the preferred test for 
assessing glycaemic control in people with diabetes. However, there are many situations 
where HbA1c is not appropriate for diagnosis of diabetes. For example, HbA1c is not 
suitable in all children and young people, in patients of any age suspected of having 
Type 1 diabetes mellitus (T1DM) and in patients with symptoms of diabetes for less 
than 2 months. It is also not suitable in patients at high diabetes risk who are acutely ill 
(e.g. those requiring hospital admission), patients taking medication that may cause 
rapid glucose rise e.g. steroids, antipsychotics or patients with acute pancreatic damage, 
including pancreatic surgery. Pregnancy or the presence of genetic, haematologic and 
illness-related factors that influence HbA1c and its measurement (for example. 
erythropoesis, altered haemoglobin glycation and erythrocyte destruction) also make 
HbA1c an inappropriate diagnostic tool for DM diagnosis. In addition, there are aspects 
of the measurement of HbA1c that are problematic and the utility and convenience of 
HbA1c compared with measures of plasma glucose for the diagnosis of diabetes needs 
to be balanced against the fact that (i) in some countries it is unavailable and not well 
enough standardized, despite being a recognized valuable tool in diabetes management; 
(ii) it does not measure day-to-day variability in glucose per se, as it reflects average 
plasma glucose over the previous eight to 12 weeks (Nathan et al 2007) (38) and (iii) 
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many people identified as having diabetes based on HbA1c will not have diabetes by 
direct glucose measurement. 
In 2016, the ADA published a set of diagnostic criteria for diabetes (12). There are four 
criteria options for diabetes diagnosis: 
(1) FPG ≥7.0 mmol/l* 
(2) 2 hr PG ≥11.1 mmol/l during OGTT* 
(3) HbA1c ≥ 48 mmol/mol* 
(4) Random PG ≥11.1 mmol/l (in individuals with symptoms of hyperglycaemia or 
hyperglycaemia crisis) 
*In the absence of unequivocal hyperglycaemia, results to be confirmed by repeat 
testing. 
 
The ADA suggested that if there is no clear clinical diagnosis, to repeat the same test 
immediately using a new blood sample. The same test with same or similar results, 
confirms the diagnosis and diagnosis is confirmed with different tests above diagnostic 
threshold. Discordant results from two separate tests require a repeat test with a result 
above diagnostic cut point. The ADA also suggested that screening for pre-diabetes can 
be done using HbA1c, FGG or 2 hr PG after OGTT criteria. When testing for T2DM 
and pre-diabetes in asymptomatic individuals, if the test is normal it should be repeated 
every 3 years. 
 
This study was initiated in 2009 and used the WHO 2006 criteria for diabetes diagnosis 
(2). If this study was being initiated in current times, then perhaps the more modern 
approach [according to WHO (2011) criteria] of using HbA1c as a diagnostic test for 
diabetes would be used (37). The use of HbA1c as a diagnostic test for diabetes is also a 
favoured option of the ADA (2016) (12). However, using HbA1c alone in initial 
diabetes screening identifies approximately 20% fewer cases of diabetes than diagnosis 
based on fasting and 2 hr postload glucose levels, as described by Wang et al (2011) 
(39). 
 
1.6 Glucose Biomarkers - History 
An attempt was made to identify any biomarkers that predict progression from 
abnormal glucose tolerance to T2DM. Glycaemic control and beta cell function were 
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further assessed in addition to the repeat OGTT. Glucose (fasting indicator of glucose 
homeostasis), HbA1c (intermediate term glycaemic control) and biomarkers of beta cell 
function, C-peptide and Insulin were assayed (Varvel et al 2014) (40). A glutamic acid 
decarboxylase autoantibody test (GAD antibody test) was also conducted to look for 
T1DM or latent autoimmune diabetes of adults (LADA) in any of study subjects. 
 
The antigens recognised by these antibodies include insulin, glutamic acid 
decarboxylase (GAD65 kDa isoform) and an islet cell antigen IA-2 or ICA-512. C-
peptide is a peptide composed of 31 amino acids and is produced from the pancreatic 
beta cells during enzymatic cleavage of proinsulin. Proinsulin is the precursor of C-
peptide and insulin, which are produced in equal amounts during enzymatic cleavage. 
C-peptide has negligible extraction by the liver and constant peripheral clearance. It is 
mainly excreted by the kidney, and its half-life is 3-4 times longer (20-30 v 3-5 
minutes) than that of insulin. It therefore circulates at concentrations approximately five 
times higher than insulin in the systemic circulation and can therefore be used to assess 
endogenous insulin secretion Jones et al (2013)((41). Insulin is an anabolic hormone 
that promotes glucose uptake, glycogenesis, lipogenesis, and protein synthesis of 
skeletal muscle and fat tissue through the tyrosine kinase receptor pathway. Insulin is 
the most important factor in the regulation of plasma glucose homeostasis, as it 
counteracts glucagon and other catabolic hormones—epinephrine, glucocorticoid, and 
growth hormone (42). Insulin resistance is a condition in which the body produces 
insulin but does not use it effectively. When people have insulin resistance, glucose 
builds up in the blood instead of being absorbed by the cells, leading to T2DM or pre-
diabetes. Insulin testing can be used to assist in diagnosing early T2DM, where there is 
a relatively increased production of insulin with a concurrent increase in blood glucose 
levels (43). 
 
1.7 Continuous Glucose Monitoring Systems (CGMS) 
To potentially diagnose and target interventions to prevent progression to DM in those 
at greatest risk, further information as to which individuals are most likely to progress is 
needed. Adequate moment-by-moment insulin secretion and action is essential for 
glycaemic control and a marker of deteriorating carbohydrate homeostasis would be 
increased fluctuations in blood glucose levels. Health care professionals are increasingly 
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searching for tools to evaluate their patients’ glucose control in a quick and easy way to 
optimize their diabetes management. CMGS in the form of an iPro™ allows just this 
and provides an integrated measure of glucose monitoring. This is a small, discreet 
device that measures 24 hour continuous glucose levels via a glucose sensor applied 
transcutaneously (Figure 2). CGM is mostly used by diabetologists as a monitoring tool, 
used to look at interstitial glucose profiles and identify trends; it is also particularly 
useful in adults and children to solve specific clinical questions. Clinically it has many 
uses and currently, it can be used for the detection of hypoglycaemia, as described by 
Schopman (2013) (44), with post-hypoglycaemic hyperglycaemia as a cause of sub-
optimal glycaemic control. It can also be used to help elucidation the cause of nocturnal 
seizures in patients with insulin treated diabetes as well as in the determination of 
glycaemic excursions above and below ideal in individuals with satisfactory HbA1c 
levels, as described by Buckingham (2008) (45). CGM is used as a tool to examine the 
benefits (or otherwise) of a change from multiple daily insulin injections to insulin 
pump therapy and treatment adjustment – e.g. moving from oral anti-diabetic drugs to 
insulin or basal-bolus adjustments; it is also used to look for hyperglycaemic peaks 
during pregnancy. CGM has also been used as a research tool (46). It has been 
demonstrated that CGM can be associated with reducing A1C without increasing the 
risk of hypoglycemia vs finger stick testing alone, as described by Chiasson et al (2002) 
(29), Torgerson et al (2004) (30) and Griffin et al 2011 (31). 
 
Figure 2: CGM iPro™ unit 
-The CGM iPro™ was a small, discreet device that measured 24 hour continuous glucose levels via a glucose sensor 
applied transcutaneously. 
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As OGTT and HbA1c are not ideal in capturing moment-by-moment glycaemic 
variability, we propose the use of continuous glucose sensing to quantify this. CGMS 
(Medtronic) are accurate, as described by Guerci et al (2003) (50) and measure 
interstitial glucose levels every 10 seconds, the results of which are stored as a 
smoothed average over 5 minutes. This can occur continuously for up to 3 days with a 
single sensor, as described by Sachedina et al (2003) (51). Monitors are externally 
calibrated by the subject who performs self monitoring of blood glucose (SMBG) four-
point testing in each 24 hour period. A typical CGM tracing with four-point testing can 
be seen in Figure 3 which illustrates how much more information on the glucose profile 
can be obtained (hyperglycemia, hypoglycemia and variability patterns) and how 
excessive glucose variability can be even in patients that appear to be well controlled 
from SMBG four-point and HbA1c testing, respectively (46) (52). CGMS documents 
continuous glucose variations throughout the day, rather than during a short OGTT or 
discontinuous home blood glucose testing, thereby offering a definite advantage. 
 
 
Figure 3: Typical CGM Tracing with four-point SMBG testing 
-Monitors were externally calibrated by the subject who performed SMBG four-point testing in each 24 hour period. 
A typical CGM tracing with four-point testing is seen above and illustrates the added information on the glucose 
profile that can be obtained. Glucose variability can also be observed, even in patients that appear to be well 
controlled from SMBG testing. 
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CGM is one of the latest advancements in diabetes management. A traditional glucose 
meter uses the information from a finger stick test for a blood glucose value that 
represents only a snapshot in time. CGM monitors continuously, to let you see what’s 
happening between finger stick tests. That way, one can watch glucose levels and 
patterns that you may not have been able to see before. 
 
1.8 Aims and Objectives: Study Hypothesis 
Aim: To assess whether CGMS can help identify people with abnormal glucose 
tolerance who progress to Type 2 diabetes mellitus (T2DM). 
 
Objectives: The following research objectives were compiled in order to facilitate the 
study aim. 
 
(1) To obtain ethical approval for the study, via the NHS Local Research Ethics 
Committee (NHS LREC) mechanism, South East Wales Research Ethics 
Committee (SEWREC) and from the School, Cardiff University. 
(2) To obtain statistical advice from the Professor of Statistics, Professor Robert 
Newcombe, Cardiff University School of Medicine, regarding study sample 
size. 
(3) To collate a study sample of fifty individuals from the general population, 
composed of subjects who have had an abnormal OGTT and consented to study 
participation. 
(4) To obtain demographic data and a thorough medical history, medication history, 
family history and social history on all study subjects at baseline, Year 1 and 
Year 3. 
(5) To obtain GAD antibody status, C-peptide and Insulin levels on all study 
subjects at baseline. 
(6) To perform OGTT, check HbA1c and perform CGM on all study subjects at 
baseline, Year 1 and Year 3. 
(7) To construct glycaemic excursion variables to reflect glucose fluctuations 
observed in CGM and apply them in Excel 2007 to the raw CGM sensor data. 
(8) To analyse baseline, Year 1 and Year 3 data. 
(9) To separate by inspection, CGM profiles for each study subject into 3 groups 
based on variability (least variability, medium variability and most variability). 
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(10) To use the Paired Sample t-Test to compare differences in two means of 
the set parameters as the study progressed with time. 
(11) To use independent sample t Test to compare the means of two 
independent groups (diabetes and non diabetes) at Year 1 and Year 3, in order to 
determine any significant difference between them, when tested against a 
number of baseline parameters. 
(12) To use one way analysis of variance (ANOVA) at baseline, to evaluate 
any significant difference between the CGM profiles by inspection and the 
statistically constructed CGM parameters. 
(13) To use binary logistic regression analysis to estimate the relationships 
among variables. Baseline parameters were tested for Year 1 and Year 3 
outcome, using binary logistic regression analysis, to see if any of them affected 
the outcome or influenced each other. 
 
Null Hypothesis: CGM can be used to predict progression from abnormal glucose 
tolerance (pre-diabetes) to T2DM. 
 
1.9 Study Timeframe 
This study began in 2009 and continued until 2012. The parameters chosen for analysis 
and the outcome indicators together with the technologies used were a reflection of this 
time. If this study had been conducted in more recent times, then some of the 
parameters chosen for analysis and outcome indicators selected would be in line with 
current guidelines. The technologies employed would also be more modern and at the 
cutting edge of diabetes care, in this regard. 
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2.0 Materials and Methods 
2.1 Ethics 
Cardiff University School of Medicine requires that all research involving human 
participants, human material or human data is subject to formal ethical review and 
approval before such work can be started. This study had been granted approval via the 
NHS LREC mechanism SEWREC and from the School, Cardiff University. With 
regard to data storage and security, hard copies of any study data were kept securely at a 
NHS research location, lock coded and could only be accessed by agreed members of 
the research team. Any computer files that contained personal or identifier data were 
password protected and only accessed by agreed members of the team (53). 
 
2.2 Statistical Advice 
Statistical advice regarding sample size was obtained from the Professor of Statistics, 
Robert Newcombe, Cardiff University School of Medicine. A proposed sample size of 
50 subjects (n = 50) with confirmed IFG/IGT on OGT testing was considered 
justifiable. This was based on the assumption that 30% of subjects will have a diagnosis 
of definite diabetes by 2 years and that half the remaining subjects, i.e. 35% will have 
reverted to normal. Comparing those who become diabetic with those who revert to 
normal would have a power of 80% to detect a shift of exactly 1 standard deviation in 
the mean value for any parameter tested, using a test at the conventional two-sided 
alpha level, as described by McCrum- Gardner (2010) (54) and Cohen (1977) (55). 
 
The effect size (ES) in a population is intrinsically linked to three other statistical 
properties, as described by Cohen (1977) (55) and Cohen (1992) (56): 
(i) The sample size on which the sample effect size is based. 
(ii) The probability level at which we will accept an effect as being statistically 
significant (the α level); typically an α level of 0.5 is used. 
(iii) The ability of a test to detect an effect of that size (known as the statistical power). 
The power of a test is the probability that a given test will find an effect assuming that 
one exists in the population. 
 
The probability of failing to detect an effect when one genuinely exists is β, the 
probability of a Type II error. It follows that the probability of detecting an effect if one 
exists must be the opposite of not detecting that effect i.e. (1-β). Cohen (1977) (55) 
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suggested that we would hope to have a 0.2 probability of failing to detect a genuine 
effect, and so the corresponding level of power he recommended was 1-0.2 = 0.8. 
Therefore, a power of 0.8 or an 80% chance of detecting an effect if one genuinely 
exists should be aimed for and is the minimum accepted level. 
 
2.3 Recruitment Population 
The recruitment of subjects for the study took place over a 20 month period between 
October 2009 and June 2011. In total, 486 patients referred for out-patient Oral Glucose 
Tolerance Testing (OGTT), from either their General Practitioner or a Secondary Care 
Physician, respectively, were screened. Patients either attended The University Hospital 
of Wales, Cardiff or Llandough Hospital, Penarth for testing. All patients referred for 
OGTT were felt to have ‘a priori’ - a reason to undergo testing and thus were deemed as 
intermediate risk with regard to progression to DM. 
 
2.4 OGTT 
Patients who were referred for OGTT attended out-patients phlebotomy suite at The 
University Hospital of Wales, Cardiff or Llandough Hospital, Penarth between 08.45 
and 09.30am for testing. The OGTT test was conducted by the by UHW phlebotomy 
staff. Three days prior to the test, the patients were asked to have a normal diet 
containing more than 150g carbohydrate daily and were instructed to fast from 10pm 
the previous evening. This gave a minimum 10 hour fasting period, where the patients 
refrained from eating or drinking anything other than water, until the test was 
completed. For an OGTT, the WHO recommends 75g of anhydrous glucose (or its 
equivalent) in a final volume of 300 ml is used (57). In our OGTT protocol, 113 mL 
Polycal was poured into a designated beaker and water was added to the 200 mL mark 
and the contents of the beaker were mixed. This was consumed within 5 minutes and 
then the patients drank a further 100 mL of water to make the final volume 300 mL. The 
patients were warned of the possible side effects of nausea, vomiting, diarrhoea, as the 
glucose drink was hyperosmolar. The patients were allowed to drink additional water 
during the test if needed and were asked to sit quietly throughout the test, smoking not 
being permitted. The test was not performed during intercurrent illness. Venous blood 
was sent for laboratory glucose analysis before taking the glucose load (zero minutes) 
and 120 minutes after consumption of the glucose load. 
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2.5 Screening Population 
As stated in Section 2.2, 486 patients in total were screened over a 20 month period. All 
subjects between the ages of 18-80 years were considered. Subjects unable or unwilling 
to give informed consent or unable or unwilling to comply with research requirements 
were excluded. In addition, pregnant females, an intercurrent illness with prognosis of < 
2 years and subjects with a known previous allergic reaction to adhesive plasters were 
also excluded. Gender, ethnic origin, nationality, religion, belief or sexual orientation 
was irrelevant in the decision to recruit (see APPENDIX 1: CGM Study Protocol). 
 
When the patients attended for their clinically indicated OGTT, if they met the study 
inclusion criteria as stated above (see APPENDIX 1: Study Protocol), they were invited 
to participate in the study. Eligible candidates were given a patient information sheet 
(see APPENDIX 1: Patient Information Sheet) and were able to make an informed 
decision at this point as to whether they wished to participate in the study or not. Those 
patients who agreed to participate in the study then completed and signed a study 
consent form and subject contact details were obtained (see APPENDIX 1: Patient 
Consent Form). Informed consent was obtained from the Principle Investigator (PI). All 
patients were free to leave the hospital after the OGTT and the result of the test was 
automatically sent to the referring Physician. 
 
Subjects who had consented and wanted to participate in the study were contacted and 
invited to participate in the study if (i) they met the study inclusion criteria, (ii) had 
given informed consent and (iii) had a positive OGTT - found to have IFG or IGT, as 
per the diagnostic criteria below (58). If subjects did not meet the study inclusion 
criteria - were normal glucose tolerant (NGT) or had T2DM, they were excluded and 
not invited to participate in the study. A study information letter was sent to the GPs of 
participating subjects (see APPENDIX 1: GP Letter). 
 
Diagnostic Criteria (58) 
Normal Glucose Tolerance (NGT) 
Both of the following criteria must be met: 
- Fasting glucose ≤6.0 mmol/l 
- 2 hour GTT glucose <7.8 mmol/l 
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Diabetes Mellitus 
Either of the following is diagnostic: 
-Fasting glucose > 7.0 mmol/l 
-Random glucose > 11.1 mmol/l 
-2 hour GTT glucose > 11.1 mmol/l 
 
Impaired Fasting Glucose (IFG) 
Both the following criteria must be met: 
-Fasting glucose >6.1 -6.9 mmol/l 
-2 hour GTT glucose <7.8 mmol/l 
 
Impaired Glucose Tolerance (IGT) 
Both of the following criteria must be met: 
-Fasting glucose <7.0 mmol/l 
-2 hour GTT glucose > 7.8 mmol/l but < 11.1 mmol/l 
 
2.6 Study Schedule 
2.6.1 Baseline Schedule 
OGTT positive subjects attended at baseline (t = 0 months) where informed signed 
consent was re-obtained by the PI (see APPENDIX 1). Demographic data was obtained, 
including: height, weight, body mass index (BMI), together with past medical history, 
drug history, smoking status and any family history of diabetes. A blood test was also 
obtained for HbA1c analysis. Subjects were then instructed as described in Section 2.7 
in self monitoring of blood glucose (SMBG) and the CGM was fitted, as described in 
Section 2.8 following education of its use. A single CGM sensor was worn by each 
subject for a period of up to three whole days (maximum of six whole days via two 
sensors in total) and subjects were asked to perform meter tests of their blood glucose 
levels (SMBG) at least four specified times of the day (four point testing) day while 
undergoing CGM. 
 
2.6.2 Year 1 Follow Up 
At t = 1 year, subjects returned following an overnight fast, for repeat testing. Those 
that did not respond were presumed to have withdrawn consent. Informed signed 
consent was re-obtained by the PI, using the original consent form (see APPENDIX 1) 
and demographic data was obtained, including: height, weight, body mass index (BMI), 
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together with past medical history, drug history, smoking status and any family history 
of diabetes. Subjects then underwent an OGTT, as described in Section 2.4 and blood 
samples were also obtained for HbA1c analysis, anti –GAD antibody, C-peptide and 
insulin. Subjects were then instructed as described in Section 2.7 in SMBG and the 
CGM was fitted, as described in Section 2.8 following education of its use. A single 
CGM sensor was worn by each subject for a period of up to three whole days and 
subjects were asked to perform meter tests of their blood glucose levels (SMBG) at least 
four specified times of the day (four-point testing) day while undergoing CGM. The 
OGTT and HbA1c results obtained at this stage were forwarded to the GPs to ensure 
continuity of care of the subjects and implementation of treatment where necessary (see 
APPENDIX 1). 
 
2.6.3 Year 3 Follow Up 
At t = 3 years, subjects returned following an overnight fast, for repeat testing. Those 
that did not respond were presumed to have withdrawn consent. Informed signed 
consent was re-obtained by the PI, using the original consent form and demographic 
data was obtained, including: height, weight, BMI, together with past medical history, 
drug history, smoking status and any family history of diabetes. Patients were given a 
standardised questionnaire regarding implemented change post initial positive OGTT 
testing. Subjects then underwent a fasting blood test and samples were obtained for 
analysis of FPG and HbA1c. The FPG and HbA1c results obtained at this stage were 
forwarded to the GPs to ensure continuity of care of the subjects and implementation of 
treatment where necessary (see APPENDIX 1). 
 
At Year 3, FPG was performed and used as outcome indicator, instead of OGTT. 
Although ethical approval was obtained for a OGTT at Year 3, when the study subjects 
contacted and invited back, they were not keen to have OGTT; however, they were 
happy to attend for a FPG. Therefore, in order to gain a Year 3 outcome FPG was used. 
 
2.7 Self Monitoring of Blood Glucose (SMBG) 
Blood glucose monitoring is a way of testing the concentration of glucose in the blood. 
All subjects enrolled in the study were taught SMBG using the OneTouch® Ultra ® 
blood glucose meter and were educated with regard to finger prick testing and the use of 
test strips. The blood glucose test was performed by piercing the skin of the finger, 
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lateral to the nail base, as illustrated in Figure 4, with a single use safety lancet 
(Unistick® 3 Comfort) (59). 
 
 
Figure 4: Single use safety lancet: Unistick® 3 Comfort (59) 
-The blood glucose test was performed by piercing the skin of the finger, lateral to the nail base with a single use 
safety lancet (Unistick® 3 Comfort). 
 
The small drop of blood obtained was then applied to a disposable ‘One Touch® Ultra® 
single coded test strip’ as illustrated in Figure 5 (60), which was pre- inserted into the 
OneTouch® Ultra ® blood glucose meter, an electronic device for quantitatively 
measuring glucose in whole blood. 
 
 
Figure 5: One Touch® Ultra® test strips 
-The small drop of blood obtained from finger prick testing for SMBG was then applied to a disposable ‘One Touch® 
Ultra® single coded test strip’. 
 
Prior to being used, the One Touch®Ultra® blood glucose meter was plasma calibrated, 
thus allowing easy comparison with laboratory methods. After 5 seconds the level of 
blood glucose was shown on the meters digital display. In this study, the blood glucose 
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meters were One Touch®Ultra® blood glucose meters, which had an inbuilt data 
download system which connected to the PC via an external cable. 
 
2.8 Continuous Glucose Monitoring System (CGMS) 
CGMS is a continuous glucose monitoring system which measures the glucose levels in 
interstitial fluid. CGMS measures the glucose level of interstitial fluid every 10 seconds 
and the results are stored as a smoothed average over 5 minutes, as described by Boyne 
et al (2003) (61). A typical CGM system usually consists of three components: a 
disposable sensor that measures glucose levels, a transmitter that is attached to the 
sensor and a receiver that displays and stores glucose information (Figure 6). The 
information in the receiver is then converted into estimated mean values of glucose 
standardized to capillary blood glucose levels measured during calibration. 
 
Figure 6: Schematic diagram illustrating the theory behind CGM (62)(63) 
-The CGM system comprised of three components: a disposable sensor that measured interstitial glucose levels, a 
transmitter that was attached to the sensor and sat on the surface of the skin and a receiver that displayed and stored 
glucose information. The information in the receiver was then converted into estimated mean values of glucose 
standardized to capillary blood glucose levels measured during calibration. 
 
It’s known that glucose travels first from the blood vessels and capillaries into the 
interstitial fluid. As CGMS sensor glucose (SG) readings measures interstitial glucose 
while SMBG meter measures glucose levels in the blood, the BG meter readings from 
SMBG and SG readings from CGMS rarely match exactly i.e. there is a lag in real time 
glucose levels by 5 to 10 minutes. This is normal and should be expected. However, 
when glucose levels are rising or falling quickly, there is a larger difference between the 
BG meter values and the SG readings i.e. typically post-prandially. When the BG value 
is rising, its value is greater than the SG that follows behind it, but when the BG falls 
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the BG in front is now less than the SG value. Clinically, knowing the direction and 
speed of glucose changes is useful and can be more useful than individual BG or sensor 
readings, which are momentary snapshots of glucose measurement. When using CGM 
trends are the key (63). The CGMS used in this study was a Medtronic CGM device; a 
typical Medtronic CGM kit is illustrated in Figure 7. 
 
Figure 7: Typical Medtronic CGM kit (64) 
-A typical Medtronic CGM kit used for each study subject consisted of a re-usable Medtronic sensor inserter, a single 
use glucose Sof-sensor®, a re-usable Medtronic iPro™ charger, a re-usable Medtronic iPro™ CGM transmitter and a 
single use IV3000 Smith and Nephew transparent adhesive dressing. 
 
2.8.1 CGM Sensor and Sensor Insertion 
Currently, available CGM devices are considered minimally invasive enzyme-coated 
electrodes. These devices measure interstitial glucose concentrations and convert these 
values to blood glucose levels. The sensor catheter has electrodes impregnated with 
glucose oxidase (the same enzyme used to measure glucose levels as a test strip), which 
is introduced into the subcutaneous tissue. The reaction between interstitial fluid 
glucose and glucose oxidase located on the electrode produces hydrogen peroxide. This 
reaction converts the interstitial glucose into an electrical current proportional to the 
glucose concentration at the site of the catheter insertion, which travels to the 
transmitter attached. Devices using enzyme-coated catheters require frequent 
calibrations to correct variations in the reaction between the electrode and the 
subcutaneous tissue, as well as fluctuations in glucose and oxygen diffusion at the site 
of the electrode (65), as described by Burge et al (2008) (66). The CGM used the 
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Medtronic Sof-sensor® in this study (Figure 8). The Sof-sensor® was stored in the 
fridge at 4 0C (+2 °C to +27°C). Prior to using it the sensor package was removed from 
the fridge to warm up to room temperature for about 15 minutes before opening the 
sensor package to prevent condensation. 
 
Figure 8: The glucose Sof-sensor® (63) 
-The glucose Sof-sensor® had a gold catheter electrode impregnated with glucose oxidase, which was introduced into 
the subcutaneous tissue. The reaction between interstitial fluid glucose and glucose oxidase located on the electrode 
produced a reaction which converted the interstitial glucose into an electrical current proportional to the glucose 
concentration at the site of the catheter insertion, which travelled to the transmitter attached. 
In order for the sensors to be inserted, the subjects were in a standing position. In each 
subject, the sensor was placed 2 inches from the umbilicus, after the area was cleaned 
with a steri-wipe (NICE-PAK International Ltd) and areas of the natural body bend 
were avoided. In order for the sensor to be inserted, the sensor was removed from the 
packaging and placed into an insertion device. With a push of a button the glucose 
sensor was inserted with a needle, via the insertion device. It was inserted anywhere 
between a 45 and 60 degree angle, just under the skin of the abdomen (67). The needle 
and insertion device were removed after the glucose sensor was in place. The sensors 
had a lifespan of 3 days and the subjects had to have the sensor replaced once during the 
six days they wore the sensor in total. With a push of a button the glucose sensor was 
inserted with a needle, via the insertion device. It was inserted anywhere between a 45 
and 60 degree angle, just under the skin of the abdomen (67). The needle and insertion 
device were removed after the glucose sensor was in place 
2.8.2 CGM Transmitter 
The Medtronic CGM transmitter [A] is a small lightweight device that attaches to the 
glucose sensor [B] and gathers glucose data (Figure 9). In this study, the CGM non 
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implanted Medtronic iPro™ transmitter was used. Prior to each sensor use, the 
transmitter was cleaned and charged and the transmitter was recharged after each sensor 
use i.e. every three days. 
 
 
Figure 9: Medtronic CGM transmitter attaches to glucose Sof-sensor® 
-The Medtronic CGM non implanted iPro™ transmitter [A] was a small lightweight device that attached to the 
glucose sensor [B] and gathered glucose data. 
 
In each subject, when the sensor had been inserted, the transmitter was then attached. 
This CGM unit was then taped to the abdomen with IV3000 Smith and Nephew 
transparent adhesive dressing as illustrated in Figure 2. The Medtronic transmitter used 
in this study was waterproof and could be worn while swimming or showering to a 
depth of three metres and the subjects were advised of this when they attended. The 
CGM monitors were externally calibrated by the subject who was advised to perform 
pre-meal finger prick home glucose testing at least four times in each 24 hour period, as 
described above. The BG meter readings used for calibration were essential in ensuring 
the glucose sensor maintained its accuracy over time. The best time to calibrate the 
Medtronic Sof-sensor® (63) is when glucose levels are least likely to be changing 
rapidly and this is why all subjects were requested to check BM pre-prandially. 
The iPro™ transmitter gathered glucose data and stored it until the subject was 
instructed to return. After 3 days, the data was ready to be downloaded and Solutions 
2.2A® Software for CGMS® iPro™ was used in conjunction with the Continuous 
Glucose Recorder to extract glucose data from the CGMS® iPro™ wirelessly or via the 
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ComLink™ connected to a PC. The Solutions® Software was pre installed on the PC 
and for each subject, glucose data was downloaded from the CGMS iPro™ Recorder 
and stored as a uniquely coded patient data file on the PC. The software applied a 
retrospective regression calibration algorithm to the CGMS iPro™ download data. The 
relative accuracy of the SG values produced by the regression algorithm was evaluated 
with the reference meter BG values used for the calibration. Each Meter BG used for 
calibration was paired with the corresponding sensor values generated by the calibration 
algorithm at the same point in time. The paired sensor and meter values were 
statistically evaluated for Coefficient of Correlation and Mean Absolute Difference 
(68). 
 
2.8.3 CGM Result Profiles: An Example 
Prior to the study, the CGMS was trialled on a normoglycaemic test subject ‘SAP’. Five 
types of report were generated: Sensor Summary, Sensor Daily Details, Sensor Modal 
Day, Sensor Modal Time Periods and Sensor Data. Examples of these reports are 
demonstrated below, as generated for test subject ‘SAP’. 
41 
 
 
Figure 10: Example: Sensor Summary report (i) for test subject 'SAP' 
-The Sensor Summary report displayed a tabular summary of statistical data from the CGMS iPro™ Recorder as well 
as the Meter Glucose data, with each column containing one 24 hour period of data. 
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Figure 11: Example Sensor Summary report (ii) for test subject 'SAP' 
The Sensor Summary report displayed a tabular summary of statistical data from the CGMS iPro™ Recorder as well 
as the Meter Glucose data, with each column containing one 24 hour period of data. 
 
The Sensor Summary report displayed a tabular summary of statistical data from the 
CGMS iPro™ Recorder as well as the Meter Glucose data, with each column containing 
one 24 hour period of data. An example of this, generated for test subject ‘SAP’ is 
demonstrated in Figure 10 and Figure 11. The Sensor Daily Details is another type of 
report generated and this provided up to fourteen days of individual data plots. Graphs 
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were defined with glucose concentrations on the vertical axis and time on the horizontal 
axis. The plots showed the sensor data, meter values and user events during each 24 
hour period, with the target range set by the investigator; this was indicated by the blue 
dashed line (lower limit) and the red dashed line (upper limit). Individual glucose sensor 
values were used to draw a profile line on each sensor detail graph. A gap in the profile 
indicated an interruption in glucose monitoring. Each day was plotted with a different 
colour: 
 
Sunday – Black; Monday – Blue; Tuesday – Red; Wednesday – Green; Thursday – 
Magenta; Friday – Cyan; Saturday - Olive Green 
 
Figure 12: Example: Sensor Daily Details for test subject 'SAP' 
-The Sensor Daily Details provided up to fourteen days of individual data plots. Graphs were defined with glucose 
concentrations on the vertical axis and time on the horizontal axis. The plots showed the sensor data, paired meter 
values (blue diamond), unpaired meter values (red diamond) and user events during each 24 hour period, with target 
ranges indicated by the blue dashed line (lower limit) and the red dashed line (upper limit). Individual glucose sensor 
values were used to draw a profile line on each sensor detail graph. A gap in the profile indicated an interruption in 
glucose monitoring. Each day was plotted with a different colour. 
 
An example of this, generated for test subject ‘SAP’ is demonstrated in Figure 12. Each 
graph also plotted Meter BG values, which were displayed as a blue diamond for paired 
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meter values and red crosses for unpaired meter values. The maximum glucose value 
reportable from the CGMS was 22.2 mmol/l and the minimum was 2.2 mmol/l and any 
glucose values outside this range were displayed as a flat line. The Sensor Modal Day 
report was another type of report generated by the CGMS and an example of this, 
generated for test subject ‘SAP’ is demonstrated in Figure 13. The Sensor Modal Day 
presented all of the glucose data over a 24 hour period, with each day represented as 
separate plot line in a different colour. Labelling of axes, reportable glucose values and 
day plot colours were the same as those in Sensor Daily details. 
 
Figure 13: Example: Sensor Modal Day for test subject 'SAP' 
-This demonstrated all of the glucose data over a 24 hour period, with each day being represented by a plot line of a 
different colour (7 days in total). 
 
A further report generated was the Sensor Data report, which is a computerised logbook 
that presented all of the data entered in the patient file and downloaded from the meter 
and CGMS iPro™ recorder memory for a patient download. The Sensor Data report 
obtained from test subject ‘SAP’ can be seen in the example below (Figure 14). 
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Figure 14: Example: Sensor Data report for test subject 'SAP' 
-The above section of sensor data was taken from the computerised logbook for the test subject. Two readings of 
interest can be seen, (i) the meter values, i.e. the SMBG readings taken by the subject and (ii) the sensor values in 
mmol/L, calculated from the sensor glucose electronic signal and the calibration constants. *ISIG = CGMS monitor 
signal value in nano amp units; **VCTR = CGMS monitor signal value in Voltage units; ***Valid ISIG = Validated 
sensor signals reported in nano amp units. 
 
In Figure 14, two readings of interest can be seen, (i) the meter values, i.e. the SMBG 
readings taken by the subject and (ii) the sensor values in mmol/L, calculated from the 
sensor glucose electronic signal and the calibration constants. The sensor values for 
each study subject formed the raw data, on which the statistical analysis of the study 
was based. 
 
2.9 Glucose Biomarkers 
An attempt was made to identify any biomarkers that predict progression from 
abnormal glucose tolerance to T2DM. Therefore, for each study subject that attended 
one year follow up, glycaemic control and beta cell function were further assessed in 
addition to the repeat OGTT. Glucose (fasting indicator of glucose homeostasis), 
HbA1c (intermediate term glycaemic control) and biomarkers of beta cell function, C-
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peptide and Insulin were assayed (Varvel et al 2014) (40); GAD Antibody was also 
tested. At one year follow up, an additional 10ml of peripheral venous blood was 
obtained for each study subject at 0 minutes (fasting) for this analysis. Ideally, the 
analysis of GAD Antibody, C-peptide and Insulin would have been conducted at 
baseline, however the original ethically agreed study protocol did not have this analysis 
incorporated. An amendment to the original study protocol was submitted and agreed by 
the Ethics committee in order for this analysis to occur at Year 1. For this particular 
procedure, peripheral venous blood was taken into BD Vacutainers® and the sample 
was inverted five times. It was left to stand for 20 minutes at room temperature and then 
spun on a swing bucket centrifuge for 10 minutes at 1000 G. The serum was extracted 
using a pipette and stored in a labelled eppendorf tube at -800c. At the end of the 1 year 
follow up testing for all subjects, the stored frozen samples were batched and sent to the 
Diabetes Research Unit, Swansea University on dry ice for analysis of GAD Antibody, 
C-peptide and Insulin. 
 
2.9.1 GAD Antibody 
A glutamic acid decarboxylase autoantibody test (GAD antibody test) was also 
conducted to look for type 1 diabetes mellitus or latent autoimmune diabetes of adults 
(LADA) in any of study subjects. The antigens recognised by these antibodies include 
insulin, glutamic acid decarboxylase (GAD65 kDa isoform) and an islet cell antigen IA-
2 or ICA-512. In this study, Glutamic Acid Decarboxylase (GAD) was assayed by Dr 
Gareth Dunseath at the Diabetes Research Unit, Swansea University, using a kit 
(GDE/96) obtained from RSR Ltd. The assay sensitivity was 0.06 U/ml, with an assay 
range of 0 - 2000 U/ml and a reference range of <5 U/ml = negative; ≥5 U/ml = positive 
(69). 
 
2.9.2 C-peptide 
C-peptide is a peptide composed of 31 amino acids and is produced from the pancreatic 
beta cells during enzymatic cleavage of proinsulin. Proinsulin is the precursor of C-
peptide and insulin, which are produced in equal amounts during enzymatic cleavage. 
C-peptide has negligible extraction by the liver and constant peripheral clearance. It is 
mainly excreted by the kidney, and its half-life is 3-4 times longer (20-30 v 3-5 
minutes) than that of insulin. It therefore circulates at concentrations approximately five 
times higher than insulin in the systemic circulation and can therefore be used to assess 
endogenous insulin secretion (70). 
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The C-Peptide Assay kit (IV2-004/104) was obtained from Invitron and assayed by Dr 
Gareth Dunseath at the Diabetes Research Unit, Swansea University. The assay had a 
sensitivity of 5 pmol/ml and a 100% specificity for human C-peptide; the assay range 
was 0-5.00 pmol/ml, with a reference range of 0.17-0.96 pmol/ml (71). 
 
2.9.3 Insulin 
Insulin is an anabolic hormone that promotes glucose uptake, glycogenesis, lipogenesis, 
and protein synthesis of skeletal muscle and fat tissue through the tyrosine kinase 
receptor pathway. Insulin is the most important factor in the regulation of plasma 
glucose homeostasis, as it counteracts glucagon and other catabolic hormones—
epinephrine, glucocorticoid, and growth hormone, as described by FJ (1995) (70). 
Insulin resistance is a condition in which the body produces insulin but does not use it 
effectively. When people have insulin resistance, glucose builds up in the blood instead 
of being absorbed by the cells, leading to T2DM or pre-diabetes. Insulin testing can be 
used to assist in diagnosing early T2DM, where there is a relatively increased 
production of insulin with a concurrent increase in blood glucose levels (43). 
 
The insulin assay kit was obtained from Invitron (IV2-001/101) Invitron Ltd and 
assayed by Dr Gareth Dunseath at the Diabetes Research Unit, Swansea University. The 
assay had a sensitivity of 0.25 mU/L and a 100% specificity for human insulin, with an 
assay range of 0 - 1200 pmol/L (0 - 200 mU/L) and a reference range of fasting plasma 
of 6 - 100 pmol/L (1 - 16 mU/L) (72). 
 
2.10 Statistical Analysis 
In order to perform the statistical analysis, the CGM subject data was exported from 
Solutions 2.2A® Software for CGMS® iPro™ into Microsoft Office Excel 2007. Initial 
data review and construction of specific data selectors and tables occurred here. The 
cleaned data was then imported into a statistical package, IBM SPSS Statistics 20, for 
the final data analysis to occur. 
 
As the aim of this study was to attempt to predict progression from abnormal OGTT to 
T2DM, the progression of each subject following a repeat OGTT/ FPG, HbA1c +/-
CGM was compared to analogous baseline data. This occurred for study subjects at one 
and three year follow up respectively. With regard to glucose variability, the CGM 
subject outcome data (which was analysed in SPSS) was derived from the CGM sensor 
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data (as described in 2.8.3, Figure 14 ) at baseline and one year follow up, respectively. 
The raw CGM sensor data for each subject at both baseline and one year follow up was 
exported into Microsoft Office Excel 2007. As an attempt was being made to identify 
any biomarkers that predict progression from abnormal glucose tolerance, a marker of 
deteriorating carbohydrate homeostasis would be increased fluctuations in blood 
glucose levels. In this study, continuous glucose sensing was used to quantify the 
glucose fluctuations, to assess whether CGMS could help identify people with abnormal 
glucose tolerance who progress to T2DM. Glycaemic excursion variables were 
constructed and applied in Excel 2007 to the raw CGM sensor data which had been 
imported; this was done with the assistance of Professor Richard Ollerton (Sydney 
Australia). This generated outcome data for each study subject at baseline and year one 
follow up. This outcome data for each study subject at baseline and year one follow up 
was then imported into SPSS Statistics 20 for further analysis. The glycaemic excursion 
parameters devised were as follows: 
 
(i): Average Glucose (Av Gl): The average glucose over a day for each subject. 
(ii): Average Glucose Excursion from Average (Av Gl excursion from Av): This 
calculated how far the data varied from the average over the day. 
(iii): Average above Normal Glucose (Av above Norm Gl): This calculated how far the 
average daily values above a representative "normal" glucose value. 
(iv): Average Glucose Excursion from Normal Glucose (Av Gl excursion from norm 
Gl): This calculated a similar variability as Av Gl excursion from Av but used the 
"normal" glucose value rather than the daily average as the baseline. 
 
For each study subject, the glucose variability subject outcome data from CGM based 
on the chosen parameter of glycaemic excursion noted above (i-iv) underwent statistical 
analysis in SPSS Statistics 20, with regard to correlation with both OGTT and HbA1c 
results, for both baseline and follow up data. This was in order to compare glycaemic 
variability and monitor any change with time. It was also to identify any markers that 
predicted progression from abnormal glucose tolerance to T2DM based on glycaemic 
variability results detected by CGM. This process was conducted based on raw sensor 
data that reflected a complete 24 hours. 
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2.11 SPSS Results Information 
While working in SPSS Statistics 20, for the purpose of this study, a number of 
individual variables were grouped and labelled within their individual variable group. 
 
2.11.1 Age 
The age of the study subjects was noted as part of the demographic data collected at 
baseline. Subjects were labelled in SPSS Statistics 20 for the analysis as follows (73): 
 
1 Young Adulthood 15 years - 24 years 
2 Middle Adulthood 25 years - 44 years 
3 Older Adulthood 45 years - 64 years 
4 Adult Retirement Age  > 65 years 
 
2.11.2 BMI 
The BMI of the study subjects (weight [kg]/height [m2]) was noted as part of the 
demographic data collected at baseline, Year 1 and Year 3 follow - up. Subjects were 
labelled in SPSS Statistics 20 for the analysis, as follows (74): 
 
1 Underweight (BMI < 18.5 kg/m2) 
2 Normal weight (BMI 18.5 to 25 kg/m2) 
3 Overweight (BMI 25 to 30 kg/m2) 
4 Obese (BMI > 30 kg/m2) 
 
2.11.3 Smoking Status 
The smoking status of the study subjects was noted as part of the social history 
collected. Subjects were labelled in SPSS Statistics 20 for the analysis, as follows: 
 
0 non smoker (non smoker + ex- smoker) 
1 smoker 
 
2.11.4 CGM Profiles 
The CGM profiles of the study subjects at baseline and Year 1 follow up were visually 
inspected and divided into three categories according to normal glucose variability. The 
categories were labelled least variability (APPENDIX 2), medium variability 
(APPENDIX 3) and most variability (APPENDIX 4). This was repeated for the Year 1 
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subjects CGM profiles. Subjects were labelled in SPSS Statistics 20 for the analysis as 
follows: 
 
0 least variability 
1 medium variability 
2 most variability 
 
The CGM profiles of the study subjects at baseline and Year 1 follow up were inspected 
blindly by the PI [CGM profiles labelled (SAP)] and by an independent observer, a 
Lead Diabetic Specialist Nurse [CGM Profiles labelled (PUMP)]. 
 
2.11.5 Study Subject Identification 
At the start of the study, each of the subjects that constituted the study sample were 
given a unique identification code i.e. ‘IPRO’ plus a number 01 to 045, which they kept 
throughout the study. At baseline the suffix ‘a’ was added to the unique identifier; at 
Year 1, the suffix ‘b’ was added to the unique identifier and at Year 3, the suffix ‘c’ was 
added to the unique identifier. This was in order to collect and hold the data 
confidentially. 
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3.0 Results: Screening Data 
3.1 Analysis of Screening Data 
The recruitment period for the study occurred between 26th October 2009 and 20th June 
2011. In total, 486 subjects were screened over this 20 month period. All subjects made 
an informed decision as to whether they wished to participate in the study or not, when 
they attended for their oral glucose tolerance test (OGTT). Those subjects who agreed to 
participate were then contacted if they met the study inclusion criteria and on the basis 
of their OGTT result i.e. were found to have either impaired fasting glucose (IFG) or 
impaired glucose tolerance (IGT). They were invited to attend for continuous glucose 
monitoring (CGM). If subjects did not meet the study inclusion criteria i.e. were normal 
glucose tolerant (NGT) or had Type 2 diabetes (DM) they were excluded at this point 
and were not invited to attend for CGM. This process resulted in a total of 486 subjects 
being screened. 
 
Out of the 486 subjects screened 72.4 % (n = 352) agreed to participate in the study and 
were not discounted based on initial exclusion criteria. 27.6 % (n = 134) either declined 
outright to participate or were excluded based on initial exclusion criteria. 
 
3.1.1 Gender 
Out of the 486 subjects screened, 42.2% (n = 205) were female and 57.8% (n = 281) 
were male. 
 
3.1.2 Age (years) 
Out of the 486 subjects eligible for screening, 2 did not give their date of birth and so 
were classed as missing data. The mean age was 58.39 years and the median age was 
59.50 years. The minimum age was 19 years and the maximum age was 90 years, a 
range in age of 71.5 years (Table 1) (Figure 15). 
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Table 1: Total Subjects Screened: Age 
 
 
 
 
 
 
 
 
 
 
Figure 15: Total Subjects Screened: Age 
-484 subjects were screened in the study. The mean age of the subjects screened was 58.39 years and the median age 
of the subjects screened was 59.50 years, with a range of 71.5 years. 
 
3.1.3 Consent 
As already discussed, out of 486 subjects initially screened for the study, 352 subjects 
agreed to participate and 134 subjects did not give consent to participate in the study or 
were discounted based on study exclusion criteria, respectively. If one looked at the 134 
subjects who did not give consent to participate in the study or discounted at the outset 
based on study exclusion criteria, n = 58 (11.9 %) did not actually attend for the initial 
screening appointment (DNA); n = 29 (6%) did not give consent to participate in the 
N 
Valid 484 
Missing 2 
Mean 58.39 
Median 59.50 
Std. Deviation 14.41 
Range 71.50 
Minimum 19.00 
Maximum 90.50 
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study at the outset; n = 22 (4.5%) were aged over 80 years (and therefore were excluded 
based on study criteria), n = 7 (1.4%) samples / results were lost in processing; n= 5 
(1%) were excluded on medical grounds (as discussed in Section 2.5); n = 4 (0.8%) 
cancelled OGTT appointment; n = 4 (0.8%) declined at the outset due to language 
difficulties; n = 2 (0.4%) had labelling/request form errors; n = 1 (0.2%) was excluded 
due to pregnancy; n = 1 (0.2%) had eaten when they should have been fasted and n = 1 
(0.2%) did not return for the OGTT 120 minute blood test (Table 2). 
 
Table 2: Screened Subjects Outcome 
Screened Subject Outcome Frequency % Cumulative 
Percent 
 
CONSENTED (NGT/DM) 208 42.8 42.8 
ABSCONDED MID TEST 1 .2 43.0 
CANCELLED 4 .8 43.8 
CHANGED MIND 99 20.4 64.2 
DECLINED AT OUTSET 29 6.0 70.2 
DECLINED AT OUTSET-
LANGUAGE 
4 .8 71.0 
DNA 58 11.9 82.9 
EATEN 1 .2 83.1 
ENTERED (IFG / IGT) 45 9.3 92.4 
EXCLUDED AS 
PREGNANT 
1 .2 92.6 
EXCLUDED MEDICAL 
GROUNDS 
5 1.0 93.6 
EXCLUDED OVER 80 22 4.5 98.1 
LOST SAMPLES 7 1.4 99.6 
NO FORM 1 .2 99.8 
WRONG LABEL 1 .2 100.0 
Total 486 100.0  
 
3.1.3.1 Consent and Gender 
If consent to participate in the study is looked at with regard to gender, out of initial 352 
subjects who agreed to participate, 206 (58.52%) were male and 146 (41.48%) were 
female. If one looked at the initial 134 subjects who did not give agree to participate in 
the study at the outset or were discounted based on study exclusion criteria, 75 
(55.97%) were male and 59 (44.03%) were female (Figure 16). 
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Figure 16: Total Subjects Screened: Consent according to Gender 
-Consented subjects consisted of 206 (58.52%) males and 146 (41.48%) females. This compared to 134 non 
consenting subjects, consisting of 75 (55.97%) males and 59 (44.03%) females. 
 
3.1.3.2 Consent and Age 
If consent to participate in the study is looked at with regard to age, out of initial 352 
subjects who agreed to participate, there were no missing values. The mean age was 
58.99 years and the median age was 60.47 years. The minimum age was 20.52 years 
and the maximum age was 79.93 years, with a range of 59.41 years (Figure 17). 
 
If one looked at the initial subjects who did not agree to participate in the study at the 
outset or were discounted based on study exclusion criteria, (Non Consented Group), 
the mean age was 56.77 years and the median age was 55.80 years. The minimum age 
was 18.98 years and the maximum age was 90.47 years, with a range of 71.50 years 
(Figure 18). 
 
Therefore, as the mean age of the consented population was 58.99 years and the mean 
age of the non-consented population was 56.77 years, the consented population was 
similar to the non-consented population with regard to age. As 58.52% males gave 
consent as opposed to 55.97% males who did not give consent and 41.48% females 
gave consent as opposed to 44.03% who did not give consent, the consented population 
was also similar to the non-consented population with regard to gender. 
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Figure 17: Consented Subjects Age Statistics 
-The mean age of consented subjects was 58.99 and the median age was 60.47 years, respectively. The minimum age 
was 20.52 and the maximum age was 79.93 years, respectively, with a range of 59.41 years. Std Dev was 12.13. 
 
 
 
Figure 18: Non Consented Subjects Age Statistics 
-The mean age of non consented subjects was 56.77 and the median age was 55.80 years, respectively. The minimum 
age was 18.98 and the maximum age was 90.47 years, respectively, with a range of 71.50 years. Std Dev was 19.12. 
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3.2 Analysis of OGTT Data 
There were 352 subjects who agreed to participate in the study and fitted the study 
inclusion criteria. All underwent OGTT, which demonstrated n = 208 (42.8%) subjects 
had either NGT (n = 65) or DM (n = 143) and n = 144 (29.7%) subjects had either 
IFG/IGT or both. This group of 144 subjects were the key group of subjects suitable to 
be invited for CGM studies. The 144 subjects in this group were all contacted to attend 
for CGM studies, however, n = 99 (20.4%) subjects changed their mind about 
participating in the study despite initially agreeing and being eligible and therefore were 
lost at this point. This left a total of n = 45 (9.3%) subjects, with either IFG/IGT or both 
to be entered into the study (Table 3; Figure 19; Figure 20). 
 
Table 3: OGTT Results of Consented Subjects (n = 352) 
 OGTT Total 
DM IFG IGT NGT 
DECISION 
CHANGED MIND 
Count 0 49 50 0 99 
% within DECISION 0.0% 49.5% 50.5% 0.0% 100.0% 
% within OGTT 0.0% 71.0% 66.7% 0.0% 28.1% 
ENTERED 
Count 0 20 25 0 45 
% within DECISION 0.0% 44.4% 55.6% 0.0% 100.0% 
% within OGTT 0.0% 29.0% 33.3% 0.0% 12.8% 
UNSUITABLE 
Count 143 0 0 65 208 
% within DECISION 68.8% 0.0% 0.0% 31.2% 100.0% 
% within OGTT 100.0% 0.0% 0.0% 100.0% 59.1% 
Total 
Count 143 69 75 65 352 
% within DECISION 40.6% 19.6% 21.3% 18.5% 100.0% 
% within OGTT 100.0% 100.0% 100.0% 100.0% 100.0% 
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Figure 19: OGTT Results of Consented Subjects (n = 352) 
-OGTT demonstrated n = 208 subjects had either NGT (n = 65) or DM (n = 143) and n = 144 subjects had either 
IFG/IGT or both. 
 
 
 
Figure 20: OGTT Results of Consented Subjects 
-OGTT testing on consented subjects revealed n = 65 subjects had NGT and n = 143 subjects had DM and were 
unsuitable. Of the suitable subjects, n = 99 changed their mind, leaving n = 45 subjects, with either IFG/IGT or both 
entered into the study. 
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3.2.1 Gender 
If one looks at consented subjects by gender, out of the 352 subjects with OGTT results, 
41.48% (n = 146) were female and 58.52% (n = 206) were male (Table 4; Figure 21). 
 
Table 4: OGTT Results of Consented Subjects by Gender 
 Gender Total 
Female Male 
OGTT 
NGT 27 38 65 
IFG 29 40 69 
IGT 34 41 75 
DM 56 87 143 
Total 146 206 352 
 
*Looking specifically at the 146 females, 38.36% had DM, 19.86% had IFG, 23.29% had IGT and 18.49% had NGT; 
43.15% having IFG/IGT or both. Looking specifically at the 206 males, 42.23% had DM, 19.42% had IFG, 19.90%, 
had IGT and 18.45% had NGT; 39.32% having IFG/IGT or both. 
 
 
Figure 21: OGTT Results of Consented Subjects by Gender. 
-Regarding females, 38.36% (n=56) had DM, 19.86% (n = 29) had IFG, 23.29% (n = 34) had IGT and 18.49% (n = 
27) had NGT; 43.15% (n = 63) having IFG/IGT or both at OGTT. Regarding males, 42.23% (n = 87) had DM, 
19.42% (n = 40) had IFG, 19.90%, (n = 41) had IGT and 18.45% (n = 38) had NGT; 39.32% (n = 81) having 
IFG/IGT or both at OGTT. 
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3.2.2 Age 
If one looks at consented subjects by age, the mean age of the NGT was 57.42 years, 
with a range of 58.93 years (minimum 20.52 years; maximum 79.45 years). The mean 
age of the IFG was 58.55 years, with a range of 49.79 years (minimum 28.85 years; 
maximum 78.64 years). The mean age of the IGT was 59.86 years, with a range of 
56.20 years (minimum 21.74 years; maximum 77.94 years). The mean age of the DM 
was 59.46 years, with a range of 57.57 years (minimum 22.36 years; maximum 79.93 
years); (Table 5). 
 
Table 5: OGTT Results of Consented Subjects by Age Statistics 
OGTT Mean N Std. Deviation Minimum Maximum Range Median % of Total Sum 
NGT 57.42 65 12.99 20.52 79.45 58.93 59.79 18.0% 
IFG 58.55 69 11.28 28.85 78.64 49.79 59.95 19.5% 
IGT 59.86 75 11.81 21.74 77.94 56.20 60.42 21.6% 
DM 59.46 143 12.34 22.36 79.93 57.57 60.54 40.9% 
Total 58.9938 352 12.13 20.52 79.93 59.41 60.47 100.0% 
 
3.3 Consort Diagram of Screening Data 
The recruitment outcome for each subject approached to take part in the study can be 
found summarised in the consort diagram below (Figure 22). 
 
3.4 Summary: Chapter 3 
In summary, the analysis of screening data and recruitment of study subjects occurred 
over a 20 month period, between 26th October 2009 and 20th June 2011. In total, of the 
486 subjects that were screened 352 subjects agreed to participate in the study and 134 
subjects did not agree to participate or were excluded based on study criteria. With 
regard to the (n = 352) subjects that agreed to participate and were suitable for study 
participation, the breakdown of the OGTT result demonstrated 40% had DM (T2DM), 
40% had IFG/IGT and 20% were NGT. Out of the 352 that did agree to participate in 
the study, a further 208 were lost to the study at this point, as they were unsuitable 
based on OGTT result (NGT or DM). This left 144 subjects suitable for the study 
(IFG/IGT or both). However, 99 of these subjects changed their mind when contacted to 
attend for the study. This resulted in 45 suitable subjects (9.3%) being entered into the 
study at baseline (year 0). 
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With regard to the (n = 352) subjects that agreed to participate and were suitable for 
study participation, the breakdown of the OGTT result demonstrated 40% had DM 
(T2DM), 40% had IFG/IGT and 20% were NGT. These percentages are in keeping with 
what is reported in the general literature (75)(76). When one looked at ‘drop - out’ rate 
for this study, (n = 99) of (n = 144) suitable subjects changed their mind when they 
were contacted to attend. This gave a ‘drop out’ rate (at this point in proceedings) of 
68.75%. This resulted in an increased amount of time being allocated to recruitment, in 
order to obtain a sufficient number of subjects for the study (as described in section 
2.2). 
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Figure 22: Consort Diagram Summarising Screening Outcome for all Subjects 
-n = 352 subjects agreed to participate in the study and 134 did not. 208 were unsuitable, leaving 144 suitable study 
subjects (IFG/IGT or both), of which 99 of these changed their mind. This resulted in 45 suitable subjects being 
entered into the study at baseline (year 0). 
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4.0 Results: Study Data 
4.1 Analysis of Baseline Data 
Out of the original screening population, a total of n = 45 (9.3%) subjects, with either 
IFG/IGT or both to be entered into the study at baseline (Figure 22). 
 
4.1.1 Gender 
Out of the 45 baseline subjects (n = 45), 42.2% (n = 19) were female and 57.8% (n = 
26) were male. 
 
4.1.2 Age (years) 
The mean age of the baseline subjects (n = 45) was 59.05 years, with a range in age of 
57.4 years (minimum age 21.4 and maximum age 78.8 years) (Figure 23). 
 
 
Figure 23: Baseline Subjects Age Statistics (years). 
-The mean age of the baseline subjects screened was 59.06 years, with a range of 57.4 years and a standard deviation 
of 11.95. 
 
When age was broken down into categories as described in Section 2.11.1, 2.2 % of the 
subjects were in young adulthood, 6.7% of the subjects were in middle adulthood, 
57.8% of the subjects were in older adulthood and 33.3% were of adult retirement age 
(Table 6). 
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Table 6: Baseline Subjects per Age Categories 
 Frequency % 
 
young adulthood 1 2.2 
middle adulthood 3 6.7 
older adulthood 26 57.8 
adult retirement age 15 33.3 
Total 45 100.0 
 
4.1.3 Ethnicity 
When ethnicity was considered, 91.1% (n = 41) baseline subjects (n = 45) were 
Caucasian and 8.9% (n = 4) baseline study subjects were non Caucasian. 
 
4.1.4 Body Mass Index (BMI) 
With regard to BMI, as per the categories stated in Section 2.11.2, 6.7% (n = 3) of the 
subjects at baseline (n = 45) were classed as having normal weight, 31.1% (n = 14) were 
classes as being overweight and 62.2% (n = 28) fell into the obese category. No 
underweight subjects were present (Figure 24). 
 
 
Figure 24: Baseline Subjects: BMI 
-With regard to BMI, the majority of the baseline subjects were overweight (31.1%) or obese (62.2%). 
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4.1.5 Family History of Diabetes 
The baseline subjects (n = 45) were questioned regarding family history of diabetes and 
44.4% (n = 20) of them had a positive family history of DM and 55.6% (n = 25) did not. 
 
4.1.6 Smoking Status 
The baseline subjects (n = 45) were asked about their smoking status. Results 
demonstrated that 68.9% (n = 31) were non smokers, 13.3% (n=6) were smokers and 
17.8% (n = 8) were ex-smokers (Figure 25). 
 
 
 
Figure 25: Baseline Subjects: Smoking Status 
-68.89% of the baseline subjects were non smokers, 17.78% were ex-smokers and 13.33% were smokers. 
 
4.1.7 Blood Pressure (BP) Status 
The baseline subjects (n = 45) were asked if they had a history of hypertension. 68.9% 
(n = 31) did have hypertension and were on medication for this and 31.1% (n = 14) did 
not have hypertension. 
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4.1.8 Lipid Status 
The baseline subjects (n = 45) were asked whether they were being prescribed lipid 
lowering therapy. 46.7% (n = 21) were on lipid lowering medication and 53.3% (n = 24) 
reported that they were not. 
 
4.1.9 OGTT 0 minutes Glucose (mmol/l) 
The mean fasting plasma glucose (FPG) in the baseline subjects (n = 45) was 6.25 
mmol/L, with a maximum value of 6.9 mmol/l and a minimum value of 4.8 mmol/l. 
This demonstrated a range of FPG of 2.1 mmol/l, with a standard deviation (Std Dev) of 
0.45 (Figure 26a). IFG in baseline subjects (n = 45) was seen when FPG > 6.1 mmol/l 
and was indicated by the vertical red line on the X axis, as illustrated in Figure b. 
 
 
Figure 26a: Baseline Subjects: OGTT 0 minutes Glucose (mmol/l) 
-FPG for baseline subjects (n = 45) demonstrated a mean of 6.25 mmol/l and a Std Dev of 0.45. 
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Figure 26b: Baseline Subjects: OGTT 0 minutes Glucose (mmol/l) 
-Baseline subjects (n = 45) are labelled IPRO-01 to IPRO-47, as can be seen from the Y axis (IPRO-04 and IPRO-12 
withdrew from the study prior to its initiation). The X axis represents FPG (mmol/l) and a FPG > 6.1mmol/l for 
baseline subjects reflected IFG; this point on the X axis was indicated by the vertical red line. 
 
4.1.10 OGTT 2 Hour Glucose (mmol/l) 
The mean OGTT 2 hour Glucose in the baseline subjects (n = 45) was 7.87 mmol/l, with a maximum value of 
with a maximum value of 11.0 mmol/l and a minimum value of 4.3 mmol/l. This gave a range of OGTT 2 hour 
range of OGTT 2 hour Glucose values of 6.7 mmol/l and a Std Dev of 1.81 (Figure 27: Baseline Subjects OGTT 
2 hour Glucose (mmol/l) 
). 
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Figure 27: Baseline Subjects OGTT 2 hour Glucose (mmol/l) 
-The OGTT 2 Hour Glucose for baseline subjects (n = 45) demonstrated a mean of 7.88 mmol/l and a Std Dev of 
1.81. 
 
4.1.11 HbA1c (mmol/mol) 
The mean HbA1c in the baseline subjects (n = 40) was 43.92 mmol/mol, with a maximum of 53 mmol/mol and 
maximum of 53 mmol/mol and a minimum of 37 mmol/mol (range 16 mmol/mol) (Figure 28: Baseline 
Subjects: HbA1c (mmol/mol) 
). 
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Figure 28: Baseline Subjects: HbA1c (mmol/mol) 
-The HbA1c for baseline subjects (n = 40) had a mean of 43.83 mmol/mol and a Std Dev of 3.82, with a maximum of 
53 mmol/mol and a minimum of 37 mmol/mol (range 16 mmol/mol). 
 
4.1.12 CGM Glucose Excursion Parameters 
As described in Section 2.10, four CGM based glucose excursion parameters were 
devised and the results at baseline for each subject (n = 45) are seen in Table 7. 
 
Table 7: Summary of CGM Glucose Parameters - Baseline 
 MEAN Baseline 
Av Gl (mmol/l) 
MEAN Baseline 
AvGl excursion 
from Av (mmol/l) 
MEAN Baseline 
Av above norm 
Gl (mmol/l) 
MEAN Baseline 
Av Gl excursion 
from norm Gl 
(mmol/l) 
N 
Valid 45 45 45 45 
Missing 0 0 0 0 
Mean 6.73 .99 2.23 2.48 
Std. Deviation .66 .34 .66 .65 
Range 3.13 1.86 3.13 3.02 
Minimum 5.27 .36 .77 1.03 
Maximum 8.40 2.22 3.90 4.05 
 
The CGM Mean Average Glucose for the baseline data (n = 45) was 6.73 mmol/l, with a maximum and 
a maximum and minimum CGM Mean Average Glucose of 8.40 and 5.27 mmol/l, respectively (Table 7; Figure 
respectively (Table 7; Figure 29: Baseline Subjects: CGM Mean Average Glucose (mmol/l) 
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). The CGM Mean Average Glucose Excursion from the Average Glucose (mmol/l) for the baseline data (n = 
45) was 1.0 mmol/l, with a maximum and minimum CGM Mean Average Excursion from the Average Glucose 
of 2.22 and 0.36 mmol/l, respectively (Table 7, Error! Reference source not found.). The CGM Mean Average 
Glucose above Normal Glucose (mmol/l) for the baseline data (n = 45) was 2.23 mmol/l, with a maximum and 
mmol/l, with a maximum and minimum CGM Mean Average Glucose above Normal Glucose of 3.90 and 0.77 
Glucose of 3.90 and 0.77 mmol/l, respectively (Table 7; Figure 31: Baseline Subjects CGM: Mean Average 
Glucose above Normal Glucose (mmol/l) 
). The CGM Mean Average Glucose Excursion from Normal Glucose (mmol/l) for the baseline data (n = 45) 
was 2.49 mmol/l, with a maximum and minimum CGM Mean Average Glucose Excursion from Normal 
Glucose of 4.05 and 1.03 mmol/l, respectively (Table 7, Figure 32: Baseline Subjects CGM: Mean Average 
Glucose Excursion from Normal Glucose (mmol/l) 
). 
 
 
Figure 29: Baseline Subjects: CGM Mean Average Glucose (mmol/l) 
-The CGM Mean Average Glucose for the baseline data (n = 45) was 6.73 mmol/l, with a maximum and minimum 
CGM Mean Average Glucose of 8.40 and 5.27 mmol/l, respectively. 
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Figure 30: Baseline Subjects: CGM Mean Average Glucose Excursion from the Average Glucose (mmol/l) 
-The CGM Mean Average Glucose Excursion from the Average Glucose (mmol/l) for the baseline data (n = 45) was 
1.0 mmol/l, with a maximum and minimum CGM Mean Average Excursion from the Average Glucose of 2.22 and 
0.36 mmol/l, respectively 
 
 
 
Figure 31: Baseline Subjects CGM: Mean Average Glucose above Normal Glucose (mmol/l) 
-The CGM Mean Average Glucose above Normal Glucose (mmol/l) for the baseline data (n = 45) was 2.23 mmol/l, 
with a maximum and minimum CGM Mean Average Glucose above Normal Glucose of 3.90 and 0.77 mmol/l, 
respectively. 
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Figure 32: Baseline Subjects CGM: Mean Average Glucose Excursion from Normal Glucose (mmol/l) 
-The CGM Mean Average Glucose Excursion from Normal Glucose (mmol/l) for the baseline data (n = 45) was 2.49 
mmol/l, with a maximum and minimum CGM Mean Average Glucose Excursion from Normal Glucose of 4.05 and 
1.03 mmol/l, respectively. 
 
4.1.13 CGM Profiles 
CGM was conducted on all the subjects at baseline (n= 45). Each CGM profile (Sensor Modal Day) was then 
Modal Day) was then inspected by eye and the profiles were placed in one of three groups, according to the 
groups, according to the “flatness” or “peakiness” of the profile. The three groups were labelled least 
labelled least variability, as illustrated in Figure 33: CGM Profile (SAP) - Least Variability: (a subject 
illustration) 
, medium variability as illustrated in Figure 34: CGM Profile (SAP) - Medium Variability: (a subject 
illustration) 
 and most variability, as illustrated in Figure 35: CGM Profiles (SAP) - Most Variability: (a subject 
illustration) 
. 
 
A representative example of each of these three different profiles described above can 
be seen in the illustrations below. The CGM profiles were inspected blindly by the PI 
(CGM profiles SAP) and by an independent observer (CGM Profiles PUMP); the 
independent observer was a Lead Diabetic Specialist Nurse. CGM profiles for each 
subject at baseline can be seen in the APPENDIX, as APPENDIX 2: Least Variability; 
APPENDIX 3 – medium variability and APPENDIX 4 – most variability. 
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Figure 33: CGM Profile (SAP) - Least Variability: (a subject illustration) 
-Sensor Modal Day demonstrated all of the glucose data over a 24 hour period from subject IPRO-05a, with each day 
represented as separate plot line in a different colour. 
 
Figure 34: CGM Profile (SAP) - Medium Variability: (a subject illustration) 
-Sensor Modal Day demonstrated all of the glucose data over a 24 hour period from subject IPRO-38a, with each day 
represented as separate plot line in a different colour. 
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Figure 35: CGM Profiles (SAP) - Most Variability: (a subject illustration) 
-Sensor Modal Day demonstrated all of the glucose data over a 24 hour period, from subject ipro-06a, with each day 
represented as separate plot line in a different colour. 
 
One can see that when the CGM (SAP) profiles were inspected (Table 8), 20% (n = 9) 
of them were observed to demonstrate least variability, 48.9% (n = 22) were observed to 
demonstrate medium variability and 31.1% (n = 14) were observed to demonstrate most 
variability. These results closely mirrored the independent observers assessment of 
variability ( 
Table 9), which demonstrated 22.2% (n = 10) of the CGM (PUMP) profiles were 
observed to demonstrate least variability, 46.7% (n = 21) were observed to demonstrate 
medium variability and 31.1% (n = 14) were observed to demonstrate most variability. 
When this was looked at in more detail, there was only a single disagreement between 
assessors. The investigator placed one less CGM profile in the least variability category, 
compared to the independent observer (PUMP); the remainder were identical. 
 
Table 8: Baseline Subjects CGM Profiles (SAP) 
 Frequency % 
 
least variability 9 20.0 
medium variability 22 48.9 
most variability 14 31.1 
Total 45 100.0 
 
Table 9: Baseline Subjects CGM Profiles (PUMP) 
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 Frequency % 
 
least variability 10 22.2 
medium variability 21 46.7 
most variability 14 31.1 
Total 45 100.0 
 
At baseline, each of the four CGM parameters described in Section 2.10, were looked at with regard to their 
with regard to their relationship with the CGM profile groups. As both the PI (SAP) and the independent 
the independent observer (PUMP) findings were very similar, with regard to the degree of observed glucose 
of observed glucose variation in the subjects CGM profiles, for the purpose of this study, the investigators 
study, the investigators observations of CGM Profiles (SAP) were used in the remaining analysis. The CGM 
analysis. The CGM parameter Mean Baseline Average Glucose was 6.14 mmol/l for least variability CGM 
least variability CGM profile (SAP), rising to 6.70 mmol/l for medium variability CGM profile (SAP) up to 
profile (SAP) up to 7.17 mmol/l for most variability CGM profile (SAP) (Figure 36: Summary: Baseline 
Subjects CGM Parameters v CGM Profiles (SAP) 
). The CGM parameter Mean Baseline Average Glucose Excursion from Average (mmol/l) was 0.65 mmol/l for 
least variability CGM profile (SAP), rising to 0.92 mmol/l for medium variability CGM profile (SAP) up to 
1.34 mmol/l for most variability CGM profile (SAP) (Figure 36: Summary: Baseline Subjects CGM 
Parameters v CGM Profiles (SAP) 
). The CGM parameter Mean Baseline Average Glucose above Normal Glucose (mmol/l) was 1.64 mmol/l for 
least variability CGM profile (SAP), rising to 2.20 mmol/l for medium variability CGM profile (SAP), up to 
2.67 mmol/l for most variability CGM profile (SAP) (Figure 36: Summary: Baseline Subjects CGM 
Parameters v CGM Profiles (SAP) 
). The CGM parameter Mean Baseline Average Glucose Excursion from Normal Glucose (mmol/l) was 1.81 
mmol/l for least variability CGM profile (SAP), rising to 2.41 mmol/l for medium variability CGM profile 
(SAP), up to 3.04 mmol/l for most variability CGM profile (SAP) (Figure 36: Summary: Baseline Subjects 
CGM Parameters v CGM Profiles (SAP) 
). 
 
75 
 
 
Figure 36: Summary: Baseline Subjects CGM Parameters v CGM Profiles (SAP) 
-At baseline, for CGM profile (SAP): the CGM parameter Mean Baseline Average Glucose was 6.14 mmol/l for least 
variability, rising to 6.70 mmol/l for medium variability and up to 7.17 mmol/l for most variability; the CGM 
parameter Mean Baseline Average Glucose Excursion from Average (mmol/l) was 0.65 mmol/l for least variability, 
rising to 0.92 mmol/l for medium variability and up to 1.34 mmol/l for most variability; the CGM parameter Mean 
Baseline Average Glucose above Normal Glucose (mmol/l) was 1.64 mmol/l for least variability, rising to 2.20 
mmol/l for medium variability and up to 2.67 mmol/l for most variability; the CGM parameter Mean Baseline 
Average Glucose Excursion from Normal Glucose (mmol/l) was 1.81 mmol/l for least variability, rising to 2.41 
mmol/l for medium variability and  up to 3.04 mmol/l for most variability. 
 
At baseline, each of the four CGM parameters described in Section 2.10, were looked at with regard to their 
with regard to their relationship with the CGM profile groupings. As the degree of variability of the subject 
variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to most 
variability to most variability, the mean of each of the four CGM parameters was observed to increase also, as 
observed to increase also, as discussed above, which can be seen from the mean plots (Figure 37: Summary 
Baseline Subjects CGM Parameters v CGM Profile (SAP) - Mean Plots 
) (Figure 38: Summary Baseline Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
) (Figure 39: Summary Baseline Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
) (Figure 40: Summary Baseline Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
) respectively. 
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Figure 37: Summary Baseline Subjects CGM Parameters v CGM Profile (SAP) - Mean Plots 
-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average Glucose (mmol/l) was also observed to increase. 
 
 
Figure 38: Summary Baseline Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average Glucose excursion from Average (mmol/l) was also observed 
to increase. 
 
 
77 
 
 
Figure 39: Summary Baseline Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average above normal Glucose (mmol/l) was also observed to 
increase. 
 
 
Figure 40: Summary Baseline Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average Glucose excursion from normal Glucose (mmol/l) was also 
observed to increase. 
 
4.1.14 OGTT Results 
The OGTT outcome at baseline for all subjects (n = 45) demonstrated 44.4% (n= 20) subjects with IFG, 40% 9 
(n = 18) subjects with both IFG and IGT and 15.6% (n = 7) subjects as having IGT (Table 10, Figure 41: 
Baseline OGTT Outcome 
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). 
 
Table 10: Baseline OGTT Outcome 
 Frequency Percent 
 
IFG 20 44.4 
IFG+IGT 18 40.0 
IGT 7 15.6 
Total 45 100.0 
 
 
Figure 41: Baseline OGTT Outcome 
-The OGTT outcome at baseline for all subjects (n = 45) demonstrated 44.4% (n= 20) subjects with IFG, 40% 9 (n = 
18) subjects with both IFG and IGT and 15.6% (n = 7) subjects as having IGT. 
 
If one looked at age at baseline with regard to OGTT outcome, one can see that there were very few young 
were very few young adults with IFG, IGT or both, while those who were in middle adulthood appeared to 
adulthood appeared to have a fairly even distribution of subjects in all OGTT categories. IFG was 
IFG was demonstrated to be more prominent in older subjects, while IGT was demonstrated to be more 
demonstrated to be more prominent in subjects of adult retirement age (Table 11, Figure 42: Baseline OGTT 
Outcome: Age 
). If one looked at gender at baseline with regard to OGTT, there appeared to be more male subjects with IFG 
and IFG+IGT than females, who themselves appeared to have more IGT (Table 12, Figure 43: Baseline OGTT 
Outcome: Gender 
). If one looked at OGTT outcome with regard to ethnicity, it is very difficult to make any real informative 
comments in this instance, given over 90% of the study subjects were Caucasian (Table 13, Figure 44: Baseline 
OGTT Outcome: Ethnicity 
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). Out of the 20 subjects that had a positive family history (FHx) of DM, 60% of them at baseline had 
IFG+IGT, while this outcome was far less prominent in those who didn’t have a FHx of DM (Table 14, Figure 
DM (Table 14, Figure 45: Baseline OGTT Outcome: FHX DM 
). If one looked at BMI at baseline with regard to OGTT, it was demonstrated that 62% of the subjects were 
classed as obese while only approximately 7% of subjects fell into the normal category. Of those subjects that 
were obese, over 50% of them had IFG (Table 15, Figure 46: Baseline OGTT Outcome: BMI 
). If one looked at OGTT outcome at baseline with regard to smoking status, 68% of the subjects were non 
smokers and almost 20% of subjects were ex-smokers, leaving 13% of study subjects that smoked. If one 
that smoked. If one looked at the subjects that smoked, 50% had IFG at baseline OGTT (Table 16, Figure 47: 
(Table 16, Figure 47: Baseline OGTT Outcome: Smoking 
). If one looked at OGTT outcome at baseline with regard to hypertension, approximately70% of the subjects 
had hypertension and approximately 30% of subjects did not have hypertension. Of those subjects that had 
hypertension, more that 80% of them had IFG or IFG+IGT (Table 17, Figure 48: Baseline OGTT Outcome: 
Hypertension 
). If one looked at OGTT outcome at baseline, approximately the same number of subjects had dyslipidemia to 
those who didn’t. Of those subjects who didn’t have dyslipidemia, 50% of them had IFG rather than IFT+IGT 
and IGT (Table 18, Figure 49: Baseline OGTT Outcome: Dyslipidemia 
). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11: Baseline OGTT Outcome: Age 
 MIXBaseline OGTT result Total 
IFG IFG+IGT IGT 
baseline age 
groups 
young adulthood 
Count 0 0 1 1 
% within baseline age 
groups 
0.0% 0.0% 100.0% 100.0% 
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% of Total 0.0% 0.0% 2.2% 2.2% 
middle adulthood 
Count 1 1 1 3 
% within baseline age 
groups 
33.3% 33.3% 33.3% 100.0% 
% of Total 2.2% 2.2% 2.2% 6.7% 
older adulthood 
Count 14 10 2 26 
% within baseline age 
groups 
53.8% 38.5% 7.7% 100.0% 
% of Total 31.1% 22.2% 4.4% 57.8% 
adult retirement 
age 
Count 5 7 3 15 
% within baseline age 
groups 
33.3% 46.7% 20.0% 100.0% 
% of Total 11.1% 15.6% 6.7% 33.3% 
Total 
Count 20 18 7 45 
% within baseline age 
groups 
44.4% 40.0% 15.6% 100.0% 
% of Total 44.4% 40.0% 15.6% 100.0% 
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 42: Baseline OGTT Outcome: Age 
-If one looked at age at baseline with regard to OGTT outcome, one can see that there were very few young adults 
with IFG, IGT or both, while those who were in middle adulthood appeared to have a fairly even distribution of 
subjects in all OGTT categories. IFG was demonstrated to be more prominent in older subjects, while IGT was 
demonstrated to be more prominent in subjects of adult retirement age. 
 
Table 12: Baseline OGTT Outcome: Gender 
 MIXBaseline OGTT result Total 
IFG IFG+IGT IGT 
Gender F 
Count 9 6 4 19 
% within Gender 47.4% 31.6% 21.1% 100.0% 
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% within MIXBaseline OGTT result 45.0% 33.3% 57.1% 42.2% 
% of Total 20.0% 13.3% 8.9% 42.2% 
M 
Count 11 12 3 26 
% within Gender 42.3% 46.2% 11.5% 100.0% 
% within MIXBaseline OGTT result 55.0% 66.7% 42.9% 57.8% 
% of Total 24.4% 26.7% 6.7% 57.8% 
Total 
Count 20 18 7 45 
% within Gender 44.4% 40.0% 15.6% 100.0% 
% within MIXBaseline OGTT result 100.0% 100.0% 100.0% 100.0% 
% of Total 44.4% 40.0% 15.6% 100.0% 
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 43: Baseline OGTT Outcome: Gender 
-If one looked at gender at baseline with regard to OGTT, there appeared to be more male subjects with IFG and 
IFG+IGT than females, who themselves appeared to have more IGT; F = female; M = male. 
 
 
 
 
 
 
Table 13: Baseline OGTT Outcome: Ethnicity 
 
 
MIXBaseline OGTT result Total 
IFG IFG+IGT IGT 
Ethnicity Caucasian 
Count 19 16 6 41 
% within Ethnicity 46.3% 39.0% 14.6% 100.0% 
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% within MIXBaseline OGTT result 95.0% 88.9% 85.7% 91.1% 
% of Total 42.2% 35.6% 13.3% 91.1% 
n.Caucasian 
Count 1 2 1 4 
% within Ethnicity 25.0% 50.0% 25.0% 100.0% 
% within MIXBaseline OGTT result 5.0% 11.1% 14.3% 8.9% 
% of Total 2.2% 4.4% 2.2% 8.9% 
Total 
Count 20 18 7 45 
% within Ethnicity 44.4% 40.0% 15.6% 100.0% 
% within MIXBaseline OGTT result 100.0% 100.0% 100.0% 100.0% 
% of Total 44.4% 40.0% 15.6% 100.0% 
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 44: Baseline OGTT Outcome: Ethnicity 
-If one looked at OGTT outcome with regard to ethnicity, it is very difficult to make any real informative comments 
in this instance, given over 90% of the study subjects were Caucasian. 
 
 
 
 
 
 
Table 14: Baseline OGTT outcome: FHx DM 
 MIXBaseline OGTT result Total 
IFG IFG+IGT IGT 
FHx DM Yes 
Count 6 12 2 20 
% within Family History DM 30.0% 60.0% 10.0% 100.0% 
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% within MIXBaseline 
OGTT result 
30.0% 66.7% 28.6% 44.4% 
% of Total 13.3% 26.7% 4.4% 44.4% 
No 
Count 14 6 5 25 
% within Family History DM 56.0% 24.0% 20.0% 100.0% 
% within MIXBaseline 
OGTT result 
70.0% 33.3% 71.4% 55.6% 
% of Total 31.1% 13.3% 11.1% 55.6% 
Total 
Count 20 18 7 45 
% within Family History DM 44.4% 40.0% 15.6% 100.0% 
% within MIXBaseline 
OGTT result 
100.0% 100.0% 100.0% 100.0% 
% of Total 44.4% 40.0% 15.6% 100.0% 
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 45: Baseline OGTT Outcome: FHX DM 
-Out of the 20 subjects that had a positive family history (FHx) of DM, 60% of them at baseline had IFG+IGT, while 
this outcome was far less prominent in those who didn’t have a FHx of DM. 
 
 
 
 
 
Table 15: Baseline OGTT Outcome: BMI 
 MIXBaseline OGTT result Total 
IFG IFG+IGT IGT 
BMI Normal Count 1 1 1 3 
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baseline % within BMI baseline 33.3% 33.3% 33.3% 100.0% 
% within MIXBaseline OGTT result 5.0% 5.6% 14.3% 6.7% 
% of Total 2.2% 2.2% 2.2% 6.7% 
Overweight 
Count 4 8 2 14 
% within BMI baseline 28.6% 57.1% 14.3% 100.0% 
% within MIXBaseline OGTT result 20.0% 44.4% 28.6% 31.1% 
% of Total 8.9% 17.8% 4.4% 31.1% 
obese 
Count 15 9 4 28 
% within BMI baseline 53.6% 32.1% 14.3% 100.0% 
% within MIXBaseline OGTT result 75.0% 50.0% 57.1% 62.2% 
% of Total 33.3% 20.0% 8.9% 62.2% 
Total 
Count 20 18 7 45 
% within BMI baseline 44.4% 40.0% 15.6% 100.0% 
% within MIXBaseline OGTT result 100.0% 100.0% 100.0% 100.0% 
% of Total 44.4% 40.0% 15.6% 100.0% 
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 46: Baseline OGTT Outcome: BMI 
-If one looked at BMI at baseline with regard to OGTT, it was demonstrated that 62% of the subjects were classed as 
obese while only approximately 7% of subjects fell into the normal category. Of those subjects that were obese, over 
50% of them had IFG. 
 
 
 
Table 16: Baseline OGTT Outcome: Smoking 
 MIXBaseline OGTT result Total 
IFG IFG+IGT IGT 
Smoking non Count 14 13 4 31 
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Status smoker % within Baseline Smoking Status 45.2% 41.9% 12.9% 100.0% 
% within MIXBaseline OGTT 
result 
70.0% 72.2% 57.1% 68.9% 
% of Total 31.1% 28.9% 8.9% 68.9% 
Smoker 
Count 3 1 2 6 
% within Baseline Smoking Status 50.0% 16.7% 33.3% 100.0% 
% within MIXBaseline OGTT 
result 
15.0% 5.6% 28.6% 13.3% 
% of Total 6.7% 2.2% 4.4% 13.3% 
ex smoker 
Count 3 4 1 8 
% within Baseline Smoking Status 37.5% 50.0% 12.5% 100.0% 
% within MIXBaseline OGTT 
result 
15.0% 22.2% 14.3% 17.8% 
% of Total 6.7% 8.9% 2.2% 17.8% 
Total 
Count 20 18 7 45 
% within Baseline Smoking Status 44.4% 40.0% 15.6% 100.0% 
% within MIXBaseline OGTT 
result 
100.0% 100.0% 100.0% 100.0% 
% of Total 44.4% 40.0% 15.6% 100.0% 
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 47: Baseline OGTT Outcome: Smoking 
-If one looked at OGTT outcome at baseline with regard to smoking status, 68% of the subjects were non smokers 
and almost 20% of subjects were ex-smokers, leaving 13% of study subjects that smoked. If one looked at the 
subjects that smoked, 50% had IFG at baseline OGTT. 
 
Table 17: Baseline OGTT Outcome: Hypertension 
 MIXBaseline OGTT result TOTAL 
IFG IFG+IGT IGT  
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Baseline 
 Hypertension 
yes 
Count 11 15 5 31 
% within Baseline Hypertension 35.5% 48.4% 16.1% 100% 
% within MIXBaseline OGTT result 55.0% 83.3% 71.4% 68.9% 
% of Total 24.4% 33.3% 11.1% 68.9% 
no 
Count 9 3 2 14 
% within Baseline Hypertension 64.3% 21.4% 14.3% 100% 
% within MIXBaseline OGTT result 45.0% 16.7% 28.6% 31.1 
% of Total 20.0% 6.7% 4.4% 31.1 
Total 
Count 20 18 7 45 
% within Baseline Hypertension 44.4% 40.0% 15.6% 100% 
% within MIXBaseline OGTT result 100.0% 100.0% 100.0% 100% 
% of Total 44.4% 40.0% 15.6% 100% 
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 48: Baseline OGTT Outcome: Hypertension 
-If one looked at OGTT outcome at baseline with regard to hypertension, approximately70% of the subjects had 
hypertension and approximately 30% of subjects did not have hypertension. Of those subjects that had hypertension, 
more that 80% of them had IFG or IFG+IGT. 
 
 
 
 
 
 
Table 18 Baseline OGTT Outcome: Dyslipidemia 
 MIXBaseline OGTT result TOTALS 
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IFG IFG+IGT IGT  
Baseline 
Dyslipidemia 
yes 
Count 8 9 4 21 
% within Baseline Dyslipidemia 38.1% 42.9% 19.0% 100% 
% within MIXBaseline OGTT result 40.0% 50.0% 57.1% 46.7% 
% of Total 17.8% 20.0% 8.9% 46.7% 
no 
Count 12 9 3 24 
% within Baseline Dyslipidemia 50.0% 37.5% 12.5% 100% 
% within MIXBaseline OGTT result 60.0% 50.0% 42.9% 53.3% 
% of Total 26.7% 20.0% 6.7% 53.3% 
Total 
Count 20 18 7 45 
% within Baseline Dyslipidemia 44.4% 40.0% 15.6% 100% 
% within MIXBaseline OGTT result 100.0% 100.0% 100.0% 100% 
% of Total 44.4% 40.0% 15.6% 100% 
      
*MIXBaseline OGTT Result = Baseline OGTT result outcome: IFG, IFG+IGT or IGT. 
 
 
 
Figure 49: Baseline OGTT Outcome: Dyslipidemia 
-If one looked at OGTT outcome at baseline, approximately the same number of subjects had dyslipidemia to those 
who didn’t. Of those subjects who didn’t have dyslipidemia, 50% of them had IFG rather than IFT+IGT and IGT 
 
4.1.15 Summary: Chapter 4 
In summary, at baseline more men than women participated in study (60:40 split) and over 90% of the total 
over 90% of the total baseline subjects fell into the older adulthood or retirement age group. The majority of 
group. The majority of subjects at baseline were Caucasian (> 90%) and obese (63%). It was demonstrated 
was demonstrated that approximately half of the baseline subjects had a positive FHx of DM and 10% 
smoked. Interestingly, 70% of baseline subjects were on prescribed medication for hypertension and 50% of 
them were on prescribed medication for dyslipidemia. At baseline, the mean subject FPG was 6.25 mmol/l, the 
mean subject 2 hr OGTT result was 7.87 mmol/l and the mean subject HbA1c was 43.92 mmol/mol. In general, 
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when the CGM profiles (SAP) were inspected by eye, approximately 20% of them were thought to 
demonstrate least variability, 50% medium variability and 30% most variability. As the degree of variability 
of the subject CGM profiles (SAP) increased from least variability to most variability, the mean of each of the 
four CGM parameters was observed to increase also (Figure 36: Summary: Baseline Subjects CGM 
Parameters v CGM Profiles (SAP) 
), which is what you would expect to observe. From the OGTT at baseline for study 
subjects, one can suggest that IFG is most prominent in older, obese males, who smoke 
and have hypertension. 
  
89 
 
5.0 Results: Study Data: Analysis of Year 1 and Year 3 Data 
5.1 Analysis Variables 
At Year 1, all subjects from the baseline study were invited back for re- analysis. At 
Year 1, a number of parameters were analysed, including age and study follow up 
interval, BMI, OGTT 0 hrs (FPG), OGTT 2 hours, HbA1c, CGM Glucose Excursion 
Parameters and CGM Profiles. At Year 3, variables which were analysed included age 
and follow up interval, BMI, OGTT 0 hrs (FPG) and HbA1c. The aim of this was to 
identify any parameter that demonstrated trends associated with progression to DM 
(T2DM). 
 
At baseline there were 45 subjects (n = 45) and out of these 37 (n = 37) returned for re 
analysis. Therefore, 82.2% of subjects re-attended at Year 1. At Year 3, 15.6% of the 
original baseline subjects (n = 7) did not return for re-analysis and 84.4% (n = 38) did, a 
response rate of 84.4%. This was an increase of 2.2% in response rate compared to Year 
1. The subjects that developed DM (T2DM) at Year 1 were also included in the subjects 
invited for re-analysis at Year 3. 
 
5.1.1 Age (years) 
At Year 1 and Year 3, approximately 80% of subjects returned for re analysis. 
Approximately 80% of these were either older adults or adults of retirement age. When 
baseline age categories were compared to Year 1 and Year 3 subjects, one can see that 
the majority of subjects were still in older adulthood or of adult retirement age. When 
we looked back to see the OGTT status at baseline for the non returners at both Year 1 
and Year 3 respectively, 50% of them had IFG. When we looked at the follow up time 
interval, between subjects attending for re-analysis we can see from Table 19 that at 
Year 1, the mean time interval for re attendance from baseline was 1.3 years (maximum 
2.37 – minimum 0.85 years). At Year 3, the mean time interval for re-attendance from 
baseline was 3.64 years (maximum 4.75 – minimum 2.74). The interval between Year 1 
and Year 3 attendances was 2.32 years. 
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Table 19: Baseline, Year 1 and Year 3: Re-attendance Intervals 
 interval (0 to 1) 
years 
interval (0 to 3) 
years 
interval (1 to 3) 
years 
N 
Valid 36 38 34 
Missing 9 7 11 
Mean 1.31 3.64 2.32 
Std. Deviation .35 .48 .32 
Range 1.52 2.01 1.49 
Minimum .85 2.74 1.65 
Maximum 2.37 4.75 3.14 
 
5.1.2 Body Mass Index (BMI) 
At baseline 31.1% (n = 14) were classed as being overweight and 62.2% (n = 28) fell 
into the obese category; mean BMI at baseline was 33.26. At Year 1, the n = 37 subjects 
were re-assessed for BMI and if one takes into account an 82.2% return rate, almost 
60% were still classed as obese, with a mean BMI of 33.48. Similar findings were also 
seen at Year 3, where BMI mean was 32.54. If one takes into account an 84.4% return 
rate, over 50% were classed as obese, albeit with a slight improvement in BMI from 
previous years. In general however, the majority of subjects in this study were either 
overweight or obese (Table 20). Interestingly, all of the subjects that were obese at 
baseline were still obese at Year 3. 
 
Table 20: BMI: Summary - Baseline, Year 1 and Year 3 
 N Minimum Maximum Mean Std. Deviation 
Baseline BMI (kg/m^2) 45 21.59 48.65 33.26 6.50 
Year 1 BMI (kg/m^2) 37 20.44 47.37 33.48 6.49 
Year 3 BMI (kg/m^2) 38 19.38 49.15 32.54 6.93 
Valid N 34     
 
5.1.3 OGTT 0 minutes Glucose (mmol/l) 
At baseline, the mean subject FPG was 6.25 mmol/l, which increased in a stepwise 
fashion as the study progressed with time. At Year 1, the mean subject OGTT at 0 
minutes Glucose (mmol/l) i.e. the FPG was 6.24 mmol/l. The minimum FPG was 4.20 
mmol/l and the maximum was 7.70 mmol/l, with a range of 3.50 mmol/l (Table 21, 
Figure 50: Year 1 Subjects OGTT: FPG - 0 min (mmol/l)). 
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Table 21: OGTT 0 minutes Glucose (FPG): Summary: - Baseline, Year 1 and Year 3 
 N Minimum Maximum Mean Std. Deviation 
Baseline OGTT 0 mins 
(mmol/l) 
45 4.8 6.9 6.25 .45 
Year 1 OGTT 0 mins 
(mmol/l) 
36 4.20 7.70 6.24 .71 
Year 3 FPG (mmol/L) 37 4.60 16.30 6.96 1.83 
Valid N 32     
 
 
 
Figure 50: Year 1 Subjects OGTT: FPG - 0 min (mmol/l) 
-At Year 1 (n = 36), the mean FPG was 6.24 mmol/l and the Std Dev was 0.71. 
 
At Year 3, FPG was performed and used as outcome indicator, instead of OGTT. Although ethical approval 
Although ethical approval was obtained for a OGTT at Year 3, when the study subjects contacted and invited 
contacted and invited back, they were not keen to have OGTT; however, they were happy to attend for a FPG. 
happy to attend for a FPG. Therefore, in order to gain a Year 3 outcome FPG was used. The mean fasting 
The mean fasting plasma glucose (FPG) at Year 3 (n = 37) was 6.96 mmol/l, which was an increase of 0.71 
an increase of 0.71 mmol/l from baseline. At Year 3, the maximum FPG demonstrated was up to 16.30 mmol/l, 
was up to 16.30 mmol/l, with a corresponding minimum FPG of 4.60 mmol/l. The range at Year 3 was 11.70 
at Year 3 was 11.70 mmol/l compared to the baseline range of 2.1 mmol/l (Figure 51: Year 3 Subjects OGTT: 
FPG - 0 min (mmol/l) 
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). This demonstrated a degree of FPG instability, as at Year 1, (n = 8) subjects had 
progressed and had crossed the threshold to DM (T2DM) (a subject ratio of 6: 1: 1 - 
IFG+IGT: IFG: IGT). At Year 3, a further (n = 13) subjects had progressed and 
demonstrated DM (T2DM) based on FPG, (over 50% of which were IFG+IGT at Year 
1), which was almost 50% of the study subjects. If one looked at the baseline OGTT of 
the subjects (n = 21) who had progressed to DM by Year 3 (based on FPG), a subject 
ratio of 9:3:9 – IFG+IGT: IGT: IFG was demonstrated; i.e. 86% of the subjects (divided 
equally) were either a mix of IFG+IGT or purely IFG had progressed to DM (TDM) by 
Year 3. If one looked at the FPG at Year 3 of the (n = 8) subjects found to be DM at 
Year 1, all of them continued to have elevated FPG ≥ 6.5 mmol/l except one (this 
subject was taking oral anti-diabetic medication). 
 
 
Figure 51: Year 3 Subjects OGTT: FPG - 0 min (mmol/l) 
-FPG for Year 3 subjects demonstrated a mean of 6.96 mmol/l and a Std Dev of 1.83. 
 
5.1.4 OGTT 2 Hour Glucose (mmol/l) 
At baseline, the mean 2 Hour Glucose (mmol/l) was 7.87 mmol/l, with a range of 6.7 mmol/l. The OGTT 2 
mmol/l. The OGTT 2 Hour Glucose at Year 1 was 8.04 mmol/l, an increase of 0.17 mmol/l. At Year 1, the 
mmol/l. At Year 1, the maximum value was 12.70 mmol/l and the minimum value was 4.4 mmol/l, with an 
4.4 mmol/l, with an increased range of 8.30 mmol/l (Table 22, Figure 52: Year 1 Subjects OGTT [2 hours] 
(mmol/l) 
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). At Year 1, (n = 8) subjects had progressed to T2DM and of these only one of these 
had pure IGT at baseline, the majority of them (75%) had IFG+IGT. In this study, an 
OGTT was not conducted at Year 3, as when the study subjects were contacted and 
invited back for OGTT, they were not keen to have it; they did however, consent for 
FPG, which was used as an indicator of outcome. 
 
Table 22: OGTT 2 hours (mmol/l): Summary - Baseline and Year 1 
 N Minimum Maximum Mean Std. Deviation 
Baseline OGTT 120 mins 
(mmol/l) 
45 4.3 11.0 7.87 1.81 
Year 1 OGTT 120mins 
( mmol/l) 
36 4.40 12.70 8.04 2.06 
Valid N 36     
 
 
 
Figure 52: Year 1 Subjects OGTT [2 hours] (mmol/l) 
-At Year 1 (n = 36), the 2 hour subject OGTT mean was 8.04 mmol/l and the Std Dev was 2.06. 
 
5.1.5 HbA1c (mmol/mol) 
At 1 Year, the mean subject HbA1c (n = 37) was 45.08 mmol/mol (with a maximum of 62.0 mmol/mol and a 
62.0 mmol/mol and a minimum of 37 mmol/mol), rising from 43.92 mmol/mol at baseline to 48.84 mmol/mol in 
baseline to 48.84 mmol/mol in subjects at Year 3. The minimum HbA1c at Year 3 was 38 mmol/mol and the 
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38 mmol/mol and the maximum was 105 mmol/mol, giving a range of 67 mmol/mol, which was increased 
compared to the baseline range of 16 mmol/mol (Table 23, Figure 53: Year 1 Subjects HbA1c (mmol/mol) 
 and Figure 54: Year 3 Subjects HbA1c (mmol/mol) 
). 
 
Table 23: HbA1c: Summary - Baseline, Year 1 and Year 3 
 N Minimum Maximum Mean Std. Deviation 
Baseline HbAlc (mmol/l) 40 37.00 53.00 43.92 3.82 
Year 1 HbAlc (mmol/l) 37 37.00 62.00 45.08 4.76 
Year 3 HbA1c (nmol/mol) 38 38.00 105.00 48.84 12.28 
Valid N 31     
 
 
 
Figure 53: Year 1 Subjects HbA1c (mmol/mol) 
-At Year 1 (n = 37), the mean HbA1c was 45.08 mmol/mol and the Std Dev was 4.76. 
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Figure 54: Year 3 Subjects HbA1c (mmol/mol) 
-At Year 3, (n = 38), the mean HbA1c was 48.84 mmol/mol and the St Dev was 12.26. 
 
5.1.6 CGM Glucose Excursion Parameters 
As described in Section 2.10, four CGM based glucose excursion parameters were 
devised and the results at Year 1 for each subject (n = 37) are seen in ( In this study, 
CGM was not conducted at Year 3, as when the study subjects were contacted and 
invited back, they were not keen to have it; in addition, PI/funding availability at this 
time was also limiting factor. 
 
Table 24). In this study, CGM was not conducted at Year 3, as when the study subjects 
were contacted and invited back, they were not keen to have it; in addition, PI/funding 
availability at this time was also limiting factor. 
 
Table 24: Summary of CGM Glucose Parameters - Year 1 
 MEAN Year1 
AvGl (mmol/l) 
MEAN Year1 
AvGl excursion 
from Av 
(mmol/l) 
MEAN Year1 
Av above norm 
Gl (mmol/l) 
MEAN Year1 
AvGl excursion 
from norm Gl 
(mmol/l) 
N 
Valid 37 37 37 37 
Missing 8 8 8 8 
Mean 6.89 1.15 2.39 2.70 
Std. Deviation 1.04 .58 1.04 1.10 
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Range 5.44 3.00 5.44 5.16 
Minimum 5.03 .41 .53 1.03 
Maximum 10.47 3.41 5.97 6.19 
 
Table 24 is a summary of the CGM glucose parameters at Year 1. Each of these 4 
parameters was then looked compared at baseline to year 1. 
 
CGM Mean Average Glucose for the Year 1 data (n = 37) was 6.89 mmol/l at Year 1, compared to a lower 
compared to a lower baseline value of 6.73 mmol/l. The maximum and minimum CGM Mean Average Glucose 
Mean Average Glucose at Year 1 was 10.47 and 5.03 mmol/l (a range of 5.44 mmol/l), compared to range of 
compared to range of 3.13 mmol/l at baseline (Table 25, Figure 55: Year 1 Subjects CGM Mean Average 
Glucose (mmol/l) 
). 
 
Table 25: Comparison Table: CGM Mean Average Glucose (mmol/l) 
 N Minimum Maximum Mean Std. Deviation 
MEAN Baseline Av Gl 
(mmol/l) 
45 5.27 8.40 6.73 .66 
MEAN Year1 AvGl (mmol/l) 37 5.03 10.47 6.89 1.04 
Valid N 37     
 
 
 
Figure 55: Year 1 Subjects CGM Mean Average Glucose (mmol/l) 
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-CGM Mean Average Glucose for the Year 1 data (n = 37) was 6.89 mmol/l, with a maximum and minimum CGM 
Mean Average Glucose of 10.47 and 5.03 mmol/l (a range of 5.44 mmol/l). 
 
 
 
 
The CGM Mean Average Glucose Excursion from the Average Glucose (mmol/l) for Year 1 data (n = 37) was 
1.15 mmol/l, compared to a lower excursion at baseline of 0.99 mmol/l. The maximum and minimum CGM 
Mean Average Excursion from the Average Glucose was 3.41 and 0.41 mmol/l (a range of 3.0 mmol/l), 
compared to a smaller range of 1.86 mmol/l at baseline (Table 26, Figure 56: Year 1 Subjects CGM Mean 
Average Glucose Excursion from the Average Glucose (mmol/l) 
). 
 
Table 26: Comparison Table: CGM Mean Average Glucose Excursion from the Average Glucose (mmol/l) 
 N Minimum Maximum Mean Std. Deviation 
MEAN Baseline AvGl 
excursion from Av (mmol/l) 
45 .36 2.22 .99 .34 
MEAN Year1 AvGl 
excursion from Av (mmol/l) 
37 .41 3.41 1.15 .58 
Valid N 37     
 
 
 
 
Figure 56: Year 1 Subjects CGM Mean Average Glucose Excursion from the Average Glucose (mmol/l) 
-The CGM Mean Average Glucose Excursion from the Average Glucose (mmol/l) for the Year 1 data (n = 37) was 
1.15 mmol/l, with a maximum and minimum CGM Mean Average Excursion from the Average Glucose of 3.41 and 
0.41 mmol/l (a range of 3.0 mmol/l). 
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The CGM Mean Average Glucose above Normal Glucose (mmol/l) for the Year 1 data (n = 37) was 2.39 
mmol/l, compared to a mean at baseline of 2.23 mmol/l. The maximum and minimum CGM Mean Average 
Glucose above Normal Glucose at Year 1 was 5.97 and 0.53 mmol/l (range of 5.44 mmol/l) compared to a 
reduced range at baseline of 3.13 mmol/l, respectively (Table 27, Figure 57: Year 1 Subjects CGM: Mean 
Average Glucose above Normal Glucose (mmol/l) 
). 
 
Table 27: Comparison Table: CGM Mean Glucose above Normal Glucose (mmol/l)) 
 N Minimum Maximum Mean Std. Deviation 
MEAN Baseline Av above 
norm Gl (mmol/l) 
45 .77 3.90 2.23 .66 
MEAN Year1 Av above 
norm Gl (mmol/l) 
37 .53 5.97 2.39 1.04 
Valid N 37     
 
 
 
 
Figure 57: Year 1 Subjects CGM: Mean Average Glucose above Normal Glucose (mmol/l) 
-The CGM Mean Average Glucose above Normal Glucose (mmol/l) for the Year 1 data (n = 37) was 2.39 mmol/l, 
with a maximum and minimum CGM Mean Average Glucose above Normal Glucose at Year 1 of 5.97 and 0.53 
mmol/l (range of 5.44 mmol/l). 
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The CGM Mean Average Glucose Excursion from Normal Glucose (mmol/l) for the Year 1 data (n = 37) was 
2.70 mmol/l, compared to 2.48 mmol/l at baseline. The maximum and minimum CGM Mean Average Glucose 
Excursion from Normal Glucose was 6.19 and 1.03 mmol/l at Year 1 with a range of 5.16 mmol/l (compared to 
a reduced range of 3.02 mmol/l at baseline) (Table 28, Figure 58: Year 1 Subject CGM: Mean Average 
Glucose Excursion from Normal Glucose (mmol/l) 
). 
 
Table 28: Comparison Table: CGM Mean Average Glucose Excursion from Normal Glucose (mmol/l) 
 N Minimum Maximum Mean Std. Deviation 
MEAN Baseline Av Gl 
excursion from norm Gl 
(mmol/l) 
45 1.03 4.05 2.48 .656 
MEAN Year1 AvGl 
excursion from norm Gl 
(mmol/l) 
37 1.03 6.19 2.70 1.10 
Valid N 37     
 
 
 
 
Figure 58: Year 1 Subject CGM: Mean Average Glucose Excursion from Normal Glucose (mmol/l) 
-The CGM Mean Average Glucose Excursion from Normal Glucose (mmol/l) for the Year 1 data (n = 37) was 2.70 
mmol/l, with a maximum and minimum CGM Mean Average Glucose Excursion from Normal Glucose of 6.19 and 
1.03 mmol/l (range of 5.16 mmol/l). 
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5.1.7 CGM Profiles 
CGM was done on all the subjects at Year 1 (n= 37). Each CGM profile (Sensor Modal 
Day) was then inspected by eye and the profiles were placed in one of three groups, 
according to the “flatness” or “peakiness” of the profile. The three groups were labelled 
least variability, medium variability and most variability. As at baseline, each subject 
CGM profile was then placed into one of these groups following inspection. The CGM 
profiles were inspected blindly by the investigator (CGM profiles SAP) and by an 
independent observer (CGM Profiles PUMP) (the independent observer was a Lead 
Diabetic Specialist Nurse). CGM profiles for each subject at Year 1 can be seen in the 
APPENDIX, as APPENDIX 2: Least Variability; APPENDIX 3 – medium variability 
and APPENDIX 4 – most variability. 
 
Table 29: Year 1 Subjects CGM Profiles (SAP) 
 Frequency % 
Valid 
’non returners’ 8 17.8 
least variability 8 17.8 
medium variability 16 35.6 
most variability 13 28.9 
Total 45 100.0 
 
In Table 29, out of the 45 baseline subjects, n = 8 (17.8%) did not attend at Year 1 and 
were classed as ‘non returners’. One can see that 17.8% (n = 8) of the CGM (SAP) 
profiles were observed to demonstrate least variability, 35.6% (n = 16) were observed to 
demonstrate medium variability and 28.9% (n = 13) were observed to demonstrate most 
variability. These results closely mirrored the independent observer assessment of 
variability (Table 30). 
 
Table 30: Year 1 Subjects CGM Profiles (PUMP) 
 Frequency % 
 
‘non returners’ 8 17.8 
least variability 9 20.0 
medium variability 16 35.6 
most variability 12 26.7 
Total 45 100.0 
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In Table 30, out of the 45 baseline subjects n = 8 (17.8%), did not attend at Year 1 and 
were classed as ‘non returners’. One can see that 20% (n = 9) of the CGM (PUMP) 
profiles were observed to demonstrate least variability, 35.6% (n = 16) were observed to 
demonstrate medium variability and 26.7% (n = 12) were observed to demonstrate most 
variability. These results closely mirrored the investigators assessment of variability. 
 
When this was looked at in more detail, there were two disagreements between 
assessors. The investigator placed one less CGM profile in the least variability category, 
compared to the independent observer (PUMP), who placed the subject in the medium 
category; also the investigator placed one more subject in the most variability category 
compared to the independent observer (PUMP) who placed it in the medium variability 
category; the remainder were identical. 
 
As one was interested in progression to DM (T2DM), one looked at what happened at Year 1 with regard to 
Year 1 with regard to the CGM profiles visually and whether the categories the subjects were places into by 
were places into by eye had any bearing on what the outcome was at year 3. The three subjects that were 
subjects that were illustrated at baseline were IPRO-05a, IPRO-38a and IPRO-06a. At Year 1, these subjects 
Year 1, these subjects were labelled IPRO-05b, IPRO-38b and IPRO-06b, respectively and can be seen 
and can be seen illustrated below (Figure 59: CGM Profile (SAP): Subject IPRO-05b 
, Figure 60: CGM Profile (SAP): Subject IPRO-38b 
 and Figure 61: CGM Profile (SAP): Subject IPRO-06b 
). 
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Figure 59: CGM Profile (SAP): Subject IPRO-05b 
-Sensor Model Day over a 24 hour period, each day represented by as a separate plot line in a different colour. CGM 
profile (SAP) categorised as having medium variability at Year 1. 
 
 
Figure 60: CGM Profile (SAP): Subject IPRO-38b 
-Sensor Model Day over a 24 hour period, each day represented by as a separate plot line in a different colour. CGM 
profile (SAP) categorised as having most variability at Year 1. 
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Figure 61: CGM Profile (SAP): Subject IPRO-06b 
-Sensor Model Day over a 24 hour period, each day represented by as a separate plot line in a different colour. CGM 
profile (SAP) categorised as having most variability at Year 1. 
 
At baseline, IPRO-05 CGM profile (SAP) was categorised as having least variability 
and at Year 1 this had changed to medium variability. However, the OGTT result at 
baseline had not changed and subject IPRO-05 remained IFG+IGT at Year 1. At Year 3, 
IPRO-05 was not a diabetic on FPG testing. At baseline, IPRO-38 CGM profile (SAP) 
was categorised as having medium variability and at Year 1, this had changed to having 
most variability. At baseline and Year 1, subject-38 had IFG and at Year 3 was DM on 
FPG testing. At baseline, IPRO-06 CGM profile (SAP) was categorised as being most 
variable and at Year 3, this remained the case. At baseline subject IPRO-06 had 
IFG+IGT at baseline and was DM (T2DM) at year 1. Just looking at these examples, it 
may be that the CGM profile category at baseline may have a bearing on the outcome. 
 
At Year 1, each of the four CGM parameters described in Section 2.10, were looked at 
with regard to their relationship with the CGM profile groups. As both the Investigator 
(SAP) and the independent observer (PUMP) findings were very similar, with regard to 
the degree of observed glucose variation in the subjects CGM profiles, for the purpose 
of this study, the investigators observations of CGM Profiles (SAP) were used in the 
remaining analysis. As the degree of variability of the subject CGM profiles (SAP) 
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increased from least variability to most variability, the mean of each of the four CGM 
parameters was observed to increase also. 
 
The CGM parameter Mean Year 1 Average Glucose was 5.96 mmol/l for least variability CGM profile (SAP), 
variability CGM profile (SAP), rising to 6.65 mmol/l for medium variability CGM profile (SAP) up to 7.16 
profile (SAP) up to 7.16 mmol/l for most variability CGM profile (SAP) (Figure 62: Summary: Year 1 Subjects 
CGM Parameters v CGM Profiles (SAP) 
). The CGM parameter Mean Year 1 Average Glucose Excursion from Average (mmol/l) was 0.65 mmol/l for 
least variability CGM profile (SAP), rising to 0.97 mmol/l for medium variability CGM profile (SAP) up to 
1.68 mmol/l for most variability CGM profile (SAP) (Figure 62: Summary: Year 1 Subjects CGM Parameters 
v CGM Profiles (SAP) 
). The CGM parameter Mean Year 1 Average Glucose above Normal Glucose (mmol/l) was 1.48 mmol/l for 
least variability CGM profile (SAP), rising to 2.15 mmol/l for medium variability CGM profile (SAP), up to 
3.26  mmol/l for most variability CGM profile (SAP) (Figure 62: Summary: Year 1 Subjects CGM Parameters 
v CGM Profiles (SAP) 
). The CGM parameter Mean Year 1 Average Glucose Excursion from Normal Glucose (mmol/l) was 1.68 
mmol/l for least variability CGM profile (SAP), rising to 2.38 mmol/l for medium variability CGM profile 
(SAP), up to 3.73 mmol/l for most variability CGM profile (SAP) (Figure 62: Summary: Year 1 Subjects CGM 
Parameters v CGM Profiles (SAP) 
). 
 
 
Figure 62: Summary: Year 1 Subjects CGM Parameters v CGM Profiles (SAP) 
-The CGM parameter Mean Year 1 Average Glucose was 5.96 mmol/l for least variability CGM profile (SAP), rising 
to 6.65 mmol/l for medium variability CGM profile (SAP) up to 7.16 mmol/l for most variability CGM profile 
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(SAP). The CGM parameter Mean Year 1 Average Glucose Excursion from Average (mmol/l) was 0.65 mmol/l for 
least variability CGM profile (SAP), rising to 0.97 mmol/l for medium variability CGM profile (SAP) up to 1.68 
mmol/l for most variability CGM profile (SAP). The CGM parameter Mean Year 1 Average Glucose above Normal 
Glucose (mmol/l) was 1.48 mmol/l for least variability CGM profile (SAP), rising to 2.15 mmol/l for medium 
variability CGM profile (SAP), up to 3.26 mmol/l for most variability CGM profile (SAP). The CGM parameter 
Mean Year 1 Average Glucose Excursion from Normal Glucose (mmol/l) was 1.68 mmol/l for least variability CGM 
profile (SAP), rising to 2.38 mmol/l for medium variability CGM profile (SAP), up to 3.73 mmol/l for most 
variability CGM profile (SAP). 
 
At Year 1, each of the four CGM parameters described in Section 2.10, were looked at with regard to their 
with regard to their relationship with the CGM profile groupings. As the degree of variability of the subject 
variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to most 
variability to most variability, the mean of each of the four CGM parameters was observed to increase also, as 
observed to increase also, as seen from the mean plots (Figure 63: Summary: Year 1 Subjects CGM 
Parameters v CGM Profiles (SAP) - Mean Plots 
a-d). The mean plots demonstrated a fairly positive linear correlation for each of these 
graphically, indicating a likely relationship between these two variables. 
 
 
Figure 63: Summary: Year 1 Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average Glucose excursion from normal Glucose (mmol/l) was also 
observed to increase. 
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Figure 63: Summary: Year 1 Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
 
-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average Glucose excursion from normal Glucose (mmol/l) was also 
observed to increase. 
 
 
Figure 63: Summary: Year 1 Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
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-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average Glucose excursion from normal Glucose (mmol/l) was also 
observed to increase. 
 
 
 
Figure 63: Summary: Year 1 Subjects CGM Parameters v CGM Profiles (SAP) - Mean Plots 
 
-As the degree of variability of the subject CGM profiles (SAP) observed by eye, increased from least variability to 
most variability, the mean of MEAN Baseline Average Glucose excursion from normal Glucose (mmol/l) was also 
observed to increase. 
5.1.8 OGTT Results 
At Year 1, 20% (n = 9) of subjects either did not return or refused an OGTT, respectively. These were labelled 
respectively. These were labelled as ‘missing’ on the Table below; (n = 8) did not return and (n = 1) refused a 
and (n = 1) refused a repeat OGTT. The OGTT outcome at Year 1 for all subjects (n = 36), taking into account 
36), taking into account those who did not return, demonstrated 22.5% (n = 10) subjects had IFG, 15.6% (n = 
had IFG, 15.6% (n = 7) subjects had both IFG and IGT, 11.1% (n = 5) subjects had IGT and 15.6% (n = 7) 
and 15.6% (n = 7) had progressed to DM (T2DM) (Table 31; Figure 64: Year 1 Subjects OGTT Outcome 
). 
 
Table 31: MIX Year 1 OGTT Result 
 Frequency % 
 
‘Missing’ 9 20.0 
DM 7 15.6 
IFG 10 22.2 
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IFG+IGT 7 15.6 
IGT 5 11.1 
NGT 7 15.6 
Total 45 100.0 
 
 
 
Figure 64: Year 1 Subjects OGTT Outcome 
- The OGTT outcome at Year 1 for all subjects (n = 36), taking into account those who did not return (the cream bar) 
demonstrated 22.2% (n = 10) subjects had IFG, 15.6% (n = 7) subjects had both IFG and IGT, 11.1% (n = 5) subjects 
had IGT and 15.6% (n = 7) had progressed to DM (T2DM). 
If one looked at OGTT outcome at Year 1 (n = 36), for female gender, after taking into account those who did 
not return, 31.6% (n = 6) had IFG, 15.8% (n = 3) had IFG+IGT, 10.5% (n = 2) had IGT, 0% had DM (T2DM) 
and 10.5% (n = 2) had NGT (normal glucose tolerance). If OGTT outcome at Year 1 was looked at for male 
gender, after taking into account those who did not return, 15.4% (n = 4) of the male gender had IFG, 15.4% 
(n = 4) had IFG+IGT, 11.5% (n = 3) had IGT and 4.4% (n = 5) had NGT. Approximately 1/3 of the male 
gender at Year 1 had progressed to DM (T2DM) [26.9% (n = 7). Further analysis of this data demonstrated 
that 60% of females had IFG versus 40% of males, 42.9% of females had IFG+IGT versus 57.1% of males, 
40% of females had IGT versus 60% of males and 28.6% females had NGT versus 57.8% males. Interestingly, 
100% males were found to have progressed to having DM (T2DM) at Year 1 (Figure 65: MIX Year 1 OGTT 
Outcome: Gender 
); no females had. 
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Figure 65: MIX Year 1 OGTT Outcome: Gender 
-The OGTT outcome at Year 1 (n = 36), for female gender, taking into account those who did not return (cream bar), 
31.6% (n = 6) had IFG, 15.8% (n = 3) had IFG+IGT, 10.5% (n = 2) had IGT, 0% had DM (T2DM) and 10.5% (n = 2) 
had NGT (normal glucose tolerance). If OGTT outcome at Year 1 was looked at for male gender, taking into account 
those who did not return (cream bar), 15.4% (n = 4) of the male gender had IFG, 15.4% (n = 4) had IFG+IGT, 11.5% 
(n = 3) had IGT and 4.4% (n = 5) had NGT. 
 
 
 
 
 
If one looked at OGTT outcome at Year 1 for ethnicity, out of the (n = 41) Caucasians subjects at baseline, 
17.1% (n = 7) did not return or refused repeat OGTT at Year 1; 22% (n = 9) had IFG, 17.1% (n = 7) had IFG 
+ IGT, 12.2 % (n = 5) had IGT, 17.1% (n = 7) had DM (T2DM) and 14.6% (n = 6) had NGT. With regard to (n 
= 4) Non Caucasian subjects at baseline, 50% (n = 2) of them did not return for repeat OGTT at Year 1; 25% 
(n = 1) had IFG, 0% had IFG+IGT, IGT and DM (T2DM) and 25% (n = 1) had NGT. Further analysis of this 
data demonstrated that 90% of Caucasians versus 10.0% of Non Caucasians had IFG, 100% of Caucasians 
versus 0% of Non Caucasians had IFG +IGT, IGT and DM (T2DM) respectively and 85.7% Caucasians 
versus 14.3% Non Caucasians had NGT. In this study, only Caucasians were seen to progress to DM (T2DM) 
at Year 1, but the numbers of non-Caucasians in this study group were very small, and this may be the reason 
for this (Figure 66: MIX Year 1 OGTT Outcome: Ethnicity 
). 
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Figure 66: MIX Year 1 OGTT Outcome: Ethnicity 
-The OGTT outcome at Year 1 for ethnicity, out of the (n = 41) Caucasians subjects at baseline, 17.1% (n = 7) did not 
return or refused repeat OGTT at Year 1 (cream bar); 22% (n = 9) had IFG, 17.1% (n = 7) had IFG + IGT, 12.2 % (n 
= 5) had IGT, 17.1% (n = 7) had DM (T2DM) and 14.6% (n = 6) had NGT. With regard to (n = 4) Non Caucasian 
subjects at baseline, 50% (n = 2) of them did not return for repeat OGTT at Year 1 (cream bar); 25% (n = 1) had IFG, 
0% had IFG+IGT, IGT and DM (T2DM) and 25% (n = 1) had NGT. 
 
 
 
 
If one looked at OGTT outcome for subjects at Year 1 with regard to FHx of DM, (n = 9) subjects did not 
return or refused OGTT repeat at Year 1: (n = 5) of these had a FHx of DM and (n = 4) of these did not. Of the 
subjects with a FHx of DM and did not return for testing at Year 1, 10% (n = 2) had IFG, 20% (n = 4) had 
IFG+IGT, 10% (n = 2) had IGT, 20% (n = 4) had DM (T2DM) and 15% (n = 3) had NGT. Of those subjects 
who did not have a FHx of DM and did not return for testing at Year 1, 32% (n = 8) had IFG, 12% (n = 3) had 
IFG+IGT, 12% (n = 3) had IGT, 12% (n = 3) had DM (T2DM) and 16% (n = 4) had NGT. Further analysis of 
this data demonstrated that of those subjects that had IFG, 80% had no FHx of DM versus 20% that did. Of 
those subjects that had IFG+IGT, 42.9% did not have a FHx of DM while 57.1% did. Of those subjects that 
had IGT, 60% did not have a FHx of DM while 40% of them did. Of those subjects with DM (T2DM), 57.1% 
DM (T2DM), 57.1% did have a FHx of DM and 42.9% did not (Figure 67: MIX OGTT Year 1 Outcome: FHx 
). Of those subjects that had NGT, 42.9% did have FHx of DM and 57.1% did not. In 
this study, subjects found to be diabetic (T2DM) at Year 1, seemed to have a marginally 
increased presence of a FHx of DM. 
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Figure 67: MIX OGTT Year 1 Outcome: FHx 
-The OGTT outcome for subjects at Year 1 with regard to FHx of DM, (n = 9) subjects did not return or refused 
OGTT repeat at Year 1 (cream bar): (n = 5) of these had a FHx of DM and (n = 4) of these did not. Of the subjects 
with a FHx of DM and did not return for testing at Year 1, 10% (n = 2) had IFG, 20% (n = 4) had IFG+IGT, 10% (n 
= 2) had IGT, 20% (n = 4) had DM (T2DM) and 15% (n = 3) had NGT. Of those subjects who did not have a FHx of 
DM and did not return for testing at Year 1, 32% (n = 8) had IFG, 12% (n = 3) had IFG+IGT, 12% (n = 3) had IGT, 
12% (n = 3) had DM (T2DM) and 16% (n = 4) had NGT. 
 
If one looked at OGTT outcome for subjects at Year 1 with regard to BMI, (n = 9) subjects did not return or 
refused OGTT repeat at Year 1. If one looked at OGTT outcome for subjects at Year 1 (n = 37) with regard to 
BMI, of those subjects that had a normal BMI (n= 3), 33.3% (n = 1) had IFG, 33.3% (n = 1) had IGT and 
33.3% (n = 1) had DM (T2DM). Of those subjects that were overweight (n = 8), 12.5% (n = 1) had IFG, 25% (n 
= 2) had IFG+IGT and 12.5% (n= 1) had IGT, 12.5% (n = 1) had DM (T2DM) and 37.5% (n = 3) had NGT. Of 
those subjects who were classed as obese (n = 26), 30.8% (n = 8) had IFG, 19.2% (n = 5) had IFG+IGT, 11.5% 
(n = 3) had IGT, 19.2% (n = 5) had DM (T2DM) and 15.4% (n = 4) had NGT; (n = 1) subject refused to be 
weighed at Year 1, but was obese at baseline. Interestingly, the IFG group demonstrated most obese subjects 
at Year 1. Further analysis of subjects at Year 1 demonstrated that of those with IFG, 10% had a normal 
BMI, 10% were overweight and 80% were classed as obese. Of those subjects with IFG+IGT, 0% had a 
normal BMI, 28.6% were overweight and 71.4% were classed as obese. Of those subjects with IGT, 20% had a 
normal BMI, 20% were overweight and 60% were classed as obese. Of those subjects with DM (T2DM) 14.3% 
had normal BMI, 14.3% were overweight and 71.4% were classed as obese. Of those subjects with NGT, 0% 
had a normal BMI, 42.9% were overweight and 57.1% were classed as obese (Figure 68: MIX OGTT Year 1 
Outcome: BMI 
). 
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Figure 68: MIX OGTT Year 1 Outcome: BMI 
-The OGTT outcome for subjects at Year 1 with regard to BMI, (n = 9) subjects did not return or refused OGTT 
repeat at Year 1. If one looked at OGTT outcome for subjects at Year 1 (n = 37) with regard to BMI, of those subjects 
that had a normal BMI (n= 3), 33.3% (n = 1) had IFG, 33.3% (n = 1) had IGT and 33.3% (n = 1) had DM (T2DM). 
Of those subjects that were overweight (n = 8), 12.5% (n = 1) had IFG, 25% (n = 2) had IFG+IGT and 12.5% (n= 1) 
had IGT, 12.5% (n = 1) had DM (T2DM) and 37.5% (n = 3) had NGT. Of those subjects who were classed as obese 
(n = 26), 30.8% (n = 8) had IFG, 19.2% (n = 5) had IFG+IGT, 11.5% (n = 3) had IGT, 19.2% (n = 5) had DM 
(T2DM) and 15.4% (n = 4) had NGT. 
If one looked at OGTT outcome for subjects at Year 1 with regard to smoking status overall, (n = 9) subjects 
did not return or refused OGTT repeat at Year 1. If one looked at OGTT outcome for subjects at Year 1 (n = 
36) with regard to smoking status, of those subjects that smoked and taking into account those subjects who 
smoked and did not return at Year 1, 16.7% (n = 1) had IFG, 16.7% (n = 1) had IFG+IGT, 0% had IGT, 
16.7% (n = 1) had DM (T2DM) and 16.7% (n = 1) had NGT. Of those subjects that did not smoke and taking 
not smoke and taking into account those subjects who did not smoke and did not return at Year 1, 29% (n = 9) 
at Year 1, 29% (n = 9) had IFG, 12.9% (n = 4) had IFG+IGT, 16.1% (n = 5) had IGT, 19.4% (n = 6) had DM 
19.4% (n = 6) had DM (T2DM) and 12.9% (n = 4) had NGT. Of those subjects that were ex-smokers 0% had 
were ex-smokers 0% had IFG, IGT and DM (T2DM) respectively, 25% (n = 2) had IFG+IGT and 25% (n = 2) 
IFG+IGT and 25% (n = 2) had NGT. Further analysis of subjects at Year 1 demonstrated that of those 
demonstrated that of those subjects with IFG, 90% were non smokers and 10% were smokers; there were no 
smokers; there were no ex- smokers. Of those subjects with IFG+IGT, 57.1% were non smokers, 14.3% were 
smokers, 14.3% were smokers and 28.6% were ex-smokers. Of those subjects with IGT, 100% were non 
100% were non smokers. What was encouraging here, was that of those subjects with DM (T2DM) 87.5% 
DM (T2DM) 87.5% were non smokers and .of those subjects with NGT, 57.1% were non smokers, 14.3% were 
non smokers, 14.3% were smokers and 28.6% were ex-smokers (Figure 69: MIX OGTT Year 1 Outcome: 
Smoking Status 
). 
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Figure 69: MIX OGTT Year 1 Outcome: Smoking Status 
-The OGTT outcome for subjects at Year 1 with regard to smoking status, (n = 9) subjects did not return or refused 
OGTT repeat at Year 1 (cream bar). Of those subjects that smoked and taking into account those subjects who 
smoked and did not return at Year 1, 16.7% (n = 1) had IFG, 16.7% (n = 1) had IFG+IGT, 0% had IGT, 16.7% (n = 
1) had DM (T2DM) and 16.7% (n = 1) had NGT. Of those subjects that did not smoke and taking into account those 
subjects who did not smoke and did not return at Year 1, 29% (n = 9) had IFG, 12.9% (n = 4) had IFG+IGT, 16.1% 
(n = 5) had IGT, 19.4% (n = 6) had DM (T2DM) and 12.9% (n = 4) had NGT. Of those subjects that were ex-
smokers 0% had IFG, IGT and DM (T2DM) respectively, 25% (n = 2) had IFG+IGT and 25% (n = 2) had NGT. 
If one looked at OGTT outcome for subjects at Year 1 with regard to hypertension, (n = 9) subjects did not 
return or refused repeat OGTT at Year 1. If one looked at OGTT outcome for subjects at Year 1 with a 
history of hypertension and taking into account the non returners at Year 1 with a history of hypertension at 
baseline, 19.4% (n = 6) had IFG, 16.1% (n = 5) had IFG+IGT, 12.9% (n = 4) had IGT, and 19.4% (n = 6) had 
both DM (T2DM) and NGT respectively. Of those subjects who had hypertension at baseline, (n = 4) did not 
return at Year 1. Of those subjects who did not have hypertension at Year 1 and taking into account the non 
returners who did not have hypertension at baseline, 28.6% (n = 4) had IFG, 14.3% (n = 2) had IFG+IGT, 
7.1% (n = 1) had IGT, DM (T2DM) and NGT, respectively. Further analysis of subjects at Year 1 
demonstrated that of those subjects with IFG, 60% had hypertension and 40% did not. Of those subjects that 
had IFG+IGT, 71.4% did have hypertension and 28.6% did not. Of those subjects that had IGT, 80% had 
hypertension compared to 20% who did not. Interestingly, 85.7% of the subjects at Year 1 found to have 
progressed to DM (T2DM) had hypertension, while in those subjects who had reverted to NGT 14.3% of them 
had hypertension (Figure 70: MIX OGTT Year 1 Outcome: Hypertension 
). 
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Figure 70: MIX OGTT Year 1 Outcome: Hypertension 
-The OGTT outcome for subjects at Year 1 with regard to hypertension, (n = 9) subjects did not return or refused 
repeat OGTT at Year 1 (cream bar). If one looked at OGTT outcome for subjects at Year 1 with a history of 
hypertension and taking into account the non returners at Year 1 with a history of hypertension at baseline, 19.4% (n 
= 6) had IFG, 16.1% (n = 5) had IFG+IGT, 12.9% (n = 4) had IGT, and 19.4% (n = 6) had both DM (T2DM) and 
NGT respectively. Of those subjects who did not have hypertension at Year 1 and taking into account the non 
returners who did not have hypertension at baseline, 28.6% (n = 4) had IFG, 14.3% (n = 2) had IFG+IGT, 7.1% (n = 
1) had IGT, DM (T2DM) and NGT, respectively. 
 
If one looked at OGTT outcome for subjects at Year 1 with regard to lipid status, (n = 9) subjects did not 
return or refused repeat OGTT at Year 1. If one looked at OGTT outcome for subjects at Year 1 with regard 
to lipid status, of those subjects that had dyslipidemia, 19% (n = 4) had IFG, 14.3% (n = 3) had both IFG+IGT 
and IGT, respectively; 9.5% (n = 2) had DM (T2DM) and 19% (n = 4) had NGT. Of those subjects that did not 
return for Year 1 assessment, (n = 5) had dyslipidemia and (n = 4) did not; these values were taken into 
account in the calculations. Of those subjects that did not have dyslipidemia, 25% (n = 6) had IFG, 16.7% (n = 
4) had IFG+IGT, 8.3% (n = 2) had IGT, 20.8% (n = 5) had DM (T2DM) and 12.5% (n = 3) had NGT. Further 
analysis of subjects demonstrated that of those subjects with IFG, 40% had dyslipidemia and 60% did not. Of 
and 60% did not. Of those subjects that had IFG+IGT, 42.9% had dyslipidemia and 57.1% did not. Of those 
57.1% did not. Of those subjects that had IGT, 60% had dyslipidemia and 40% did not. In the group of 
In the group of subjects that that had progressed to DM (T2DM), a third of them had dyslipidemia. 
dyslipidemia. Interestingly, of those subjects that had NGT, 57.1% had dyslipidemia and 42.9% did not 
and 42.9% did not (Figure 71: MIX OGTT Year 1 Outcome: Dyslipidemia 
). 
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Figure 71: MIX OGTT Year 1 Outcome: Dyslipidemia 
-The OGTT outcome for subjects at Year 1 with regard to lipid status, (n = 9) subjects did not return or refused repeat 
OGTT (cream bar). If one looked at OGTT outcome for subjects at Year 1 with regard to lipid status, of those 
subjects that had dyslipidemia, 19% (n = 4) had IFG, 14.3% (n = 3) had both IFG+IGT and IGT, respectively; 9.5% 
(n = 2) had DM (T2DM) and 19% (n = 4) had NGT. Of those subjects that did not return for Year 1 assessment, (n = 
5) had dyslipidemia and (n = 4) did not; these values were taken into account in the calculations. Of those subjects 
that did not have dyslipidemia, 25% (n = 6) had IFG, 16.7% (n = 4) had IFG+IGT, 8.3% (n = 2) had IGT, 20.8% (n = 
5) had DM (T2DM) and 12.5% (n = 3) had NGT. 
 
 
5.1.9 Blood Assay Analysis: Glucose Biomarkers 
As already discussed, an attempt was made to identify any biomarkers that predict 
progression from abnormal glucose tolerance to T2DM. Therefore, for each study 
subject that attended Year 1 follow up, biomarkers of beta cell function C-peptide and 
Insulin were assayed in the fasting state, as described by Varvel et al (2014) (40) (Table 
32); GAD Antibody was also tested at this time. This aspect of the study ideally would 
have been conducted at baseline, however, the original ethical approval didn’t include 
this and so in order to look at these parameters, further ethical approval was sought via 
an amendment, which allowed this to occur at Year 1. 
 
Table 32: Analysis: GAD Ab, Insulin and C- Peptide 
 GAD Ab 
(U/ml) 
Insulin (pmol/L) C-peptide 
(pmol/ml 
N 
 36 36 36 
Non 
returners  
9 9 9 
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Mean 0.96 118.22 0.58 
Std. Deviation 0.52 57.92 0.27 
Range 2.10 193.80 1.17 
Minimum 0.30 33.80 0.05 
Maximum 2.40 227.60 1.22 
 
At Year 1, the mean level of GAD Ab in the (n = 36) fasted subjects was 0.96 u/ml. The 
maximum level was 2.40 U/ml and the minimum level was 0.30 U/ml. This gave a 
range of 2.10 U/ml and a Std Dev of 0.52. Given all of the subjects had GAD Ab levels 
< 5 U/ml (69), none of the subjects demonstrated serological marker positivity for 
LADA or T1DM (Table 32). 
 
At Year 1, the mean level of Insulin in the (n = 36) fasted subjects was 118.22 pmol/L. 
The maximum level was 227.6 pmol/L and the minimum level was 33.8 pmol/L, which 
gave a range of 193.8 pmol/L and a Std Dev of 57.92 (Table 32). As biochemically, the 
mean level of Insulin in the subjects tested at Year 1 was above 100 pmol/L (the 
reference range of fasting plasma for this test was 6 - 100 pmol/L) (72), it’s possible 
that this reflected a concurrent increase in insulin production and blood glucose levels in 
the subjects tested and thus could be used as a marker to assist diagnosing early T2DM. 
 
At Year 1, the mean level of fasting C-peptide in the (n = 36) subjects was 0.58 
pmol/ml. The maximum level was 1.22 pmol/ml and the minimum level was 0.05 
pmol/ml. This gave a range of 1.17 pmol/ml and a Std Dev of 0.27 pmol/ml (Table 32). 
In theory, a high fasting blood sugar with a high C-peptide value should point to T2DM 
primarily caused by insulin resistance. That is because the high C-peptide value would 
suggest a lot of insulin was being produced but insulin resistance was keeping it from 
lowering blood sugar. The fact that the maximum fasting C-peptide observed in the 
Year 1 subjects was above the reference range, could suggest the presence of insulin 
resistance (71). 
 
5.2 Analysing Progression Data 
5.2.1 Analysing Data 
Since a number of the most common statistical tests rely on the normality of a sample or 
population, it is often useful to test whether the underlying distribution is normal, or at 
least symmetric. In order to proceed with a statistical analysis of the results in this 
study, the distribution of data was looked at. In this study, there was a screening 
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population and the study sample, which came from the screening population. 
Technically, one assumed that the distribution of the study sample mean was normal. In 
order to check this assumption, the population data and the sample data was looked at in 
more detail. In SPSS, the general trend of the data distribution was visually inspected 
for normality; the frequency distribution (histogram) and the P-P plot (probability-
probability plot) were also used for checking this, as described by Ghasemi et al (2010) 
(77). 
Ideally, data should be distributed symmetrically around a centre point i.e. be normally 
distributed. In SPSS the P-P plot plotted the cumulative probability of a variable against 
the cumulative probability of a particular distribution (e.g. normal distribution). After 
data were ranked and sorted, the corresponding z-score was calculated for each rank 
(this is the expected value that the score should have in a normal distribution). The 
scores were then themselves converted to z-scores and the actual z-scores were plotted 
against the expected z-scores, as described by Ghasemi et al (2010) (77). 
For the screening population, the data appeared to be distributed symmetrically, around the centre of all 
the centre of all scores in a bell shape and therefore graphically, the screening population appeared to be 
population appeared to be normally distributed for age (age being the parameter uniform to the screening 
to the screening population) (Figure 72: The Normality of Age in the Screening Population 
). With regard to the P-P plot for age in the screening population, as the result demonstrated a straight 
diagonal line, it was proposed that this data was normally distributed (Figure 73: P-P Plot of Normality in the 
Screening Population by Age 
). 
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Figure 72: The Normality of Age in the Screening Population 
-In the screening population (n = 484), the mean age was 58.38 years (X axis) and the range was 18.49 – 90.47 years. 
Visually, the screened data set followed a bell shaped distribution i.e. was normally distributed. 
 
 
Figure 73: P-P Plot of Normality in the Screening Population by Age 
-In the screening population (n = 484) the mean was 58.38 years and the range was 18.49 – 90.47 years. Visually, the 
screened data set appeared to follow a fairly straight line and therefore, it was proposed that this data was normally 
distributed; (*Cum Prob = Cumulative Probability). 
For the sample population, a number of parameters were looked at to assess for normality visually: baseline 
age (years), baseline OGTT 0 mins (mmol/l), baseline OGTT 120 mins (mmol/l), baseline HbAlc (mmol/l), 
mean baseline Av Gl (mmol/l). For each of these parameters, the data appeared to be distributed fairly 
symmetrically, around the centre of all scores in a bell shape and therefore graphically, the sample population 
appeared to be normally distributed for these parameters, as can be seen below ( 
Figure 74: Normality in the Sample Population 
). 
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Figure 74: Normality in the Sample Population 
-Visually, the sample data set follow a bell shaped distribution i.e. was normally distributed for each of the five 
parameters investigated ie. Age (years), OGTT: FPG [0 mins] (mmol/l), OGTT 2 hour Glucose [120 mins] 
(mmol/l), HbA1c (mmol/mol) and Mean Average Glucose (mmol/l). 
 
P-P plots were then constructed for the above parameters from the sample population. 
As can be seen from (Figure 75), (Figure 76), (Figure 77), (Figure 78) and (Figure 79) 
the result demonstrated fairly straight diagonal line, it was therefore proposed that this 
data was normally distributed. 
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Figure 75: P-P Plots in the Sample Population at Baseline: Age 
Error! Reference source not found. (*Cum Prob = Cumulative Probability). 
 
 
 
Figure 76: P-P Plots in the Sample Population at Baseline: FPG 
Error! Reference source not found. (*Cum Prob = Cumulative Probability). 
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Figure 77: P-P Plots in the Sample Population at Baseline: 2 hr OGTT 
-Error! Reference source not found. (*Cum Prob = Cumulative Probability). 
 
 
 
 
Figure 78: P-P Plots in the Sample Population at Baseline: HbA1c 
Error! Reference source not found.(*Cum Prob = Cumulative Probability). 
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Figure 79: P-P Plots in the Sample Population at Baseline: Mean Average Glucose 
-Visually, the data set appeared to follow a fairly straight line and therefore, it was proposed that this data was 
normally distributed for mean baseline average glucose (*Cum Prob = Cumulative Probability). 
 
 
5.2.2 Comparing Means – Paired Sample t-Test (Dependent t-Test) 
Assuming the data were normally distributed, as the same subjects were tested at 
different time intervals (baseline, Year 1 and Year 3), the paired sample t-test (or 
dependent t-test) was used to compare differences in two means of the set parameters, 
as the study progressed in time. The means of the following 17 pairs of samples, at 
specific time intervals (stated below) were tested. 
 
A table of summary statistics for the two experimental conditions was demonstrated for 
each pair tested [pair 1 - 17]. For each condition, the mean, the number of participants 
(N), the Std Dev of the sample and the standard error (i.e. the standard deviation divided 
by the square root of the sample size) was seen (Table 33). 
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Pair 1  Baseline weight (Kg) with Year 1 weight (Kg) 
 
Pair 2  Baseline weight (Kg) with Year 3 weight (Kg) 
 
Pair 3  Year 1 weight (Kg) with Year 3 weight (Kg) 
 
Pair 4  Baseline BMI (Kg/m2) with Year 1 BMI (Kg/m2) 
 
Pair 5  Baseline BMI (Kg/m2) with Year 3 BMI (Kg/m2) 
 
Pair 6  Year 1 BMI (Kg/m2) with Year 3 BMI (Kg/m2) 
 
Pair 7  Baseline OGTT 0 mins (mmol/l) with Year 1 OGTT 0 mins (mmol/l) 
 
Pair 8  Baseline OGTT 0 mins (mmol/l) with Year 3 FPG 0 mins (mmol/l) 
 
Pair 9  Year 1 OGTT 0 mins (mmol/l) with Year 3 FPG 0 mins (mmol/l) 
 
Pair 10  Baseline OGTT 2 hours (mmol/l) with Year 1 OGTT 2 hours (mmol/l) 
 
Pair 11  Baseline HbA1c (mmol/mol) with Year 1 HbA1c (mmol/mol) 
 
Pair 12  Baseline HbA1c (mmol/mol) with Year 3 HbA1c (mmol/mol) 
 
Pair 13  Year 1 HbA1c (mmol/mol) with Year 3 HbA1c (mmol/mol) 
 
Pair 14 Mean Baseline Average Glucose (mmol/l) with Mean Year 1 Average 
Glucose (mmol/l) 
 
Pair 15 Mean Baseline Average Glucose Excursion (mmol/l) from Average with 
Mean Year 1 Average Glucose Excursion from Average (mmol/l) 
 
Pair 16 Mean Baseline Average above Normal Glucose (mmol/l) with Mean 
Year 1 Average above Normal Glucose (mmol/l) 
 
Pair 17 Mean Baseline Average Glucose Excursion from Normal Glucose 
(mmol/l) with Mean Year 1 Average Glucose Excursion from Normal 
Glucose (mmol/l) 
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Table 33: Paired t-Tests: Paired Sample Statistics 
VARIABLES Mean N Std. Deviation Std. Error 
Mean 
Pair 1 
Baseline Weight 96.85 37 20.66 3.39 
Year 1 Weight 97.37 37 20.06 3.29 
Pair 2 
Baseline Weight 94.47 38 21.30 3.45 
Year 3 Weight 94.61 38 22.26 3.61 
Pair 3 
Year 1 Weight 97.05 34 20.66 3.54 
Year 3 Weight 96.59 34 22.20 3.80 
Pair 4 
Baseline BMI 33.25 37 6.53 1.07 
Year 1 BMI 33.48 37 6.49 1.06 
Pair 5 
Baseline BMI 32.53 38 6.69 1.08 
Year 3 BMI 32.54 38 6.93 1.12 
Pair 6 
Year 1 BMI 33.37 34 6.77 1.16 
Year 3 BMI 33.13 34 7.03 1.20 
Pair 7 
Baseline OGTT 0 mins 6.27 36 .44 .073 
Year 1 OGTT 0 mins 6.24 36 .710 .11 
Pair 8 
Baseline OGTT 0 mins 6.25 37 .48 .079 
Year 3 FPG 6.96 37 1.83 .30 
Pair 8 
Year 1 OGTT 0 mins 6.23 32 .75 .13 
Year 3 FPG 6.94 32 1.91 .33 
Pair 10 
Baseline OGTT 120 mins 7.74 36 1.88 .31 
Year 1 OGTT 120mins 8.04 36 2.06 .34 
Pair 11 
Baseline HbAlc 44.03 33 4.01 .69 
Year 1 HbAlc 45.12 33 4.89 .85 
Pair 12 
Baseline HbAlc 44.00 34 3.89 .66 
Year 3 HbA1c 48.08 34 12.35 2.11 
Pair 13 
Year 1 HbAlc 45.41 34 4.82 .82 
Year 3 HbA1c 47.94 34 12.27 2.10 
Pair 14 
MEAN BL Av Gl 6.72 37 .68 .11 
MEAN Y1 AvGl 6.89 37 1.04 .17 
Pair 15 
MEAN BL AvGl exc from Av 1.01 37 .36 .06 
MEAN Y1 AvGl exc from Av 1.15 37 .58 .09 
Pair 16 
MEAN BL Av above norm Gl 2.22 37 .68 .11 
MEAN Y1 Av above norm Gl 2.39 37 1.04 .17 
Pair 17 
MEAN BL Av Gl exc from norm Gl 2.48 37 .66 .11 
MEAN Y1 AvGl exc from norm Gl 2.70 37 1.10 .18 
 
A summary of paired samples tested was also demonstrated. The Null Hypothesis in 
this instance was that there was no significant difference (i.e. no variation) between 
specified variables in each pair. For example, regarding PAIR 1- weight, the Null 
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Hypothesis would be that there was no significant difference in the mean weight 
observed at baseline compared to the mean weight observed at Year 1. 
 
For each pair, the mean differences between the scores were demonstrated, together 
with the Std Dev of the differences between the means and also the standard error (Std 
Err) of the differences between scores within each pair. The test statistic t was then 
obtained for each pair by dividing the mean of differences by the Std Err of differences. 
The size of the t was then compared against known values based on degrees of freedom 
(i.e. sample size -1). SPSS 20, used the degrees of freedom to calculate the exact 
probability that a value of t was big as the one obtained could occur if the Null 
Hypothesis were true (i.e. no difference between the means tested). In this instance, the 
two-tailed probability was demonstrated (the probability when no prediction was made 
about the direction of differences). In this test, at 95% Confidence Interval (CI), a 
p<0.05 was classed as statistically meaningful and significant and the Null Hypothesis 
was rejected at this point. 
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Table 34: T Tests: Paired Differences 
VARIABLES Paired Differences T Df Sig. (2-
tailed) Mean Std. 
Dev 
Std. 
Err 
Mean 
95% CI of the 
Difference 
Lower Upper 
Pair 1 
Baseline Weight - Year 1 
Weight 
-.52 5.59 .91 -2.38 1.34 -.56 36 .57 
Pair 2 
Baseline Weight - Year 3 
Weight 
-.13 5.56 .90 -1.96 1.69 -.14 37 .88 
Pair 3 
Year 1 Weight - Year 3 
Weight 
.45 6.78 1.16 -1.91 2.82 .39 33 .69 
Pair 4 Baseline BMI - Year 1 BMI -.22 1.95 .32 -.88 .421 -.71 36 .48 
Pair 5 Baseline BMI - Year 3 BMI -.01 2.02 .32 -.67 .65 -.03 37 .97 
Pair 6 Year 1 BMI - Year 3 BMI .23 2.43 .41 -.61 1.08 .57 33 .57 
Pair 7 
Baseline OGTT 0 mins - 
Year 1 OGTT 0 mins 
.036 .61 .10 -.17 .24 .35 35 .72 
Pair 8 
Baseline OGTT 0 mins - 
Year 3 FPG 
-.71 1.77 .29 -1.30 -.12 -2.44 36 .02 
Pair 9 
Year 1 OGTT 0 mins - 
Year 3 FPG 
-.71 1.74 .30 -1.34 -.08 -2.32 31 .02 
Par 
10 
Baseline OGTT 120 mins - 
Year 1 OGTT 120mins 
-.29 2.02 .33 -.98 .38 -.88 35 .38 
Pair 
11 
Baseline HbAlc - Year 1 
HbAlc 
-1.09 5.03 .87 -2.87 .69 -1.24 32 .22 
Pair 
12 
Baseline HbAlc - Year 3 
HbA1c 
-4.08 11.82 2.02 -8.21 .03 -2.01 33 .05 
Pair 
13 
Year 1 HbAlc - Year 3 
HbA1c 
-2.52 11.82 2.02 -6.65 1.59 -1.24 33 .22 
Pair 14 
MEAN Baseline Av Gl - 
MEAN Year1 AvGl 
-.16 .835 .13 -.44 .11 -1.21 36 .23 
Pair 15 
MEAN Baseline AvGl 
excursion from Av - MEAN 
Year1 AvGl excursion 
from Av 
-.14 .62 .10 -.35 .068 -1.36 36 .18 
Pair 
16 
MEAN Baseline Av above 
norm Gl - MEAN Year1 Av 
above norm Gl 
-.16 .83 .13 -.44 .11 -1.21 36 .23 
Pair 
17 
MEAN Baseline Av Gl 
excursion from norm Gl  - 
MEAN Year1 AvGl 
excursion from norm Gl 
-.21 .90 .14 -.51 .08 -1.43 36 .15 
 
Results were as follows: 
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PAIR 1: (M 96.85, SE 3.397) t(36) = -0.56, p >0.05 (0.574). There is a 57.3% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted.  
PAIR 2: (M 94.47, SE 3.456) t(37) = -0.149, p >0.05 (0.883). There is an 88.3% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 3: (M 97.05, SE 3.544) t(33) = 0.393, p >0.05 (0.697). There is a 69.7% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 4: (M 33.25, SE 1.074) t(36) = -0.714, p >0.05 (0.480). There is a 48% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 5: (M 32.53, SE 1.086) t(37) = -0.037, p >0.05 (0.971). There is a 97.1% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 6: (M 33.37, SE 1.160) t(33) = 0.570, p >0.05 (0.573). There is a 57.3% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. Therefore, for weight and BMI, there was no significant difference between 
the means of these parameters at baseline, Year 1 or Year 3, as the study progressed 
with time to its outcome (PAIRS 1-6). 
PAIR 7: (M 6.27, SE 0.073) t(35) = 0.350, p >0.05 (0.728). There is a 72.8% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 8: (M 6.25, SE 0.790) t(36) = -2.44, p <0.05 (0.020). There is a 2% chance that 
this could happen if the Null Hypothesis was true. The Null Hypothesis was rejected, as 
there was a significant difference between the FPG at baseline and Year 3, with a 95% 
CI of -1.3 to -1.2. This indicated the boundaries within which the true mean difference 
lay and the fact that this interval did not contain a zero meant the true value of the mean 
difference was unlikely to be zero. 
PAIR 9: (M 6.23, SE 0.132) t(31) = -2.32, p <0.05 (0.027). There is a 2.7% chance that 
this could happen if the Null Hypothesis was true. The Null Hypothesis was rejected, as 
there was a significant difference between the FPG at Year 1 (OGTT) and Year 3, with 
a 95% CI of -1.34 to -0.86. This indicated the boundaries within which the true mean 
difference lay and the fact that this interval did not contain a zero meant the true value 
of the mean difference was unlikely to be zero. This demonstrated that a significant 
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difference was seen for between the means of FPG at baseline and Year 3 and also at 
Year 1 and Year 3, as the subjects progressed through the study with time. The 
difference between the mean FPG at baseline and Year 1 was not significant (PAIRS 7-
9). 
PAIR 10: (M 7.74, SE 0.313) t(35) = -0.881, p >0.05 (0.385). There is a 38.5% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. This demonstrated at baseline and Year 1, there was no significant difference 
between the means at 2hr OGTT as the study progressed with time (PAIR 10). 
PAIR 11: (M 44.03, SE 0.698) t(32) = -1.24, p >0.05 (0.223). There is a 22.3% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 12: (M 44.00, SE 0.667) t(33) = -2.016, p >0.05 (0.052). There is a 5.2% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. This pairing, between the HbA1c at baseline and Year 3 was almost 
significant. 
PAIR 13: (M 45.41, SE 0.827) t(33) = -1.24, p >0.05 (0.221). There is a 22.1% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. This demonstrated that the mean of the HbA1c at baseline and Year 3 
approached the significance level to be different, but the HbA1c means at baseline and 
Year 1 and again at Year 1 and Year 3 were not significantly different, as the subjects 
progressed through the study with time (PAIRS 11-13). 
PAIR 14: (M 6.72, SE 0.112) t(36) = -1.21, p >0.05 (0.231). There is a 23.1% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 15: (M 1.01, SE 0.060) t(36) = -1.36, p >0.05 (0.180). There is an 18% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. 
PAIR 16: (M 2.22, SE 0.112) t(36) = -1.21, p >0.05 (0.231). There is a 23% chance that 
this could happen if the Null Hypothesis was true. The Null Hypothesis was accepted. 
PAIR 17: (M 2.48, SE 0.110) t(36) = -1.43, p >0.05 (0.159). There is a 15.9% chance 
that this could happen if the Null Hypothesis was true. The Null Hypothesis was 
accepted. This demonstrated that the 4 CGM parameters used in this study to look at 
progression, when looked at individually, their means were not significantly different at 
baseline to the means for each at Year 1 (PAIRS 14-17). 
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5.3 Summary: Chapter 5 
In summary, at Year 1, all subjects from the baseline study were invited back for re- 
analysis. A number of parameters were analysed at Year 1, including age, study follow 
up interval, BMI, OGTT 0 hrs (FPG), OGTT 2 hours, HbA1c, CGM Glucose Excursion 
Parameters and CGM Profiles. At Year 3, variables which were analysed included age 
and follow up interval, BMI, OGTT 0 hrs (FPG) and HbA1c. The aim of this was to 
identify any parameter that demonstrated trends associated with progression to DM 
(T2DM). With regard to the study subjects, the majority of them were in the older 
adulthood or of adult retirement age. In general, the majority of subjects in this study 
were either overweight or obese and interestingly all of the subjects that were obese at 
baseline were still obese at Year 3. With regard to attendance rates, 82.2% of baseline 
subjects re-attended at Year 1 and 84.4% re-attended at Year 3, a response rate of over 
80%. All of the subjects had GAD Ab levels < 5 U/ml (69) demonstrating that none of 
the subjects demonstrated serological marker positivity for LADA or T1DM. 
 
As the study progressed with time, it was demonstrated that the mean subject FPG, the 
mean 2 Hour Glucose (mmol/l) and the mean subject HbA1c (n = 37) all increased in a 
stepwise fashion. With regard to CGM parameters: CGM Mean Average Glucose, CGM 
Mean Average Glucose Excursion from the Average Glucose (mmol/l), CGM Mean 
Average Glucose above Normal Glucose (mmol/l) and CGM Mean Average Glucose 
Excursion from Normal Glucose (mmol/l), again all increased in a stepwise fashion as 
the study progressed with time. With regard to the visually inspected CGM (SAP) 
Profiles, 17.8% of them were observed to demonstrate least variability, 35.6% were 
observed to demonstrate medium variability and 28.9% were observed to demonstrate 
most variability. These results closely mirrored the independent observer assessment of 
variability. At Year 1, each of the four CGM parameters, were looked at with regard to 
their relationship with the CGM profile groups. As the degree of variability of the 
visually inspected subject CGM profiles (SAP) increased from least variability to most 
variability, the mean of each of the four CGM parameters was observed to increase also 
(Figure 63: Summary: Year 1 Subjects CGM Parameters v CGM Profiles (SAP) - Mean 
Plots 
a-d). The mean plots demonstrated a fairly positive linear correlation for each of these 
graphically, indicating a likely relationship between these two variables. 
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One assumed that the distribution of the study sample mean was normal. In order to 
check this assumption, the population data and the sample data was looked at in more 
detail. For the screening population, the data appeared to be distributed symmetrically, 
around the centre of all scores in a bell shape and therefore graphically, the screening 
population appeared to be normally distributed for age (age being the parameter uniform 
to the screening population) (Figure 72: The Normality of Age in the Screening 
Population 
). With regard to the P-P plot for age in the screening population, as the result 
demonstrated a straight diagonal line, it was proposed that this data was normally 
distributed (Figure 73: P-P Plot of Normality in the Screening Population by Age 
). Assuming the data were normally distributed, as the same subjects were tested at 
different time intervals (baseline, Year 1 and Year 3), the paired sample t-test (or 
dependent t-test) was used to compare differences in two means of the set parameters. 
This included demographic data, biochemical tests and CGM parameters, as the study 
progressed with time. The Null Hypothesis in this instance was that there was no 
significant difference (i.e. no variation) between specified variables in each pair with 
time. The Null Hypothesis was accepted when at the 95% confidence interval (p >0.05). 
However, when p<0.05, this was classed as statistically meaningful and significant and 
the Null Hypothesis was rejected (Table 33) (Table 34). 
 
Pair 1 Baseline weight (Kg) with Year 1 weight (Kg) = The Null Hypothesis was 
accepted. 
Pair 2 Baseline weight (Kg) with Year 3 weight (Kg) = The Null Hypothesis was 
accepted. 
Pair 3 Year 1 weight (Kg) with Year 3 weight (Kg) = The Null Hypothesis was 
accepted. 
Pair 4 Baseline BMI (Kg/m2) with Year 1 BMI (Kg/m2) = The Null Hypothesis was 
accepted. 
Pair 5 Baseline BMI (Kg/m2) with Year 3 BMI (Kg/m2) = The Null Hypothesis was 
accepted. 
Pair 6 Year 1 BMI (Kg/m2) with Year 3 BMI (Kg/m2) = The Null Hypothesis was 
accepted. 
Pair 7 Baseline OGTT 0 mins (mmol/l) with Year 1 OGTT 0 mins (mmol/l) = The Null 
Hypothesis was accepted. 
131 
 
Pair 8 Baseline OGTT 0 mins (mmol/l) with Year 3 FPG 0 mins (mmol/l) = The Null 
Hypothesis was rejected, as there was a significant difference between the FPG at 
baseline and Year 3. 
Pair 9 Year 1 OGTT 0 mins (mmol/l) with Year 3 FPG 0 mins (mmol/l) = The Null 
Hypothesis was rejected, as there was a significant difference between the FPG at Year 
1 (OGTT) and Year 3. 
Pair 10 Baseline OGTT 2 hours (mmol/l) with Year 1 OGTT 2 hours (mmol/l) = 
The Null Hypothesis was accepted. 
Pair 11 Baseline HbA1c (mmol/mol) with Year 1 HbA1c (mmol/mol) = The 
Null Hypothesis was accepted. 
Pair 12 Baseline HbA1c (mmol/mol) with Year 3 HbA1c (mmol/mol) = The 
Null Hypothesis was accepted. However, this pairing, between the HbA1c at baseline 
and Year 3 was almost significant. 
Pair 13 Year 1 HbA1c (mmol/mol) with Year 3 HbA1c (mmol/mol) = The Null 
Hypothesis was accepted. 
Pair 14 Mean Baseline Average Glucose (mmol/l) with Mean Year 1 Average 
Glucose (mmol/l) = The Null Hypothesis was accepted. 
Pair 15 Mean Baseline Average Glucose Excursion (mmol/l) from Average with 
Mean Year 1 Average Glucose Excursion from Average (mmol/l) = The Null 
Hypothesis was accepted. 
Pair 16 Mean Baseline Average above Normal Glucose (mmol/l) with Mean 
Year 1 Average above Normal Glucose (mmol/l) = The Null Hypothesis was accepted. 
Pair 17 Mean Baseline Average Glucose Excursion from Normal Glucose 
(mmol/l) with Mean Year 1 Average Glucose Excursion from Normal Glucose (mmol/l) 
= The Null Hypothesis was accepted. 
 
Data was analysed and for each pair one can see that in the majority of cases (for 
example for weight and BMI), the Null Hypothesis was accepted i.e. there was no 
significant difference between each of the set variables with time; time being baseline to 
Year 1, baseline to Year 3 and Year 1 to Year 3. However, a significant difference was 
seen between the means of FPG at baseline and Year 3 and also at Year 1 and Year 3, as 
the subjects progressed through the study with time; however the difference between the 
mean FPG at baseline and Year 1 was not significant. The pairing, between the HbA1c 
at baseline and Year 3 was almost significant and this demonstrated that the mean of the 
HbA1c at baseline and Year 3 approached the significance level to be different, but the 
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HbA1c means at baseline and Year 1 and again at Year 1 and Year 3 were not 
significantly different, as the subjects progressed through the study with time. With 
regard to the 4 CGM parameters used in this study to look at progression, when looked 
at individually, their means were not significantly different at baseline to the means for 
each at Year 1. 
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6.0 Results: Study Outcome 
6.1 Analysing Outcome Data 
A number of pre-selected parameters were analysed at baseline, Year 1 and Year 3 with 
regard to looking at progression towards an outcome of diabetes (T2DM) or non 
diabetes. These included a mix of glycaemic status indicators: standard biochemical 
indicators (FPG, HbA1c and OGTT 2 Hour), observed graphical indicators (CGM 
Profiles) and CGM parameter (CGM Sensor Data) indicators. Baseline data included 
information regarding subject age, ethnicity gender, FHx of DM, smoking status, 
hypertension status and dyslipidemia status. At Year 1, an outcome of DM (T2DM) or 
non diabetes was established for all study subjects following testing with OGTT. In 
addition to this, a number of parameters were analysed and compared to corresponding 
baseline data. These included FPG, OGTT 2 hours, HbA1c, plus the four CGM 
parameters (Mean Baseline Average Glucose; Mean Baseline Average Glucose 
Excursion from the Average, Mean Baseline Average above Normal and Mean Baseline 
Average Glucose Excursion from the Normal Glucose). At Year 3, an outcome of DM 
(T2DM) or non diabetes was established for all study subjects following FPG testing. In 
addition to this, the following parameters were analysed and compared to corresponding 
baseline data and Year 1 data, in order to look at progression or change over time. 
 
A breakdown of the outcome at Year 1 and Year 3 can be seen in (Table 35) and Table 
36) respectively. At year 1, 17.8% (n = 8) subjects had progressed to DM (T2DM). At 
Year 3, (n = 21) 46.6% of subjects had progressed to DM (T2DM). This would be in 
keeping with current literature with regard to the rate of progression. 
 
Table 35: Outcome: Year 1 
 Frequency Percent 
Valid 
non diabetes 29 64.4 
Diabetes 8 17.8 
Total 37 82.2 
Missing System 8 17.8 
Total 45 100.0 
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Table 36: Outcome: Year 3 
 Frequency Percent 
Valid 
non diabetes 16 35.6 
Diabetes 21 46.7 
Total 37 82.2 
Missing System 8 17.8 
Total 45 100.0 
 
At the start of this study, 4 CGM Parameters were constructed to look at whether they, 
within the CGMS framework, were able to predict progression to DM (T2DM). One of 
the most promising parameters to look at this specifically during this study was seen to 
be ‘Mean Baseline AvGl Excursion from Av’. However, when one looked at this 
particular, parameter - ‘Mean Baseline AvGl excursion from Av’ with regard to Year 3 
outcome of diabetes (T2DM), the median values were almost the same for the subjects 
with diabetes as those without. The resulting inter-quartile ranges and lowest and 
highest values of data were for each outcome was almost identical also (Figure 80). 
 
 
Figure 80: Year 3 Outcome v Mean Baseline AvGl excursion from Av 
-MEAN Baseline AvGl excursion from Av was looked at with regard to Year 3 Outcome, i.e. non diabetes or 
diabetes using a box-plot, in an attempt to graphically display the distribution of data through quartiles for each 
possible outcome. Each box was made up of a lower 25th percentile, a thick central tendency line (the median) and the 
upper 75th percentile line. The lines which extended vertically from the boxes indicated variability outside the lower 
and upper quartiles i.e. they represented the lowest and highest value of data, respectively. Outliers (which were 
values greater than 1.5 inter-quartile ranges away from the 25th or the 75th percentile), were demonstrated as 
individual points (circles = mild outlier, star = extreme outlier). 
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6.2. Independent t Test 
Assuming the data were normally distributed, the Independent Sample t-Test, or t –test 
for short, was used to compare the means of two independent groups in order to 
determine whether there was a statistically significant difference between them. The two 
outcome groups were non diabetes and diabetes. The outcome of both groups at Year 1 
and Year 3 was investigated with regard to a number of baseline variables: 
 
 Baseline Age (years) 
 Baseline OGTT 0 mins (mmol/l) 
 Baseline OGTT 2 hours (mmol/l) 
 Baseline HbA1c (mmol/mol) 
 Mean Baseline Average Glucose (mmol/l)  
 Mean Baseline Average Glucose Excursion (mmol/l) from Average 
 Mean Baseline Average above Normal Glucose (mmol/l) 
 Mean Baseline Average Glucose Excursion from Normal Glucose 
(mmol/l)Baseline BMI (Kg/m2) 
 At Year 3, the outcome of both groups was investigated with regard to Year 1 
Insulin and Year 1 C-peptide. 
A table of summary statistics for the two experimental conditions was demonstrated for 
each variable tested. For each condition, the mean, the number of participants (N), the 
Std Dev of the sample and the standard error (i.e. the standard deviation divided by the 
square root of the sample size) was seen. For example, one can see that non diabetes had 
29 participants and diabetes had 8 participants at Year 1 Outcome for all groups except 
HbA1c, who had 25 and 8 respectively. With regard to age, the mean age of those who 
were DM (T2DM) at Year 1 was 63.17 years compared to the non diabetics at Year 1, 
with a mean age of 59.7 years. On inspection of this data further, at Year 1, the mean of 
all variables (except HbA1c) was higher in the diabetic compared to the non diabetic 
group (Table 37). 
 
A summary of the independent samples tested was also demonstrated. The Null 
Hypothesis in this instance was that there was no significant difference (i.e. no 
variation) with regard to the specified variable in each group, with regard to outcome. In 
parametric testing, one assumes that the variances in experimental groups are roughly 
equal. Levene’s test was used to see whether variances were different in different 
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groups and this test tested the hypothesis that the variances in the two groups were 
equal. Where Levene’s test was p>0.05, then equal variances were assumed and the 
Null Hypothesis was accepted, assuming the variances were roughly equal and equal 
variances was assumed (EVA). This was the case for all variables except Baseline 
OGTT 120 mins and HbA1c, respectively. With regard to these two variables, the test 
statistics in the row labelled Equal Variances Not Assumed (EVNA) were used (Table 
38). 
 
Table 37: Independent t-test: Sample Statistics: Year 1 Outcome 
Variable Year 1 Outcome N Mean Std. Deviation Std. Error Mean 
Baseline Age (years) 
non diabetes 29 59.70 12.00 2.22 
Diabetes 8 63.17 9.08 3.21 
Baseline OGTT 0 mins 
(mmol/l) 
non diabetes 29 6.26 .48 .090 
Diabetes 8 6.36 .17 .062 
Baseline OGTT 120 mins 
(mmol/l) 
non diabetes 29 7.46 1.88 .35 
Diabetes 8 8.81 1.37 .48 
Baseline HbAlc (mmol/l) 
non diabetes 25 44.48 4.41 .88 
Diabetes 8 42.62 1.92 .67 
MEAN Baseline Av Gl 
(mmol/l) 
non diabetes 29 6.65 .67 .12 
Diabetes 8 6.99 .68 .24 
MEAN Baseline AvGl 
excursion from Av (mmol/l) 
non diabetes 29 .95 .28 .05 
Diabetes 8 1.22 .54 .19 
MEAN Baseline Av above 
norm Gl (mmol/l) 
non diabetes 29 2.15 .67 .12 
Diabetes 8 2.49 .68 .24 
MEAN Baseline Av Gl 
excursion from norm Gl 
(mmol/l) 
non diabetes 29 2.38 .65 .12 
Diabetes 8 2.85 .63 .22 
Baseline BMI (kg/m^2) 
non diabetes 29 33.18 6.35 1.18 
Diabetes 8 33.50 7.59 2.68 
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Table 38: Independent t test: Equality of Means: Year 1 Outcome 
 Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. T Df Sig. (2-
tailed) 
Mean 
Dif 
Std. 
Error 
Dif 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Baseline 
Age (years) 
*EVA .48 .49 -.75 35 .45 -3.46 4.58 -12.77 5.83 
**EVNA   -.88 14.52 .38 -3.46 3.90 -11.82 4.88 
Baseline 
OGTT 0 
mins 
(mmol/l) 
EVA 1.85 .18 -.54 35 .58 -.09 .17 -.45 .26 
EVNA  
 
-.88 32.00 .38 -.09 .11 -.32 .12 
Baseline 
OGTT 120 
mins 
(mmol/l) 
EVA 4.86 .03 -1.88 35 .06 -1.34 .71 -2.80 .10 
EVNA 
  
-2.25 15.18 .03 -1.34 .59 -2.61 -.07 
Baseline 
HbAlc 
(mmol/l) 
EVA 5.09 .03 1.14 31 .26 1.85 1.62 -1.45 5.16 
EVNA 
  
1.66 27.62 .10 1.85 1.11 -.42 4.13 
MEAN 
Baseline Av 
Gl (mmol/l) 
EVA .04 .84 -1.27 35 .21 -.34 .26 -.89 .20 
EVNA 
  
-1.26 11.03 .23 -.34 .27 -.94 .25 
MEAN 
Baseline 
AvGl 
excursion 
from Av 
(mmol/l) 
EVA 3.97 .05 -1.96 35 .05 -.27 .14 -.564 .00 
EVNA 
  
-1.39 8.13 .19 -.27 .19 -.73 .17 
MEAN 
Baseline Av 
above norm 
Gl (mmol/l) 
EVA .04 .84 -1.27 35 .21 -.34 .26 -.89 .20 
EVNA 
  
-1.26 11.03 .23 -.34 .27 -.94 .25 
MEAN 
Baseline Av 
Gl excursion 
from norm 
Gl (mmol/l) 
EVA .00 .92 -1.82 35 .07 -.47 .25 -.99 .05 
EVNA 
  
-1.85 11.48 .08 -.47 .25 -1.02 .084 
Baseline 
BMI 
(kg/m^2) 
EVA .20 .65 -.12 35 .90 -.31 2.64 -5.68 5.05 
EVNA 
  
-.10 9.87 .91 -.31 2.93 -6.86 6.23 
*EVA = Expected Variances Assumed; **EVNA = Expected Variances Not Assumed 
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The test statistic t was then obtained for each pair by dividing the mean of differences 
by the Std Err of differences. The size of the t was then compared against known values 
based on degrees of freedom (i.e. sample size -1). SPSS 20 used the degrees of freedom 
to calculate the exact probability that a value of t was as big as the one obtained could 
occur if the Null Hypothesis were true (i.e. no difference between the means tested). In 
this instance, the two-tailed probability was demonstrated, which was the probability 
when no prediction was made about the direction of differences. In this test, at 95% CI, 
a p<0.05 was classed as statistically meaningful and significant and the Null Hypothesis 
was rejected. In this study, the effect size was also demonstrated, which gave an 
objective measure of the importance of an effect and the strength of the relationship 
between variables. Pearson’s correlation coefficient r, is a measure of effect size and it 
is constrained to lie between 0 (no effect) and 1 (a perfect effect). Cohen’s (1992) (56) 
reference regarding effect size was used in this study i.e. r = .10 (small effect); r = .30 
(medium effect) and r = 0.50 (large effect). Results were as follows for Year 1 outcome 
(Table 37, Table 38): 
 
 Baseline Age (years): DM (M 63.17, SE 3.21) were older compared to non 
diabetics (M 59.70, SE 2.22) at Year 1, but this difference was not significant 
t(35) = - 0.75, p >0.05 (0.45). The Null Hypothesis was accepted, as there was 
no significant difference between the groups in age at Year 1. In this instance the 
effect was small (r = 0.12). 
 Baseline OGTT 0 mins (mmol/l): DM (M 6.36, SE 0.62) had higher OGTT 0 
mins compared to non diabetics (M 6.26, SE 0.90) at Year 1, but this was not 
significant t(35) = - 0.54, p >0.05 (0.58) and the size effect was small (r = 0.09). 
The Null Hypothesis was accepted, as there was no significant difference 
between the groups at Year 1 for OGTT 0 mins. 
 Baseline OGTT 2 hours (mmol/l): DM (M 8.81, SE 0.48) had higher OGTT 
120 mins compared to non diabetics (M 7.46, SE 0.88) at Year 1, which was 
significant t(15.18) = -2.25, p <0.05 (0.039). The Null Hypothesis was rejected, 
as there was a significant difference between the groups at Year 1 for OGTT 2 
hours. The effect size was also large in this instance (r = 0.50). 
 Baseline HbA1c (mmol/mol): Non diabetics (M 44.4, SE 0.88) had higher 
HbA1c compared to diabetics (M 42.62, SE 0.67) at Year 1, but this was not 
significant t(27.62) = 1.66, p >0.05 (0.10). The Null Hypothesis was accepted, as 
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there was no significant difference between the groups at Year 1 for HbA1c. The 
effect size was of medium in this instance (r = 030). 
 Mean Baseline Average Glucose (mmol/l): DM (M 6.99, SE 0.24) had higher 
Mean Baseline Average Glucose compared to non diabetics (M 6.65, SE 0.12) at 
Year 1, but this was not significant t(35) = - 1.274, p >0.05 (0.21). The effect 
size approached a medium effect (r = 0.20). The Null Hypothesis was accepted, 
as there was no significant difference between the groups at Year 1 for Mean 
Baseline Average Glucose (mmol/l). 
 Mean Baseline Average Glucose Excursion (mmol/l) from Average: DM (M 
1.22, SE 0.19) had higher Mean Baseline Average Glucose Excursion (mmol/l) 
from Average compared to non diabetics (M 0.95, SE 0.05) at Year 1. This 
result was just about significant, as t(35) = - 1.96, p >0.05 (0.05) and the effect 
size was seen to be medium in size (r = 0.31). The Null Hypothesis was rejected, 
as there was a significant difference between the groups at Year 1 for Mean 
Baseline Average Glucose Excursion (mmol/l) from Average. 
 Mean Baseline Average above Normal Glucose (mmol/l): DM (M 2.49, SE 
0.24) had higher Mean Baseline Average Glucose above Normal Glucose 
compared to non diabetics (M 2.15, SE 0.12 ) at Year 1, but this was not 
significant t(35) = - 1.27, p >0.05 (0.21). The effect size approached a medium 
effect (r = 0.20). The Null Hypothesis was accepted, as there was no significant 
difference between the groups at Year 1 for Mean Baseline Average Glucose 
above Normal Glucose (mmol/l). 
 Mean Baseline Average Glucose Excursion from Normal Glucose (mmol/l): 
DM (M 2.85, SE 0.22) had higher Mean Baseline Average Glucose Excursion 
from Normal Glucose compared to non diabetics (M 2.38, SE 0.12) at Year 1, 
which was demonstrated to be approaching significance. However, although it 
was not significant t(35) = - 1.82, p >0.05 (0.77) the effect size was medium (r = 
0.29). The Null Hypothesis was accepted, as there was no significant difference 
between the groups at Year 1 for Mean Baseline Average Glucose above Normal 
Glucose (mmol/l). 
 Baseline BMI (Kg/m2): DM (M 33.50, SE 2.68) had higher BMI compared to 
non diabetics (M33.18, SE 1.18 ) at Year 1, but this was not significant t(35) = - 
0.12, p >0.05 (0.905) and the effect size was small (r = 0.02). The Null 
Hypothesis was accepted, as there was no significant difference between the 
groups at Year 1 for BMI. 
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Results were as follows for Year 3 Outcome (Table 39, Table 40): 
 Baseline Age (years): Non Diabetics (M 59.59, SE 2.21) were older compared 
to DM (T2DM) (M 58.44, SE 2.92) at Year 1, but this difference was not 
significant t(35) =0.235, p >0.05 (0.76) and the effect size was small (r = 0.04). 
The Null Hypothesis was accepted, as there was no significant difference 
between the groups in age at Year 1. 
 Baseline OGTT 0 mins (mmol/l): DM (T2DM) (M 6.34, SE 0.0.08) had higher 
OGTT 0 mins compared to non diabetics (M 6.13, SE 0.14) at Year 1, but this 
was not significant t(35) = - 1.33, p >0.05 (0.19) . The Null Hypothesis was 
accepted, as there was no significant difference between the groups at Year 1 for 
OGTT 0 mins; the effect size approached a medium result here (r = 0.21). 
 Baseline OGTT 2 hours (mmol/l): DM (T2DM) (M 8.09, SE 0.37) had higher 
OGTT 120 mins compared to non diabetics (M 7.58, SE 0.45) at Year 1, which 
not significant t(35) = -0.87, p >0.05 (0.39) and the effect size was small (r = 
0.14). The Null Hypothesis was accepted, as there was no significant difference 
between the groups at Year 1 for OGTT 2 hours. 
 Baseline HbA1c (mmol/mol): DM (T2DM) (M 44.78, SE 0.92) had higher 
HbA1c compared to non diabetics (M 43.42.62, SE 0.87) at Year 1, but this was 
not significant t(32) = -1.03, p >0.05 (0.31). The Null Hypothesis was accepted, 
as there was no significant difference between the groups at Year 1 for HbA1c; 
the effect size approached a medium effect here (r = 0.17). 
 Mean Baseline Average Glucose (mmol/l): DM (T2DM) (M 6.88, SE 0.13) 
had higher Mean Baseline Average Glucose compared to non diabetics (M 6.65, 
SE 0.20) at Year 1, but this was not significant t(35) = - 1.02, p >0.05 (0.31). 
The Null Hypothesis was accepted, as there was no significant difference 
between the groups at Year 1 for Mean Baseline Average Glucose (mmol/l); the 
effect size approached a medium effect here (r = 0.16). 
 Mean Baseline Average Glucose Excursion (mmol/l) from Average: DM 
(T2DM) (M 1.05, SE 0.08) had higher Mean Baseline Average Glucose 
Excursion (mmol/l) from Average compared to non diabetics (M 0.96, SE 0.07) 
at Year 1, but this was not significant t(35) = -0.75, p >0.05 (0.45) and the effect 
size was small (r = 0.12). The Null Hypothesis was accepted, as there was no 
significant difference between the groups at Year 1 for Mean Baseline Average 
Glucose Excursion (mmol/l) from Average. 
141 
 
 Mean Baseline Average above Normal Glucose (mmol/l): DM (T2DM) (M 
2.38, SE 0.13) had higher Mean Baseline Average Glucose above Normal 
Glucose compared to non diabetics (M 2.14, SE 0.20 ) at Year 1, but this was 
not significant t(35) = - 1.02, p >0.05 (0.31). The Null Hypothesis was accepted, 
as there was no significant difference between the groups at Year 1 for Mean 
Baseline Average Glucose above Normal Glucose (mmol/l); the effect size 
approached a medium effect here (r = 0.16). 
 Mean Baseline Average Glucose Excursion from Normal Glucose (mmol/l): 
DM (T2DM) (M 2.65, SE 0.12) had higher Mean Baseline Average Glucose 
Excursion from Normal Glucose compared to non diabetics (M 2.39, SE 0.19) at 
Year 1, but this was not significant t(35) = - 1.13, p >0.05 (0.26) and so the Null 
Hypothesis was accepted, as there was no significant difference between the 
groups at Year 1 for Mean Baseline Average Glucose above Normal Glucose 
(mmol/l); the effect size approached a medium effect here (r = 0.18). 
 Baseline BMI (Kg/m2): Non diabetics (M 32.77, SE 1.61) had higher BMI 
compared to DM (T2DM) (M 32.46, SE 1.56) at Year 1, but this was not 
significant t(35) = - 0.13, p >0.05 (0.896), with a small effect size (r = 0.02). 
The Null Hypothesis was accepted, as there was no significant difference 
between the groups at Year 1 for BMI. 
 Year 1 Insulin (pmol/L): Non diabetics (M 125.34, SE 16.62) had higher 
venous Insulin levels in peripheral blood compared to DM (T2DM) (M 112.37, 
SE 13.60) at Year 1, but this was not significant t(30) = 0.60, p >0.05 (0.54), 
with a small effect size (r = 0.11). The Null Hypothesis was accepted, as there 
was no significant difference between the groups at Year 1 for venous Insulin 
(pmol/L). 
 Year 1 C-peptide (pmol/ml): Non diabetics (M 0.630, SE 0.072) had higher 
venous C-peptide levels in peripheral blood compared to DM (T2DM) (M 0.55, 
SE 0.06) at Year 1, but this was not significant t(30) = 0.78, p >0.05 (0.43), with 
a small effect size (r = 0.14). The Null Hypothesis was accepted, as there was no 
significant difference between the groups at Year 1 for venous C-peptide 
(pmol/ml). 
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Table 39: Independent t-tests: Sample Statistics: Year 3 Outcome 
Variable Year 3 Outcome N Mean Std. Deviation Std. Error Mean 
Baseline Age (years) 
non diabetes 16 59.59 8.87 2.21 
Diabetes 21 58.44 13.42 2.92 
Baseline OGTT 0 mins 
(mmol/l) 
non diabetes 16 6.13 .57 .14 
Diabetes 21 6.34 .37 .08 
Baseline OGTT 120 mins 
(mmol/l) 
non diabetes 16 7.58 1.83 .45 
Diabetes 21 8.09 1.70 .37 
Baseline HbAlc (mmol/l) 
non diabetes 14 43.42 3.27 .87 
Diabetes 19 44.78 4.04 .92 
MEAN Baseline Av Gl 
(mmol/l) 
non diabetes 16 6.64 .81 .20 
Diabetes 21 6.88 .59 .13 
MEAN Baseline AvGl 
excursion from Av (mmol/l) 
non diabetes 16 .96 .30 .07 
Diabetes 21 1.05 .39 .08 
MEAN Baseline Av above 
norm Gl (mmol/l) 
non diabetes 16 2.14 .81 .20 
Diabetes 21 2.38 .59 .13 
MEAN Baseline Av Gl 
excursion from norm Gl 
(mmol/l) 
non diabetes 16 2.39 .78 .19 
Diabetes 21 2.65 .59 .12 
Baseline BMI (kg/m^2) 
non diabetes 16 32.77 6.46 1.61 
Diabetes 21 32.46 7.16 1.56 
Year 1 Insulin (pmol/L) 
non diabetes 15 125.34 64.37 16.62 
Diabetes 17 112.37 56.08 13.60 
Year 1 C-peptide (pmol/ml) 
non diabetes 15 .63 .27 .072 
Diabetes 17 .55 .28 .069 
 
At Year 3, none of the variables tested demonstrated significance difference in means, 
when the outcome of the diabetes and non diabetes groups was investigated, 
respectively. This differed to what was seen at Year 1, where a significant difference in 
means between the two groups was seen for Baseline OGTT 2 hours (mmol/l) and 
Mean Baseline Average Glucose Excursion (mmol/l) from Average. In addition, at Year 
1, Mean Baseline Average Glucose Excursion from Normal Glucose (mmol/l) also 
approached significance. 
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Table 40: Independent t-test: Equality of Means: Year 3 Outcome 
 Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
F Sig. T Df Sig. (2-
tailed) 
Mean 
Dif 
Std Err 
Dif 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Baseline Age 
(years) 
*EVA 1.46 .23 .29 35 .76 1.14 3.88 -6.73 9.02 
**EVNA   .31 34.42 .75 1.14 3.67 -6.31 8.61 
Baseline OGTT 0 
mins (mmol/l) 
EVA 1.67 .20 -1.33 35 .19 -.21 .15 -.53 .11 
EVNA   -1.26 24.42 .22 -.21 .16 -.55 .13 
Baseline OGTT 
120 mins 
(mmol/l) 
EVA .68 .41 -.87 35 .39 -.50 .58 -1.69 .67 
ENA 
  
-.86 31.07 .39 -.50 .59 -1.71 .69 
Baseline HbAlc 
(mmol/l) 
EVA 1.77 .19 -1.03 31 .31 -1.36 1.31 -4.05 1.32 
EVNA   -1.06 30.67 .29 -1.36 1.27 -3.96 1.24 
MEAN Baseline 
Av Gl (mmol/l) 
EVA 1.10 .30 -1.02 35 .31 -.23 .23 -.70 .23 
EVNA   -.98 26.49 .33 -.23 .24 -.73 .25 
MEAN Baseline 
AvGl excursion 
from Av (mmol/l) 
EVA .36 .55 -.75 35 .45 -.08 .11 -.32 .15 
EVNA 
  
-.77 34.95 .44 -.08 .11 -.32 .14 
MEAN Baseline 
Av above norm 
Gl (mmol/l) 
EVA 1.10 .30 -1.02 35 .31 -.23 .23 -.70 .23 
EVNA 
  
-.98 26.49 .33 -.23 .24 -.73 .25 
MEAN Baseline 
Av Gl excursion 
from norm Gl 
(mmol/l) 
EVA 1.11 .29 -1.13 35 .26 -.25 .22 -.71 .20 
EVNA 
  
-1.09 26.95 .28 -.25 .23 -.74 .22 
Baseline BMI 
(kg/m^2) 
EVA .34 .56 .13 35 .89 .30 2.28 -4.32 4.93 
EVNA   .13 33.93 .89 .30 2.24 -4.26 4.87 
Year 1 Insulin 
(pmol/L) 
EVA .78 .38 .60 30 .54 12.97 21.28 -30.50 56.44 
EVNA   .60 28.03 .55 12.97 21.47 -31.02 56.96 
Year 1 C-peptide 
(pmol/ml) 
EVA .01 .90 .78 30 .43 .078 .10 -.12 .28 
EVNA   .78 29.65 .43 .078 .10 -.12 .28 
*EVA = Expected Variances Assumed; **EVNA = Expected Variances Not Assumed 
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6.3 Chi Square Test 
In this study, a number of categorical variables were assessed at baseline, to see if they 
had any bearing on the outcome of DM (T2DM) at Year 1 or Year 3. Pearson’s-chi 
square test is used to compare the frequency observed in certain categories to the 
frequencies one may expect to get in those categories by chance. In this study, the 
Pearson’s chi-square statistic tested whether the two variables were independent when 
tested. If the significance was small enough (p<0.05), then the Null Hypothesis was 
rejected and confidence was gained in the hypothesis that the variables in some way 
were related. In order to use to use the chi-square test the expected frequency in each 
cell should be greater than 5, otherwise there may be a loss of statistical power (and 
may fail to detect a genuine effect); i.e. the sample size may be too small and the 
sampling distribution of the test statistic may be too deviated from a chi-square 
distribution to be of any use. In these circumstances, when the sample sizes were 
deemed small, for an accurate exact probability of the chi sq statistic being accurate, 
Fishers exact test was used. 
 
Outcome: Year 1: Gender  
Chi sq (1) = 2.786, p <0.05; p value 0.102 (Fisher’s exact test). This was not significant, 
there was no association and the Null Hypothesis was accepted. Therefore, gender does 
not significantly affect risk of DM (T2DM) at Year 1. The odds ratio demonstrated that 
for females, at Year 1 their odds of being non diabetic were 5.7 times higher than if they 
had been a male; (likelihood ratio 3.162) (Figure 81). 
 
Outcome: Year 3 Gender 
Chi sq (1) = 2.733, p <0.05; p value 0.098 (Pearson’s exact test). This was not 
significant, there was no association and the Null Hypothesis was accepted. Therefore, 
baseline gender does not significantly affect risk of DM (T2DM) at Year 3 even though 
the trend suggests that it would be so for males; (likelihood ratio = 2.73) (Figure 82). 
 
Outcome: Year 1 Ethnicity 
Chi sq (1) = 0.583, p <0.05; p value 0.610 (Fisher’s exact test). This was not significant, 
there was no association and the Null Hypothesis was accepted. Therefore, ethnicity did 
not significantly affect risk of DM (T2DM) at Year 1. It was difficult to make any 
conclusions about the odds ratio, given the few numbers of non Caucasians (Figure 83). 
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Outcome: Year 3 Ethnicity 
Chi sq (1) = 0.083, p <0.05; p value 0.587 (Fisher’s exact test). This was not significant, 
there was no association and the Null Hypothesis was accepted. Therefore, ethnicity did 
not significantly affect risk of DM (T2DM) at Year 3 (Figure 84). 
 
Outcome: Year 1 Smoking Status 
Chi sq (2) = 0.035, p <0.05; p value 0.982 (Pearson’s exact test). This was not 
significant, there was no association and the Null Hypothesis was accepted. Therefore, 
smoking status did not significantly affect risk of DM (T2DM) at Year 1; (likelihood 
ratio = 0.035) (Figure 85). 
 
Outcome: Year 3 Smoking Status 
Chi sq (2) = 0.71, p <0.05; p value 0.701 (Pearson’s exact test). This was not 
significant, there was no association and the Null Hypothesis was accepted. Therefore, 
smoking status does not significantly affect risk of DM (T2 DM) at Year 3; (likelihood 
ratio = 0.721) (Figure 86). 
 
Outcome: Year 1 Hypertension 
Chi sq (1) = 0.775, p <0.05; p value 0.649 (Fisher’s exact test). This was not significant, 
there was no association and the Null Hypothesis was accepted. Therefore, baseline 
hypertension does not significantly affect risk of DM (T2DM) at Year 1. (likelihood 
ratio = 0.864) (Figure 87). 
 
Outcome: Year 3 Hypertension 
Chi sq (1) = 1.64, p <0.05; p value 0.199 (Fisher’s exact test). This was not significant, 
there was no association and the Null Hypothesis was accepted. Therefore, baseline 
hypertension does not significantly affect risk of DM (T2DM) at Year 3; (likelihood 
ratio = 1.64) (Figure 88). 
 
Outcome: Year 1 Dyslipidemia 
Chi sq (1) = 0.293, p <0.05; p value 0.701 (Fisher’s exact test). This was not significant, 
there was no association and the Null Hypothesis was accepted. Therefore, baseline 
dyslipidemia does not significantly affect risk of DM (T2DM) at Year 1.The odds ratio 
demonstrated that for subjects that had dyslipidemia, the odds of being non diabetic 
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were 1.5 times higher than if they didn’t have dyslipidemia at Year 1 (likelihood ratio = 
1.20) (Figure 89). 
 
Outcome: Year 3 Dyslipidemia 
Chi sq (1) = 1.205, p <0.05; p value 0.272 (Pearson’s exact test). This was not 
significant, there was no association and the Null Hypothesis was accepted. Therefore, 
baseline dyslipidemia does not significantly affect risk of DM (T2DM) at Year 3; 
(likelihood ratio = 1.20) (Figure 90). 
 
Outcome: Year 1 FHx of DM 
Chi sq (1) = 0.379, p <0.05; p value 0.690 (Fisher’s exact test). This was not significant, 
there was no association and the Null Hypothesis was accepted. Therefore, baseline 
FHx of DM does not significantly affect risk of DM (T2DM) at Year 1. The odds ratio 
demonstrated that for subjects that had a FHx of DM at baseline, the odds of being non 
diabetic were 0.61 times higher than if they didn’t have a FHx of DM (likelihood ratio = 
0.374) (Figure 91). 
 
Outcome: Year 3 FHx of DM 
Chi sq (1) = 0.379, p <0.05; p value 0.538 (Pearsons’s exact test). This was not 
significant, there was no association and the Null Hypothesis was accepted. Therefore, a 
baseline FHx of DM does not significantly affect risk of DM (T2 DM) at Year 3; 
(likelihood ratio 0.381) (Figure 92). 
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Figure 81: Chi-sq Year 1 Outcome: Gender 
-In the bar chart above, baseline gender does not significantly affect risk of DM (T2DM) at Year 1 (F = female; M = 
male). 
 
 
 
Figure 82: Chi-sq Year 3 Outcome: Gender 
-In the bar chart above, baseline gender does not significantly affect risk of DM (T2DM) at Year 3 (F = female; M = 
male). 
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Figure 83: Chi-sq Year 1 Outcome: Ethnicity 
-In the bar chart above, baseline ethnicity did not significantly affect risk of DM (T2DM) at Year 1; (n. caucasian = 
non caucasian). 
 
 
 
Figure 84: Chi-sq Year 3 Outcome: Ethnicity 
In the bar chart above, baseline ethnicity did not significantly affect risk of DM (T2DM) at Year 3; (n. caucasian = 
non caucasian). 
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Figure 85: Chi-sq Year 1 Outcome: Smoking Status 
-In the bar chart above, smoking status at baseline did not significantly affect risk of DM (T2DM) at Year 1. 
 
 
 
Figure 86: chi-sq Year 3 Outcome: Smoking Status 
-In the bar chart above, smoking status at baseline did not significantly affect risk of DM (T2DM) at Year 3. 
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Figure 87: Chi-sqYear 1 Outcome: Hypertension 
-In the bar chart above, the presence of hypertension at baseline does not significantly affect risk of DM (T2DM) at 
Year 1. 
 
 
 
Figure 88: Chi-sq Year 3 Outcome: Hypertension 
-In the bar chart above, the presence of hypertension art baseline does not significantly affect risk of DM (T2DM) at 
Year 3. 
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Figure 89: Chi-sq Year 1 Outcome: Dyslipidemia 
-In the bar chart above, the presence of dyslipidemia at baseline does not significantly affect risk of DM (T2DM) at 
Year 1. 
 
 
 
Figure 90: Chi-sq Year 3 Outcome: Dyslipidemia 
-In the bar chart above, the presence of dyslipidemia at baseline does not significantly affect risk of DM (T2DM) at 
Year 3. 
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Figure 91: Chi-sq Year 1 Outcome: FHx DM 
-In the bar chart above, a positive FHx of DM at baseline does not significantly affect risk of DM (T2DM) at Year 1. 
 
 
 
Figure 92: Chi-sq Year 3 Outcome: FHx DM 
-In the bar chart above, a positive FHx of DM at baseline does not significantly affect risk of DM (T2DM) at Year 3. 
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Outcome: Baseline CGM Profiles (SAP) 
Chi sq (2) = 2.957, p <0.05; p value 0.228 (Pearsons’s exact test). This was not 
significant, there was no association and the Null Hypothesis was accepted. Therefore 
baseline CGM Profiles (SAP) did not significantly affect risk of DM (T2DM) at Year 1; 
(likelihood ratio 4.59). Interestingly, at Year 1, there were no subjects with T2DM and 
least variability CGM profiles (Table 41, Figure 93). 
 
Table 41: Baseline CGM Profile SAP - Year 1 Outcome 
 Baseline CGM profiles SAP Total 
least variability medium 
variability 
most variability 
Year 1 Outcome 
non diabetes 8 12 9 29 
Diabetes 0 4 4 8 
Total 8 16 13 37 
 
 
 
Figure 93: Baseline CGM Profiles (SAP): Year 1 Outcome 
-From the bar chart above, baseline CGM Profiles (SAP) (least, medium and most variability) did not significantly 
affect risk of DM (T2DM) at Year 1. 
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Outcome: Baseline CGM Profiles (SAP) 
Chi sq (2) = 1.271, p <0.05; p value 0.530 (Pearsons’s exact test). This was not 
significant, there was no association and the Null Hypothesis was accepted. Therefore 
baseline CGM Profiles (SAP) did not significantly affect risk of DM (T2DM) at Year 3; 
(likelihood ratio 1.29) (Table 42, Figure 94). 
 
Table 42: Baseline CGM Profiles SAP - Year 3 Outcome 
 Baseline CGM profiles SAP Total 
least variability medium 
variability 
most variability 
Year 3 Outcome 
non diabetes 3 14 7 24 
Diabetes 3 4 6 13 
Total 6 18 13 37 
 
 
 
Figure 94: Baseline CGM Profiles (SAP): Year 3 Outcome 
-From the bar chart above, baseline CGM Profiles (SAP) (least, medium and most variability) did not significantly 
affect risk of DM (T2DM) at Year 3. 
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6.4 CGM Profiles 
6.4.1 Significance of CGM Profiles by Inspection 
The CGM profiles for each subject that were inspected by eye (SAP) (APPENDIX 2 – 
least variability, APPENDIX 3 - medium variability, APPENDIX 4 – most variability). 
The CGM profiles for each subject that were inspected by eye were investigated to see 
if there was a significant difference in them with regard to each of the four devised 
CGM parameters that were used to assess CGM subject data. The Null Hypothesis was 
that there was no significant difference in CGM profiles by eye per individual CGM 
parameter. 
 
At baseline (n = 45), the mean can be seen to increase as the degree of variability by eye was thought to 
was thought to increase. This was the case for all four CGM parameters investigated (Table 43). At baseline, 
the Levene Statistic was > 0.05 for all CGM parameters (range of 1.2-2.9) and so the assumption of 
homogeneity of variance had not been violated and the variances were not significantly different ( 
 
Table 44). A one way analysis of variance (ANOVA) was conducted at baseline to evaluate the Null Hypothesis 
that there was no significant difference in the CGM profiles, inspected by eye (least, medium and most 
variability) based on the four CGM parameters respectively. A cut off point of 0.05 was used as a criterion for 
used as a criterion for statistical significance. The observed significance value was less than 0.05 (p<0.05) with 
than 0.05 (p<0.05) with regard to variability (least, medium and most) for all 4 CGM parameters, respectively 
parameters, respectively ( 
Table 45). Therefore, there was a significant difference between the variability of the 
eyeballed CGM profiles for each of the CGM parameters studied at baseline; the Null 
Hypothesis was thus rejected. 
 
At Year 1 (n = 37) and the mean can be seen to increase as the degree of variability by 
eye was thought to increase. This was the case for all four CGM parameters investigated 
(Table 46). At Year 1, as at baseline, the Levene Statistic was > 0.05 for all CGM 
parameters (range of 3.2-5.7) and so the assumption of homogeneity of variance had not 
been violated and the variances were not significantly different (Table 47). A one way 
ANOVA was conducted at Year 1 to evaluate the Null Hypothesis that there was no 
significant difference in the CGM profiles inspected by eye (least, medium and most 
variability) based on the four CGM parameters respectively. A cut off point of 0.05 was 
used as a criterion for statistical significance. The observed significance value is less 
than 0.05 (p < 0.05) with regard to variability (least, medium and most) for all 4 CGM 
parameters, respectively (Table 48). Therefore, there was a significant difference and 
evidence to reject the Null Hypothesis at this level of significance. There is a significant 
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difference for each of the four CGM parameters, respectively per observed CGM profile 
inspected by eye at Year 1. 
 
Table 43: Baseline CGM Parameters v Degree of CGM Profile Variability by Eye 
 
CGM PARMETERS v 
DEGREE OF VARIABILITY BY 
EYE 
 
N 
 
Mean 
 
Std. Dev 
Std. 
Error 
95% Confidence 
Interval for Mean 
 
Min 
 
Max 
Lower 
Bound 
Upper 
Bound 
MEAN Baseline 
Av Gl (mmol/l) 
Least 9 6.13 .53 .17 5.72 6.54 5.27 6.81 
Medium 22 6.69 .50 .10 6.47 6.92 5.42 7.43 
Most 14 7.16 .69 .18 6.76 7.56 6.14 8.40 
Total 45 6.73 .66 .09 6.53 6.93 5.27 8.40 
MEAN Baseline 
AvGl excursion 
from Av (mmol/l) 
Least 9 .64 .18 .06 .50 .78 .36 .90 
Medium 22 .92 .15 .03 .85 .99 .54 1.19 
Most 14 1.34 .34 .09 1.14 1.54 .98 2.22 
Total 45 .99 .34 .05 .89 1.10 .36 2.22 
MEAN Baseline 
Av above norm 
Gl (mmol/l) 
Least 9 1.63 .53 .17 1.22 2.04 .77 2.31 
Medium 22 2.19 .50 .10 1.97 2.42 .92 2.93 
Most 14 2.66 .69 .18 2.26 3.06 1.64 3.90 
Total 45 2.23 .66 .09 2.03 2.43 .77 3.90 
MEAN Baseline 
Av Gl excursion 
from norm Gl 
(mmol/l) 
Least 9 1.80 .45 .15 1.45 2.15 1.03 2.44 
Medium 22 2.41 .44 .09 2.21 2.60 1.32 3.10 
Most 14 3.03 .60 .16 2.68 3.38 2.30 4.05 
Total 45 2.48 .65 .09 2.28 2.68 1.03 4.05 
 
 
Table 44: Baseline Test of Homogeneity of Variances 
CGM PARAMETERS Levene Statistic df1 df2 Sig. 
MEAN Baseline Av Gl 
(mmol/l) 
1.27 2 42 .29 
MEAN Baseline AvGl 
excursion from Av (mmol/l) 
2.99 2 42 .06 
MEAN Baseline Av above 
norm Gl (mmol/l) 
1.27 2 42 .29 
MEAN Baseline Av Gl 
excursion from norm Gl 
(mmol/l) 
1.54 2 42 .22 
 
 
 
 
Table 45: Baseline ANOVA of CGM Profile Variability by Eye and CGM Parameters 
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CGM PARAMETERS Sum of 
Squares 
Df Mean 
Square 
F Sig 
MEAN Baseline Av Gl 
(mmol/l) 
Between Grps 5.84 2 2.92 8.85 .00 
Within Grps 13.87 42 .33   
Total 19.72 44    
MEAN Baseline AvGl 
excursion from Av 
(mmol/l) 
Between Grps 2.89 2 1.45 25.88 .00 
Within Grps 2.35 42 .05   
Total 5.25 44    
MEAN Baseline Av 
above norm Gl 
(mmol/l) 
Between Grps 5.84 2 2.92 8.85 .00 
Within Grps 13.87 42 .33   
Total 19.72 44    
MEAN Baseline Av Gl 
excursion from norm 
Gl (mmol/l) 
Between Grps 8.53 2 4.26 17.17 .00 
Within Grps 10.43 42 .24   
Total 18.97 44    
 
 
Table 46: Year 1 CGM Parameters v Degree of CGM Profile Variability by Eye 
CGM PARAMETERS V 
DEGREES OF VARIABILITY 
BY EYE 
 
N 
 
Mean 
 
Std. Dev 
 
Std. 
Error 
95% Confidence 
Interval for Mean 
 
Min 
 
Max 
Lower 
Bound 
Upper 
Bound 
MEAN Year1 
AvGl (mmol/l) 
Least 8 5.98 .66 .23 5.42 6.53 5.03 6.82 
Medium 16 6.64 .42 .10 6.42 6.87 6.17 7.66 
Most 13 7.75 1.15 .32 7.05 8.45 6.07 10.47 
Total 37 6.89 1.04 .17 6.54 7.24 5.03 10.47 
MEAN Year1 
AvGl excursion 
from Av 
(mmol/l) 
Least 8 .64 .20 .072 .47 .81 .41 1.00 
Medium 16 .97 .22 .056 .85 1.09 .72 1.47 
Most 13 1.68 .64 .17 1.29 2.07 1.03 3.41 
Total 37 1.15 .58 .09 .95 1.34 .41 3.41 
MEAN Year1 Av 
above norm Gl 
(mmol/l) 
Least 8 1.48 .66 .23 .92 2.03 .53 2.32 
Medium 16 2.14 .42 .10 1.92 2.37 1.67 3.16 
Most 13 3.25 1.15 .32 2.55 3.95 1.57 5.97 
Total 37 2.39 1.04 .17 2.04 2.74 .53 5.97 
MEAN Year1 
AvGl excursion 
from norm Gl 
(mmol/l) 
Least 8 1.67 .54 .19 1.22 2.12 1.03 2.44 
Medium 16 2.38 .35 .08 2.19 2.57 1.82 3.25 
Most 13 3.72 1.16 .32 3.02 4.43 2.33 6.19 
Total 37 2.70 1.10 .18 2.33 3.07 1.03 6.19 
 
Table 47: Year 1 Test of Homogeneity of Variances 
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VARIABLES Levene Statistic df1 df2 Sig. 
MEAN Year1 AvGl (mmol/l) 3.27 2 34 .050 
MEAN Year1 AvGl excursion 
from Av (mmol/l) 
3.94 2 34 .029 
MEAN Year1 Av above norm Gl 
(mmol/l) 
3.27 2 34 .050 
MEAN Year1 AvGl excursion 
from norm Gl (mmol/l) 
5.76 2 34 .007 
 
 
Table 48: Year 1 ANOVA of CGM Profile Variability by Eye and CGM 
CGM PARAMETERS Sum of 
Squares 
Df Mean 
Square 
F Sig. 
MEAN Year1 AvGl 
(mmol/l) 
Between 
Groups 
17.36 2 8.68 13.48 .00 
Within Groups 21.89 34 .64   
Total 39.25 36    
MEAN Year1 AvGl 
excursion from Av 
(mmol/l) 
Between 
Groups 
6.24 2 3.12 17.71 .00 
Within Groups 5.98 34 .17   
Total 12.22 36    
MEAN Year1 Av above 
norm Gl (mmol/l) 
Between 
Groups 
17.36 2 8.68 13.48 .00 
Within Groups 21.89 34 .64   
Total 39.25 36    
MEAN Year1 AvGl 
excursion from norm 
Gl (mmol/l) 
Between 
Groups 
23.71 2 11.85 19.84 .00 
Within Groups 20.31 34 .59   
Total 44.02 36    
 
6.4.2 CGM Profiles & Outcome: Year 1 and Year 3 
At Year 1, subjects were classed as DM (T2DM) according to their OGTT result (FPG 
≥ 7.0 mmol/l) and at Year 3, a FPG ≥ 7.0 mmol/l. With regard to the subjects who 
became DM (T2DM) at Year 1 (n = 8) (Table 49), 100% of those that underwent repeat 
testing with OGTT at Year 1, had FPG ≥ 6.1 mmol/l and 62.5% of them had a Year 3 
FPG of ≥ 7.0 mmol/l. With regard to the corresponding CGM profiles (SAP) that were 
inspected by eye, 87.5% of the subjects that were classed as DM (T2DM) at Year 1 on 
OGTT results had CGM profiles (at baseline or Year 1) that were thought to be at least 
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of medium variability (apart from subject IPRO-03, who refused a repeat OGTT). At 
Year 1, for those (n = 8) subjects found to be DM (T2DM), 50% of them (n = 4) had 
been prescribed medication by their General Practitioner (GP); the other 50% (n = 4) 
had received diet and lifestyle advice. At Year 3, all subjects who had been commenced 
on medication at Year 1 by their GP had a FPG of ≤7 mmol/l; these subjects were 
scored as having DM (T2DM) at Year 3. With regard to the five subjects (n = 5) that 
received lifestyle advice from the GP at Year 1, less than 50% had improvement in their 
FPG at Year 3 on testing. The GP was contacted immediately by telephone, regarding 
subject IPRO-22, who had a FPG at Year 3 of 22.0 mmol/l. Interestingly, two subjects 
IPRO-13 and IPRO-19 did not attend for Year 1 repeat OGTT testing, but did attend at 
Year 3 and were both found to both have FPG≥ 7.0 mmol/l i.e. DM (T2DM). IPRO-06 
was DM at Year 1 and had a most variable CGM profile, which remained most variable 
at Year 3 (Figure 95). 
 
With regard to the subjects who became NGT at Year 1 (n = 7) all of them had FPG ≤ 
6.1 mmol/l (Error! Reference source not found.). With regard to the corresponding CGM profiles 
(SAP) that were inspected by eye, the majority (57.14%) (n = 4) of subjects profiles 
became less variable with time; 14.28% (n=1) of the CGM profiles (SAP) stayed the 
same and 28.57% (n = 2) of the CGM profiles (CGM) increased in variability with 
time) (Figure 96). Interestingly, at Year 3, two subjects went on to become DM (T2DM) 
i.e. FPG ≥7.0 mmol/l (IPRO-34 and IPRO-36) and both of their corresponding CGM 
profiles were observed by eye to have increased in variability also none of these 
subjects had been prescribed medication by their GP. 
 
With regard to the subjects who were found to be IFG at Year 1 (n = 10), as expected all 
of them had FPG ≥ 6.1mmol/l (Table 51). With regard to the corresponding CGM 
profiles (SAP) that were inspected by eye, the majority 40% (n = 4) of subjects profiles 
became increasingly variable with time; 30% (n=3) of the CGM profiles (SAP) stayed 
the same and 30% (n = 3) of the CGM profiles (CGM) decreased in variability with 
time. Interestingly, three subjects had been prescribed medication or given lifestyle 
advice by their GP, all of which had between medium to most variability on their 
corresponding CGM profiles (SAP), the two subjects (IPRO-35 and IPRO-38) with the 
most variability on CGM profiles (SAP) at Year 3 went on to have FPG at this point ≥ 
7.0 mmol/l (Figure 97). 
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With regard to the subjects who were found to be IFG+IGT at Year 1 (n = 7), all of them had FPG ≥ 6.1 
them had FPG ≥ 6.1 mmol/l ( 
Table 52). With regard to the corresponding CGM profiles (SAP) that were inspected 
by eye, the majority 57.1% (n = 4) of subjects profiles became increasingly variable 
with time; 28.5% (n=2) of the CGM profiles (SAP) stayed the same and 14.2% (n = 1) 
of the CGM profiles (CGM) decreased in variability with time. At Year 3, three subjects 
(IPRO-07, IPRO-11 and IPRO-21) had FPG ≥7 mmol/l and all of them had received 
lifestyle advice from the GP. Subject IPRO-18 had been placed on medication by the 
GP based on his baseline abnormal OGTT; interestingly, the corresponding CGM 
profile (SAP) appeared to increase in variability (Figure 98). 
 
With regard to the subjects who became IGT at Year 1 (n = 5) ( 
Table 53), all of them had FPG ≤ 6.1 mmol/l at Year 1. With regard to the 
corresponding CGM profiles (SAP) that were inspected by eye, the majority (60%) (n = 
3) of subjects profiles became less variable with time; 40% (n=2) of the CGM profiles 
(SAP) stayed the same and none of the CGM profiles (CGM) increased in variability 
with time. None of these subjects had been prescribed medication by their GP. Based on 
FPG at Year 3, only one subject (IPRO-02) had a FPG ≥7.0 mmol/l (Figure 99). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 49: DM (T2DM) at Year 1 with regard to CGM Profiles 
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Subject Y1 OGTT Result 
(FPG) (mmol/l) 
CGM Profile 
Baseline 
CGM Profile 
Year 1 
GP Advice Year 3 FPG 
(mmol/l) 
*IPRO-03 / Least Most Medication 6.10 
IPRO-06 7.2 Most Most Medication 7.0 
*IPRO-13 / / / / 7.7 
IPRO-14 6.1 Most Most Lifestyle 6.5 
*IPRO-19 / / / / 9.3 
IPRO-22 7.0 Most Medium Lifestyle 22.0 
IPRO-24 7.0 Most Medium Medication 6.5 
IPRO-26 7.2 Medium Medium Lifestyle 6.9 
IPRO-28 7.7 Most Most Lifestyle 8.0 
IPRO-41 7.3 Medium Medium Lifestyle 6.6 
*Subject IPRO-03 refused repeat OGTT but agreed to CGM. Subjects IPRO-13 and IPRO-19 did not attend for Year 
1 repeat OGTT testing, but attended for Year 3 FPG check. 
 
 
 
Figure 95: DM: Sensor Modal Day Subject: IPRO-06a and IPRO-06b 
-*IPRO-06a: DM at Year 1: most variability demonstrated on CGMS at baseline and Year 1, as can observed from 
the subject profiles above. 
Table 50: NGT at Year 1 with regard to CGM Profile 
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Subject Y1 OGTT Result 
(FPG) (mmol/l) 
CGM Profile 
Baseline 
CGM Profile 
Year 1 
GP Advice Year 3 FPG 
(mmol/l) 
IPRO-23 4.2 Medium Least / 4.7 
IPRO-30 5.3 Medium Least / 6.3 
IPRO-34 5.7 Least Medium / 7.6 
IPRO-36 5.7 Medium Most / 8.0 
IPRO-37 4.6 Medium Medium / 5.2 
IPRO-39 5.9 Most Medium / 6.8 
IPRO-43 5.8 Medium Least / 6.2 
*Y1 = year  
 
 
 
Figure 96: NGT Sensor Modal Day Subject: IPRO-23a and IPRO-23b 
-Medium variability at baseline on CGM Profiles by eye, least variability at Year 1, as can observed from the subject 
profiles above. 
 
 
Table 51: IFG at Year 1 with regard to CGM Profiles 
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Subject Y1 OGTT Result 
(FPG) (mmol/l) 
CGM Profile 
Baseline 
CGM Profile 
Year 1 
GP Advice Year 3 FPG 
(mmol/l) 
IPRO-16 6.2 Medium Least / 6.5 
IPRO-17 6.3 Medium Least / 6.6 
IPRO-20 6.2 Least Medium / / 
IPRO-31 6.2 Most Most Medication 6.6 
IPRO-35 6.3 Medium Most Medication 7.2 
IPRO-38 6.8 Medium Most Lifestyle 7.5 
IPRO-42 6.3 Most Medium / / 
IPRO-44 6.4 Medium Medium / 6.5 
IPRO-45 6.5 Medium Most / 6.3 
IPRO-46 6.6 Medium Medium / / 
*Y1 = Year 1 
 
 
 
Figure 97: IFG Sensor Modal Day Subject IPRO-35a and IPRO-35b 
--Medium variability at baseline on CGM Profiles by eye, most variability at Year 1, as can observed from the subject 
profiles above. 
 
 
Table 52: IFG+IGT at Year 1 with regard to CGMS Profiles 
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Subject Y1 OGTT Result 
(FPG) (mmol/l) 
CGM Profile 
Baseline 
CGM Profile 
Year 1 
GP Advice Year 3 FPG 
(mmol/l) 
IPRO-05 6.8 Least Medium / 6.6 
IPRO-07 6.3 Least Least Lifestyle 8.3 
IPRO-09 6.2 Least/Medium Medium / / 
IPRO-11 6.3 Least Most Lifestyle 7.6 
IPRO-18 6.3 Medium Most Medication 6.0 
IPRO-21 6.4 Most Medium Lifestyle 7.2 
IPRO-46 6.9 Medium Medium / 6.4 
*Y1 =Year 1 
 
 
 
Figure 98: IFG+IGT Sensor Modal Day Subject: IPRO-11a and IPRO-11b 
-Least variability at baseline on CGM Profiles by eye, most variability at Year 1, as can observed from the subject 
profiles above. 
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Table 53: IGT at Year 1 with regard to CGM Profiles 
Subject Y1 OGTT Result 
(FPG) (mmol/l) 
CGM Profile 
Baseline 
CGM Profile 
Year 1 
GP Advice Year 3 FPG 
(mmol/l) 
IPRO-01 5.9 Most Most / 6.3 
IPRO-02 6.0 Most Medium / 7.4 
IPRO-10 5.9 Most Least / 5.4 
IPRO-29 5.2 Least Least / 4.6 
IPRO-40 6.0 Most Medium / 6.7 
*Y1 = Year 1 
 
 
 
Figure 99: IGT Sensor Modal Day Subject IPRO-02a and IPRO-02b 
-Most variability at baseline on CGM Profiles by eye, medium variability at Year 1, as can observed from the subject 
profiles above. 
 
 
6.5 Regression Analysis 
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Regression analysis is a statistical process used to estimate the relationships among 
variables. The focus is on the relationship between the dependent variable (outcome) 
and one or more independent variables or predictors. It is used to understand which 
among the independent variables are related to the dependent variables. In this study, 
the outcome (dependant variable) was Year 3 FPG. 
 
Baseline Age, baseline BMI, baseline Gender, baseline FPG, baseline 2hr glucose, 
baseline HbA1c, baseline CGM for 4 parameters respectively, GAD Ab, C-peptide and 
insulin were all tested with regard to Year 3 Outcome, using a binary logistical 
statistical programme, to see if any of them affected the outcome or influenced each 
other. The Null Hypothesis being that there was no association with any of the 
measurement variables discussed above, at the p < 0.05 level and the outcome (DM i.e. 
FPG Year 3) (Table 54). 
 
In logistic regression, the Wald statistic (which has a Chi-square distribution), was used 
to assess the contribution of predictors. The Wald statistic was the value of the 
regression coefficient divided by its associated standard error; the odds ratio [Exp(B)] 
was an indicator of the change in odds resulting from a unit change in the predictor (78). 
In this study, none of the parameters tested reached significance (at the p < 0.05 level), 
with regard to outcome affect and the Null Hypothesis was accepted. 
 
 R = (1) 2.69 p > 0.05 (0.1) 
 
6.6 Summary: Chapter 6 
A number of pre-selected parameters were analysed at baseline, Year 1 and Year 3 with 
regard to looking at progression towards an outcome of diabetes (T2DM) or non 
diabetes. At Year 1, an outcome of DM (T2DM) or non diabetes was established for all 
study subjects following testing with OGTT; at Year 3, an outcome of DM (T2DM) or 
non diabetes was established for all study subjects following FPG testing. The 
parameters were analysed in order to look at progression or change over time. At 
baseline and Year 1, parameters analysed included FPG, OGTT 2 hours, HbA1c, plus 
the four CGM parameters (Mean Baseline Average Glucose; Mean Baseline Average 
Glucose Excursion from the Average, Mean Baseline Average above Normal and Mean 
Baseline Average Glucose Excursion from the Normal Glucose); at Year 3, FPG and 
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HbA1c were analysed. At Year 1, 17.8% of subjects had progressed to DM (T2DM) 
(Table 35) and at Year 3, 46.6% of subjects had progressed to DM (T2DM) Table 36). 
 
Assuming the data to be normally distributed, the Independent Sample t-Test was used 
to compare the means of two independent groups in order to determine whether there 
was a statistically significant difference between them. The two outcome groups were 
non diabetes and diabetes. The outcome of both groups at Year 1 and Year 3 was 
investigated with regard to a number of baseline variables: 
 
 Baseline Age (years) 
 Baseline OGTT 0 mins (mmol/l) 
 Baseline OGTT 2 hours (mmol/l) 
 Baseline HbA1c (mmol/mol) 
 Mean Baseline Average Glucose (mmol/l)  
 Mean Baseline Average Glucose Excursion (mmol/l) from Average 
 Mean Baseline Average above Normal Glucose (mmol/l) 
 Mean Baseline Average Glucose Excursion from Normal Glucose 
(mmol/l)Baseline BMI (Kg/m2) 
The outcome of both groups at Year 3 was investigated with regard to: 
 Year 1 Insulin and Year 1 C-peptide. 
The Null Hypothesis in this instance was that there was no significant difference (i.e. no 
variation) with regard to the specified variable in each group, with regard to outcome. 
Where Levene’s test was p>0.05, the Null Hypothesis was accepted. With regard to 
Year 1 outcome, a 95% CI, a p<0.05 was classed as statistically meaningful and 
significant and the Null Hypothesis was rejected. With regard to Baseline OGTT 120 
mins and Mean Baseline Average Glucose Excursion (mmol/l) from Average, the 
results were significant and the Null Hypothesis was rejected. There was a significant 
difference between the groups at Year 1 for Baseline OGTT 120 mins and Mean 
Baseline Average Glucose Excursion (mmol/l) from Average (Table 37, Table 38). 
With regard to Year 3 outcome, none of the variables tested demonstrated significance 
difference in means, when the outcome of the diabetes and non diabetes groups was 
investigated, respectively (Table 39, Table 40). Of the 4 CGM Parameters constructed 
to look at whether they were able to predict progression to DM (T2DM), one of the 
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most promising parameters was seen to be ‘Mean Baseline AvGl Excursion from Av’. 
However, when one looked at this particular parameter - ‘Mean Baseline AvGl 
excursion from Av’ with regard to Year 3 outcome of diabetes (T2DM), the median 
values were almost the same for the subjects with diabetes as those without, which was 
disappointing. The resulting inter-quartile ranges and lowest and highest values of data 
were for each outcome was almost identical also (Figure 80). 
 
In this study, a number of categorical variables were also assessed at baseline, to see if 
they had any bearing on the outcome of DM (T2DM) at Year 1 or Year 3. Pearson’s-chi 
square test was used to compare the frequency observed in certain categories to the 
frequencies one may expect to get in those categories by chance. Ethnicity, smoking 
status, hypertension, dyslipidemia and FHx DM did not significantly affect risk of DM 
(T2DM) at Year 1 or Year 3 and the Null Hypothesis was accepted in these cases. 
Baseline CGM Profiles (SAP) were also studied and did not significantly affect risk of 
DM (T2DM) at Year 1 and Year 3. 
 
The CGM profiles for each subject that were inspected by eye (SAP) were investigated 
to see if there was a significant difference in them with regard to each of the four 
devised CGM parameters that were used to assess CGM subject data. ANOVA was 
conducted at baseline and Year 1 to evaluate the Null Hypothesis, in that there was no 
significant difference in the CGM profiles inspected by eye (least, medium and most 
variability) based on the four CGM parameters respectively. The observed significance 
value was less than 0.05 (p<0.05) with regard to variability (least, medium and most) 
for all 4 CGM parameters, respectively ( 
 
Table 44) ( 
Table 45) (Table 47) (Table 48). Therefore, there was a significant difference between 
the variability of the visually inspected CGM profiles for each of the CGM parameters 
studied at baseline and at Year 1; the Null Hypothesis was thus rejected. 
 
Finally, regression analysis was used to understand which among the independent 
variables were related to the dependent variables. In this study, the dependent variable 
was Year 3 FPG and the independent variables were baseline Age, BMI, Gender, FPG, 
2hr glucose, HbA1c, CGM for 4 respective parameters, GAD Ab, C-peptide and insulin. 
The independent variables were all tested with regard to Year 3 Outcome, using a 
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binary logistical regression analysis to see if any of them affected the outcome or 
influenced each other. The Null Hypothesis being that there was no association with any 
of the measurement variables discussed above at the p < 0.05 level and the outcome 
(DM i.e. FPG Year 3) (Table 54). In this study, none of the parameters tested reached 
significance (at the p < 0.05 level), with regard to outcome affect and the Null 
Hypothesis was accepted. 
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Table 54: Regression Analysis - Binary Logistic 
Variables not in the Equationa 
 Score Df Sig. 
Step 0 Variables 
FHxDM(1) .012 1 .913 
Gender(1) 3.155 1 .076 
Ethnicity(1) .229 1 .632 
BaselinesmokingStatus(1) .002 1 .965 
BaselineHypertension(1) .440 1 .507 
BaselineDyslipidaemia(1) 1.357 1 .244 
BaselineAgeyears .045 1 .831 
BaselineWeightkg .153 1 .696 
BaselineBMIkgm2 .188 1 .665 
BaselineOGTT0minsmmoll 1.118 1 .290 
BaselineOGTT120minsmmo
ll 
.939 1 .332 
MIXBaselineOGTTresult 2.174 2 .337 
MIXBaselineOGTTresult(1) .018 1 .893 
MIXBaselineOGTTresult(2) .944 1 .331 
BaselineHbAlcmmoll .906 1 .341 
BaselineCGMprofilesSAP 1.402 2 .496 
BaselineCGMprofilesSAP(1) .081 1 .775 
BaselineCGMprofilesSAP(2) 1.357 1 .244 
Year1GADuml .004 1 .948 
Year1InsulinpmolL .702 1 .402 
Year1Cpeptidepmolml .396 1 .529 
MEANBaselineAvGlmmolL 3.837 1 .050 
MEANBaselineAvGlexcursio
nfromAvmmolL 
.161 1 .688 
MEANBaselineAvabovenor
mGlmmolL 
3.837 1 .050 
MEANBaselineAvGlexcursio
nfromnormGlmmolL 
3.235 1 .072 
baseline_BMI_categories .307 2 .858 
baseline_BMI_categories(1) .229 1 .632 
baseline_BMI_categories(2) .136 1 .713 
BaseAgeGrp .672 2 .715 
BaseAgeGrp(1) .545 1 .460 
BaseAgeGrp(2) .028 1 .868 
a. Residual Chi-Squares are not computed because of redundancies. 
 
Variables in the Equation 
 B S.E. Wald Df Sig. Exp(B) 
Step 0 Constant -.642 .391 2.699 1 .100 .526 
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7.0 Discussion 
During the recruitment period between October 2009 and June 2011, 486 subjects were 
screened for this study. All subjects were invited to participate in the study if they met 
the study inclusion criteria and were found to have impaired glucose tolerance on 
testing. Out of the 486 subjects screened 47 subjects were recruited to study (cohort 
group), almost meeting our study objective of n = 50. Of these 47 subjects, all have 
completed baseline (A) t = 0 investigations; two subjects requested to leave the study 
following completion of baseline t = 0 investigations. One year later, all 45 subjects of 
the cohort group were invited to return for t = 12 month follow up investigations Of the 
45 subjects contacted, 37 subjects responded and have completed 12 month follow up 
(B) investigations. The 8 outstanding subjects were withdrawn from the study at this 
point either at their request (due to personal time commitments) or being untraceable via 
all forms of communication. Of note, a 10-fold difference was observed in the subjects 
attending for OGTT to those who actually participated in the study. This data may be 
useful when planning future studies with regard to consideration of target recruitment 
numbers. At Year 3, similar numbers returned for assessment, limiting the ‘drop out’ 
rate. 
 
There is no screening programme in Wales for T2DM. Patients referred in for OGTT 
testing in this study form a group of individuals deemed to be ‘intermediate risk’, this 
being based on the fact that GP and secondary care physicians selected them from the 
population as a whole and referred them in. The risk of picking up positive OGTT 
initially from a general screen of the population as a whole would be lower. As 
previously discussed, IFG and IGT classify a pre-diabetic state and define individuals 
who may develop progressive deterioration in glucose homeostasis, leading to frank 
T2DM, as described by Gabir et al (2000) (4). Many people with IFG or IGT will not 
progress to T2DM but appear to spontaneous revert to normal, as described by Lim et al 
(2000) (5). Others may progress only very slowly, whereas in some cases the 
progression may be rapid, as described by Alberti et al (1996) (6). At Year 1, 37 
subjects (n = 37) completed 12 month follow up and (n = 8) subjects (22%) were shown 
to have progressed to diabetes on repeat OGTT testing, at Year 3, approximately half of 
the study group had become diabetic (T2DM). This result would be in excess of the 
projected numbers thought to progress in this population from initial calculations at 12 
months. Of the remaining 29 subjects, one would expect half of them to revert to 
normal, as described by Barr et al (2007) (20) and the other half to stay as IFG/IGT. In 
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this instance, 7 subjects (n =7) (19%) returned to normal glycaemia, which is less than 
anticipated at 12 months. This may be due to the clinical advice and information 
received by the patient from their referring clinician at baseline OGTT testing and also 
if any advice given was carried out. However, it would be consistent with the projected 
estimated target number at 2 years. 
 
As already discussed, therapeutic interventions have been shown to reduce the risk, or at 
least the pace of deterioration from IGT and IFG to T2DM (Riccardi et al 1985) (7) 
(Ferrannini et al 2004) (8) and (Unger and Orci 2010) (9). To target interventions 
specifically to prevent progression in those at greatest risk, further information as to 
which individuals are most likely to progress is needed. A marker of deteriorating 
carbohydrate homeostasis would be increased fluctuations in blood glucose levels. The 
use of continuous glucose sensing to quantify the fluctuations was proposed in this 
study to assess whether CGMS could help identify people with abnormal glucose 
tolerance who progress to T2DM. Unfortunately, the analysis here demonstrated here, 
as seen in Results Chapters 4, 5 and 6 that CGMS were unable to predict progression to 
diabetes in this study population. In this study, none of the analysis conducted reached 
statistical significance (p< 0.05). It may be that in a larger data set, CGM may have 
greater predictive power to predict progression to diabetes from a pre diabetic state. 
CGM, did however, identify a group, IFG subjects, who between baseline and Year 1 
appeared to demonstrate an increased risk of progression towards diabetes, which was 
also reflected in the subjects CGM profiles level of variability ie medium variability. 
This may be the group on which to focus, with regard to targeted intervention. The 
apparent baseline high risk group identified from this study was IFG. The CGM 
parameter mean average glucose excursion above the average seemed at times to be 
approaching significance in the various statistical tests, unfortunately, it was not a 
significant predictor of progression. 
 
This study had a number of strengths and weaknesses 
Strengths 
 The study was ethically approved. 
 The study subjects were reflective of a normal population. 
 The cohort of individuals with a positive OGTT, that gave consent to be 
included in the study were a precious resource. 
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 Demographic data was obtained on all subjects for past medical history 
(hypertension, dyslipidemia, cardiovascular disease, pancreatic disease and 
thyroid disease), social history (smoking history), family history of diabetes, 
medications and ethnicity. 
 The study data was analysed at baseline, Year 1 and Year 3 respectively, 
according to outcome. In order to enable a Year 3 analysis and obtain increased 
data regarding disease progression, an ethical amendment was successfully 
obtained. 
 At Year 1, 37 subjects (n = 37) out of the original 45 baseline subjects (n = 45) 
returned (82.2%), with similar numbers at Year 3 (84.4%); this demonstrated 
minimal ‘drop out’ rate. 
 As part of the study, subjects were identified that had progressed in all the 
possible combination of ways: i.e. progressed from IFG and IGT to T2DM; 
progressed from IFG and IGT to NGT, progressed from IFG to IGT or remained 
static. 
 The outcome of the 12 months repeat OGTT, which ever direction it progressed 
appeared to be reflected in the HbA1c value. 
 The CGM sensor was able to read 288 readings of interstitial glucose in any 24 
hour period. 
 There was a 10-fold difference observed in subject number attending for OGTT 
to those who actually participated in this study. This data may be useful in 
planning future studies, as it may have bearing when attempting to recruit a set 
target number. 
 In the future, the ‘raw data set’, could be used for further studies. For example, 
re-analysis at different time points, which may yield beneficial information:- 
(1)  Complete 24 hour data sets (midnight to midnight) 
(2) Complete day time data (12 hour data) (9am-9pm) 
(3) Complete night time data (12 hour data) (9pm-9am) 
(4) Meal time data. This can be split into pre-prandial (fasting) and 2 hour 
postprandial for breakfast, lunch and supper time. 
 
Weaknesses 
 The patients referred in for OGTT testing in this study form a group of 
individuals deemed to be ‘intermediate risk’, as GPs have already ‘selected’ 
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them from the population as a whole and referred them. The risk of picking up 
positive OGTT initially from a general screen of the population as a whole 
would be lower. 
 A larger cohort of subjects (i.e. > n = 45) at the start would have added power to 
the study. 
 A robust plan to analyse the subjects who withdrew from the study at each stage, 
would have provided added information to this study. 
 The age range of the subject cohort was approximately 45-70 years, which 
appeared to be biased towards the older age group. However, this may be a 
reflection of real life with regard to T2DM. 
 Initially, the study was to look at progression of disease from baseline to Year 1 
and Year 3. However, in reality some subjects returned up to 6 months after 
their exact date for re analysis. Ideally, exact date re-analysis would have been 
preferred. 
 A complete data set is optimal. In this study, the data set was incomplete in 
places; for example, (n = 1) subject out of (n = 37) subjects at Year 1 refused the 
OGTT but agreed to CGM. At Year 3, OGTT was not conducted due to patient 
choice and CGM was not conducted due to patient choice and PI/funding 
availability. Any incomplete data was accounted for during the statistical 
analysis. 
 All subjects should have had GAD Ab test at baseline rather that at Year 1. All 
subjects should also have had insulin and C-peptide testing at baseline and at 
Year 3. This was due to availability and limitation in study funding. 
 There is only a single day of complete 24 hour CGM sensor data in some study 
subjects; ideally, there should be 4-5 days of complete data to get the most 
accurate results. One could have increased the chances of achieving complete 
CGM sensor data if the subjects had agreed to wear the sensor for longer. 
However, this would have meant the subjects returning multiple times for a fresh 
sensor (which was not favoured by the subjects). If this was stipulated, then it 
may have resulted in an increased ‘drop out’ rate. 
 The CGM system requires calibration using a blood glucose value obtained from 
a home glucose meter. Therefore, any inaccuracies of the value obtained from 
the reference meter would also affect the accuracy of the value calculated by the 
CGM system. Since the sensitivity of the sensor changes also, any failure to 
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calibrate the sensor by the study subjects (at least four times daily as instructed) 
would result in inaccurate glucose readings. 
 
With the study aim in mind, a set of specific objectives were set out that were 
measurable, potentially achievable, realistic and timely. With regard to them, ethical 
approval was successfully obtained from the relevant bodies in order to conduct the 
study. Statistical advice was obtained from Professor Robert Newcombe, Cardiff 
University School of Medicine and a proposed sample size of (n = 50) with confirmed 
IFG/IGT on OGTT was considered justifiable. Demographic data, a thorough medical 
history, medication history, family history and social history was obtained at baseline 
and on all study subjects that returned for repeat testing at Year 1 and Year 3. Instead of 
ideally, obtaining GAD antibody status, C-peptide and Insulin levels on all study 
subjects at baseline, this was obtained at Year 1. This was due to the fact that the 
original ethical approval did not include GAD Ab, C-peptide or Insulin testing. An 
amended ethical approval was successful in order to achieve this. At baseline and Year 
1, OGTT, check HbA1c and CGM was performed on all study subjects. At Year 3, FPG 
was performed and used as outcome indicator, instead of OGTT. Although ethical 
approval was obtained for an OGTT and CGM at Year 3, when the study subjects 
contacted and invited back, they were not keen to have OGTT or CGM; however, they 
were happy to attend for a FPG. With the assistance of Professor Richard Ollerton, 
Professor of Statistics (Sydney Australia), glycaemic excursion variables to reflect 
glucose fluctuations observed in CGM were constructed. These were successfully 
applied in Excel 2007 to the raw CGM sensor data. Baseline, Year 1 and Year 3 data 
were successfully analysed, with regard to the study parameters and the CGM profiles 
for each study subject were separated by eye into 3 groups based on variability (least 
variability, medium variability and most variability). The paired Sample t-Test was then 
successfully used to compare differences in two means of the set parameters as the 
study progressed with time and the independent sample t Test was successfully used to 
compare the means of two independent groups (diabetes and non diabetes) at Year 1 and 
Year 3, in order to determine any significant difference between them, when tested 
against a number of baseline parameters. ANOVA was used at baseline to evaluate any 
significant difference between the CGM profiles by inspection and the statistically 
constructed CGM parameters and baseline parameters were tested successfully for Year 
1 and Year 3 outcome, using binary logistic regression analysis, to see if any of them 
affected the outcome or influenced each other. 
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In general, the research design worked well and was guided by the objectives in a 
stepwise fashion. This contributed to achieving the overall aim of the study, which was 
to assess whether CGMS can help identify people with abnormal glucose tolerance that 
progress to T2DM. In addition to this, this study enabled the PI to have an opportunity 
to educate and improve the awareness in study subjects, with regard to T2DM risk 
factor modification and prevention. In addition, this study enabled the PI to gain 
experience and knowledge in the use of new technologies, currently at the forefront of 
diabetes clinical care and research. In this study, the data was not significant and 
unfortunately CGM was not able to be used to predict progression from abnormal 
glucose tolerance (pre-diabetes) to T2DM; the Null Hypothesis was rejected. 
 
To date, there are a number of high risk patients in which the use of CGM has 
demonstrated beneficial information, to diagnose early glycaemic abnormalities, as 
described by Soliman et al (2014) (79): 
 Morbid obesity: Studies have demonstrated that in obese children and 
adolescents, CGM is superior to OGTT and HbA1C in detecting early glycaemic 
abnormalities El Awwa et al (2012). 
 
 Polycystic ovary syndrome (PCOS): Tao et al (2009) investigated 20 PCOS 
women with NGT and 20 age-matched healthy women with normal 
menstruation using OGTT and CGM. Results demonstrated CGM diagnosed an 
abnormal mode of daily glucose change in the PCOS group, characterized by a 
delayed peak of post-breakfast plasma glucose level. 
 
 Cystic fibrosis (CF): A long pre-diabetic phase of abnormal glucose tolerance 
is described in subjects with CF since childhood. Under certain circumstances, 
OGTT screening, used to diagnose CF-related diabetes (CFRD), fails to reveal 
early glucose tolerance abnormalities. In this situation, CGM could be a useful 
tool for evaluating early abnormalities of glucose tolerance in CF patients as 
described by Schiaffini et al (2010). 
 
 Thalassemia major (TM): Both insulin deficiency and resistance are reported 
in patients with β-thalassemia major. Studies have demonstrated that CGM is a 
useful method to detect the variability of glucose fluctuations and offers the 
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opportunity for better assessment of glucose homeostasis in TM patients, as 
described by Soliman et al (2013). 
 
 Gestational diabetes (GDM): A study by Bühling et al (2004), demonstrated 
that CGM detected more frequent and longer durations of hyperglycemia in 
GDM compared to non diabetic women than the SMBG and women with an 
IGT exhibited higher glucose levels than patients with gestational diabetes. 
 
 Acute coronary syndrome (ACS): Intensive monitoring for hyperglycemia is 
essential during care for ACS. Radermecker et al (2009) demonstrated that 
CGM disclosed early and frequent hyperglycaemia in non-diabetic patients with 
ACS compared to SMBG. 
 
 After renal transplantation: New onset of diabetes after transplantation 
(NODAT) and IGT are well-known complications of immunosuppressive 
therapy after transplantation, being a risk factor for cardiovascular disease 
affecting patient and graft survival. Therefore, early identification and treatment 
are of high importance. A study by Pasti et al (2013) (80) demonstrated that 
CGM analysis showed that IGT patients had higher “lowest glucose” level and 
the incidence of hypoglycemic episodes was significantly lower compared with 
patients with normal OGTT result. In IGT patients, glucose variability tended to 
be lower. 
 
 In critically ill and in perioperative, intraoperative and postoperative 
periods: Given the demonstrated benefit of euglycemia in critically ill patients 
as well as the risk for hypoglycemia during their management, Piper et al (2006) 
(81) used CGM in this instance and reported effective glucose monitoring by 
CGM; the sensor performance was also not affected by body temperature, 
ionotrope dose, or body-wall oedema. 
In summary, the use of CGM in the diagnosis of early dysglycemia (pre-diabetes) in 
high risk patients, described above, appears to be promising and in many occasions 
superior to other known diagnostic modalities namely OGTT and measurement of 
HbA1C. Its use in combination with intermittent glucose monitoring adds to its 
accuracy and reliability. 
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With regard to using CGM as an early detection test for the masses at high risk of 
T2DM, the main disadvantages and limiting factors here would be patient factors, 
practical issues, technical issues and cost. CGM systems are an emerging technology 
that allows frequent glucose measurements to monitor glucose trends in real time. Their 
use as a diagnostic tool is still developing, but the real benefit of CGM currently lies is 
in the field of clinical diabetes management. CGM is especially beneficial for 
individuals who (i) want to reduce their HbA1c target without increasing hypoglycemia 
risk; (ii) aid identification of hypo- unawareness; (iii) in pregnancy and (iv) in children 
and adolescents at or above their target HbA1c (82). When this study began in 2009, 
there was a paucity of research studies that had used CGM to look at predication of 
progression from pre-diabetes to T2DM. However, over the years the use of CGM has 
become more commonplace and is now used widely in diabetes research and clinical 
management, as described by Field (2013) (79). 
 
In the future, there are many exciting technologies that are being developed in the field 
of diabetes; for example, the Smart digital contact lens® that aims to measure blood 
glucose levels from tears (83), the Apple Inc Smart Watch® that encompasses a CGM 
Application (App) (84) and the IBG Star® Diabetes Management App (85), but to name 
a few. There are now glucose monitors that can be worn for longer time periods, 
improved sensors (Enlite) (86) and inserters and advancing pump technology, such as 
the Minimed connect (87). Abbot Freestyle Libre CGM (88) has also arrived and with 
the aid of sensor augmented pump therapy the loop towards an artificial pancreas is 
closing slowly. However, despite the benefits and uses of CGM in a clinical setting, this 
study was unable to demonstrate that CGM could predict progression from pre diabetes 
to diabetes, which is what our aim was. 
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STUDY PROTOCOL 
Continuous subcutaneous glucose monitoring to predict progression 
from abnormal glucose toleration to Type 2 diabetes mellitus 
 
PROTOCOL:  V3, 7th September, 2011 
REC reference number: 09/WSE03/31 
 
Aim: 
To assess whether continuous glucose monitoring (CGMS) can help identify people 
with abnormal glucose tolerance who progress to Type 2 diabetes mellitus (T2DM) 
within 24 months. 
 
Relevance to diabetes and Background information for the project: 
Type 2 diabetes mellitus (T2DM) is diagnosed when a person is found to have a fasting 
plasma glucose ≥7.0 mmol/l or a random glucose ≥11.1 mmol/l (Alberti KG et al, 
1998). These consensus threshold values are based on evidence which suggests the risk 
of specific complications increases significantly amongst people with plasma glucose 
levels consistently above these levels (Gabir MM et al, 2000). However, both fasting 
and post-prandial (or random) plasma glucose levels broadly follow a normal 
distribution in the general population and it is also known that increased morbidity 
(especially from macrovascular disease) is associated with more modest levels of 
glycaemia (Lim SC et al, 2000). The categories of impaired fasting glycaemia (IFG) 
(fasting glucose >6.1 mmol/l) and impaired glucose tolerance (IGT) (fasting glucose 
>7mmol/l and 2 hour post-challenge 7.8-11.1mmol/l) are an attempt at recognising 
these facts. IFG and IGT not only define cohorts at increased risk of cardiovascular 
disease, but also individuals who may develop progressive deterioration in glucose 
homeostatsis, leading to frank T2DM (Alberti KG et al, 1996). IFG and IGT are 
symptomatic, biochemical classifications, which generally come to light during 
screening programmes for T2DM (Hoerger TJ et al, 2007). However, many people with 
IFG or IGT will not progress to T2DM but appear to spontaneous revert to normal 
(Riccardi G et al, 1985). Others may progress only very slowly, whereas in some cases 
the progression may be rapid (Ferrannini E et al, 2004). 
 
Although the OGTT has the advantage of being relatively cheap and straightforward to 
perform as a basic screening test, it is limited by the fact that it is performed during a 
single two hour period, it is a non-physiological stimulus and individuals show 
variability in glucose tolerance from day to day. A number of therapeutic interventions 
will reduce the risk, or at least the pace, of deterioration from IGT and IFG to T2DM 
(Knowler WC et al, New Eng J Med 2002) (Chiasson JL et al, Lancet 2002) (Torgerson 
JS et al, 2004). In order to target interventions to prevent progression to those at greatest 
risk, we need further information as to which individuals are likely to progress. The 
documented rate of progression from IGT and IFG to T2DM varies between different 
studies (Rasmussen SS et al, 2008) (Shaw JE et al, 1999) (Meigs JB et al, 2003) (Heine 
RJ et al, 1996). In general, progression rates are lowest in those that recruit from the 
general population and highest in those that target ‘at-risk’ groups. Several 
abnormalities have been reported to be associated with a greatest risk of progression 
including age, BMI, fasting and 2 hour plasma glucose concentrations, elevated fasting 
proinsulin, low 2-hour insulin and fasting triglyceride levels (Alberti KG et al, 1996) 
(Rasmussen SS et al, 2008). 
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Progression to T2DM could be mediated by an increase in insulin resistance, further 
impairment of insulin secretion or a mixture of both (Jensen CC et al, 2002) (Abdul-
Ghani MA et al, 2006) (Kapitza C et al, 2003). As adequate moment-by-moment 
insulin secretion and action is essential for glycaemic control, one marker of 
deteriorating carbohydrate homeostasis would be increased fluctuations in blood 
glucose levels. We therefore propose the use of continuous glucose sensing to quantify 
the fluctuations. 
 
Continuous subcutaneous glucose monitors (Medtronic- Continuous Glucose 
monitoring system – CGMS) will measure subcutaneous (interstitial) glucose levels 
every 10 seconds and then store a smoothed average over 5 minutes, continuously for 
up to 3 days with a single sensor (Sachendina N et al, 2003) (Guerci B et al, 2003). The 
monitors are externally calibrated by the subject who enters the result of his/her home 
blood glucose testing (using a standard meter) at least 4 times in each 24-hour period. 
CGMS are accurate and have proved useful in the monitoring of patients with diabetes, 
including those on insulin pump therapy (Faradji RN et al, 2006). It has also been 
suggested they may be of value in identifying early transplant rejection (Faradji RN et 
al, 2006). They have the advantage of documenting continuous glucose variations 
throughout the day, rather than during a short OGTT or discontinuous home blood 
glucose testing. 
 
Inclusion Criteria: 
All people between the ages of 18-80 who have been referred for an oral glucose 
tolerance test and are found, on that test, to have impaired glucose tolerance and/or 
impaired fasting glycaemia. Gender, ethnic origin, nationality, religion, belief or sexual 
orientations are irrelevant in the decision to recruit. 
 
Exclusion Criteria: 
1.  Under the age of 18 years. In view of the increased vulnerability of children, they 
will be excluded from this study. In addition, most people <18 years old will have 
Type 1 rather than Type 2 diabetes since the prevalence of Type 2 diabetes in 
children is low. 
2. Over the age of 80 years. People become increasingly frail with age and, although 
we do not wish to exclude any group arbitrarily, a cut-off age of 80 years with 
ensure people who are vulnerable due to age and frailty are not put at increased risk. 
3. Unable or unwilling to give informed consent. We aim to recruit from as wide as 
range of people as possible. We will explain the research in detail but in plain 
language and we will provide full patient information sheets. Clearly people who are 
unwilling to give informed consent will not be recruited. In addition, people who do 
not have the capacity to give informed consent will be excluded. These will include 
people with severe cognitive impairment who are unable to retain and assimilate the 
information provided. 
4. Unable or unwilling to comply with research requirements. The study requires that 
people check their blood glucose levels at home four times a day using a glucose 
meter over 6 days. Those unwilling to do this will be excluded. In addition, people 
will need to wear continuous glucose sensor for 6 days and enter their blood glucose 
results into it. The device is no more complicated to use than a simple mobile 
telephone, but people who are unable to use it correctly, despite full education, will 
be excluded from the study. Experience from my clinical practice suggests this is a 
rare (<5%) problem. 
5. Pregnancy. Blood glucose levels are significantly affected by pregnancy and 
therefore women who are pregnant or plan to become pregnant during the follow-up 
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period of the study will be excluded. Continuous blood glucose monitoring is 
perfectly safe during pregnancy and should an unforeseen pregnancy occur in one of 
the recruited women, they will be excluded from further analysis, but no harm will 
have been caused. 
6. Intercurrent illness with prognosis of ≤2 years. The aim of this study is to assess the 
value of glucose monitoring in predicting progression to diabetes over a 3 year 
period. People who are unlikely to be able to attend for follow up appointments over 
this period of time will be excluded from the study. 
7. Known previous allergic reactions to adhesive plasters. 
 
Methods 
Recruitment 
1.  People attending for a clinically indicated oral glucose tolerance test (OGTT) at the 
University Hospital of Wales, Cardiff (UHW) will be asked to participate in the 
study. Eligible candidates will be given a patient information sheet and consented by 
the Principal Investigator (PI) 
2. The PI will obtain the results of the OGTT and contact subjects with impaired 
fasting glycaemia or impaired glucose tolerance to arrange their attendance at the 
Diabetes Centre, UHW (visit 1). 
 
Statistical Advice 
This project has been discussed with Professor Newcombe, Cardiff University School 
of Medicine and a proposed sample size of 50 subjects with IFG/IGT is considered 
justifiable. This is based on the assumption that 30% will have been diagnosed as 
having definite diabetes by 2 years and that half the remaining subjects, i.e 35% will 
have reverted to normal. A comparison of those who become diabetic with those who 
revert to normal would have a power of 80% to detect a shift of exactly 1 standard 
deviation in the mean value for any parameter, such as the peak glucose or AUC, using 
a test at the conventional two-sided alpha level. 
 
VISIT 1 
1. The PI will check that participants have understood the patient information sheet 
and that signed consent has been obtained. 
2. The PI will document a brief medical history, including family history of diabetes, 
risk factors for diabetes and current medication. 
3. Participants will be taught home blood glucose monitoring and will be given a 
glucose meter and sufficient strips to test at least 4 times a day for the following 6 
days. 
4. Participants will be fitted with a continuous subcutaneous glucose monitor (CGMS, 
Medtronic) and educated in its use. They will be given a written reminder of how 
the monitor works together with a telephone number to call should it become 
disconnected or appear to malfunction. 
5. 10 ml of blood will be taken from a peripheral vein to check HbA1c, analogous 
markers of glycaemic control, auto- antibodies and serum lipids 
6. Participants will be asked to return on day 3 for Visit 2. 
 
VISIT 2 
1. The PI will check that the participants have recorded at least 4 home blood glucose 
levels each day during the previous 3 days and resolve any questions regarding the 
use of CGMS. 
2. The glucose sensor fitted on Visit 1 will be replaced with a new sensor. 
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3. Participants will be asked to continue to check their home blood glucose levels at 
least 4 times a day for the following 3 days. 
4. Participants will be asked to return 3 days later for Visit 3. 
 
VISIT 3 
1. The PI will check that the participants have recorded at least 4 home blood glucose 
levels during the previous 3 days and resolve any questions that have arisen out of 
the use of the CGMS. 
2. The CGMS sensor and monitor will be removed. 
3. Participants will be reminded that they will be given an appointment for a repeat 
oral glucose tolerance test in 12 months time. 
 
FOLLOW UP OGTT at 12 MONTHS – VISIT 4 
1. 6-8 weeks prior to the 12 month anniversary of the first OGTT, participants will be 
contacted, inviting them to telephone the PI to make an appointment for a repeat 
OGTT. 
2. Two reminders will be sent to participants. Those that do not respond will be 
presumed to have withdrawn consent. 
3. At OGTT, a total of 20 ml of blood will also be taken from a peripheral vein via a 
canunlae (2.5 ml blood every 15 minutes, for 120 minutes in total) to check HbA1c, 
analogous markers of glycaemic control, auto- antibodies and serum lipids. 
4. The PI will obtain the results of the 12-month OGTT and contact the participants 
with the results. Those that have progressed to a diagnosis of diabetes will have their 
follow-up discussed with their general practitioners. 
5. Procedures as on Visit 1. Repeat CGM study and will be given an appointment for 
Visit 5. 
 
VISIT 5 and VISIT 6 
1. Procedures as Visit 2 and Visit 3 
 
FOLLOW UP AT OGTT at 36 MONTHS – VISIT 7 
1. 6-8 weeks prior to the 36 month anniversary of the second OGTT, participants will 
be contacted in writing, inviting them to telephone the PI to make an appointment 
for a repeat OGTT. 
2. Two reminders will be sent to participants. Those that do not respond will be 
presumed to have withdrawn consent. 
3. At OGTT, a total of 20 ml of blood will be taken from a peripheral vein via a 
canunlae (2.5 ml blood every 15 minutes for 120 minutes in total) to check HbA1c, 
analogous markers of glycaemic control, auto- antibodies and serum lipids. 
4. The PI will obtain the results of the 36-month OGTT and contact the participants 
with the result. Those that have progressed to a diagnosis of diabetes will have their 
follow-up discussed with their general practitioners. 
6. Procedures as on Visit 1. Repeat CGM study and will be given an appointment for 
Visit 8. 
 
VISIT 8 and VISIT 9 
7. Procedures as Visit 2 and Visit 3 
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PATIEMT INFORMATION LEAFLET 
Information about Research (ETHICS) 
 
STUDY TITLE:  Continuous glucose monitoring for the prediction of Type 2 
diabetes mellitus 
Version 2011/1, 7th September 2011 
We would like to invite you to take part in a research study. Before you decide you need 
to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. Talk to others about the study if 
you wish. 
 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The aim of this study is to find out whether using a device to measure the blood glucose 
levels of people continuously over several days helps identify those who will go on to 
develop Type 2 diabetes. 
 
Why have I been invited? 
You have come along today for an oral glucose tolerance test. This has been arranged 
for you by a doctor because they think you might have diabetes or you might be at risk 
of developing diabetes in the future. The results of the test today will be sent to the 
doctor who arranged it. The test may show one of three things: 
 
1. The test may be completely normal 
2. The test may show you have diabetes 
3. The test may show you do not have diabetes at present, but the blood sugar 
level is higher than a completely normal value. This is called ‘impaired fasting 
glycaemia’ or ‘impaired glucose tolerance’. 
We are interested in identifying people in the third group. Normally, the results of your 
blood tests would be kept confidential and only seen by doctors treating you. We are 
asking for your consent for our research team to look at your results and contact you 
again if they fall into this group of impaired fasting glycaemia or impaired glucose 
tolerance. 
 
We are asking everyone who has a glucose tolerance test at this hospital to help us with 
this research, except children, the very elderly, pregnant women or people who are very 
unwell for other reasons. 
 
Do I have to take part? 
It is entirely up to you to decide whether you want to take part. We will describe the 
study and go through the information sheet, which we will then give you. We will then 
ask you to sign a consent form to allow us to look at the results of the glucose tolerance 
test that you are having today. If you do not wish to sign this form or take part, we will 
not look at your results or use them for research purposes. If you do consent to us 
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looking at your results, we will contact you again if they suggest you may be suitable 
for the research study. We will then describe the study again to you and, if you wish to 
take part, we will then ask you to sign a second consent form to show you have agreed. 
You are free to withdraw at any time, without giving a reason or explaining yourself. 
This would not affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you agree to take part, the results of your glucose tolerance test today will be 
reviewed by a member of the research team. If the test is completely normal, or if it 
shows that you have diabetes, the results will be sent to the doctor who arranged your 
test, and you will hear nothing further about this research. If your glucose tolerance test 
shows you have ‘impaired glucose tolerance’ or impaired fasting glycaemia’, the results 
will be sent to the doctor who arranged your test and, in addition, you will be invited to 
participate in the next stage of the research project. You can, of course, decide not to 
take part at that stage or at any time later. 
 
Before you leave the hospital today, you will be asked to sign a Consent Form. This 
will give us permission to look at the results of your glucose tolerance test and to 
contact you again about the research project. 
 
If you do take part, you will be asked to attend the Diabetes Centre at the University 
Hospital of Wales where we will teach you how to check your own blood glucose at 
home by pricking your finger and placing a spot of blood onto a stick that fits into a 
small meter. The meter will record the result in its memory. We will ask you to check 
your blood glucose at least 4 times a day for the following 6 days. 
 
You will also be fitted with a continuous glucose monitor. This involves us placing a 
small piece of plastic (an electrode) just under the skin in your tummy. There is a sharp 
scratch, less painful than a blood test, but no other discomfort. This electrode is 
connected to a monitor, about half the size of a mobile telephone, which we will ask 
you to keep with you continuously for 3 days. We will show you how the monitor 
works as you will need to enter the results of your own blood glucose meter results at 
least 4 times a day in a written diary. You will be given a telephone number to call 
should the monitor become dislodged whilst you are at home. The monitor is designed 
to allow you to carry on with your normal work and life whilst it is connected and we 
would encourage you to just carry on with your normal activities. 
 
In addition, a total of 20 ml of blood will be taken from a peripheral vein to check 
HbA1c, analogous markers of glycaemic control, auto- antibodies and serum lipids. 
After 3 days, we will ask you to return to the Diabetes Centre so that we can replace the 
electrode. We will then want to continue using the monitor for another 3 days before 
coming back so that we can disconnect it. 
 
People with impaired glucose tolerance or impaired fasting glycaemia are at increased 
risk of developing diabetes in the future. You will be given some general advice as to 
how to reduce the risk when you come to the Diabetes Centre and this can be reinforced 
by your own General Practitioner who will be informed of your results. 
 
In order to check whether diabetes has developed, it is common practice to repeat the 
glucose tolerance test in 12 months’ time and again the year after if necessary. We will 
arrange for this to be done and following these repeat glucose tolerance tests, we will 
ask you to use the continuous glucose again for a 6 day period. In addition, a total of 20 
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ml of blood will be taken from a peripheral vein via a cannulae (2.5 ml blood every 15 
minutes) to check physiological blood markers of diabetes (HbA1c, analogous markers 
of glycaemic control, auto- antibodies and serum lipids). 
 
Each visit to the Diabetes Centre will take 2-3 hours. We are unable to compensate you 
for your loss of earnings, but we will reimburse the costs of parking at the hospital. 
 
What will I have to do? 
You will: 
Have to agree that we can look at the results of your glucose tolerance test to help us 
decide if you could take part in the monitoring study. 
 
Attend the Diabetes Centre at the University Hospital of Wales for up to 3 hours to be 
taught home blood glucose monitoring and have the continuous glucose sensor fitted. 
 
Check your blood glucose levels at home using a pin-prick device and a meter at least 4 
times a day for 6 days and enter the results into a paper diary. 
 
Wear the continuous glucose monitor at home for 6 days (returning to the Diabetes 
Centre on day 3 to have the electrode changed). 
 
Have a repeat glucose tolerance test and repeat the use of the glucose monitor in 12 
months and 24 months’ time. 
 
Have a blood test to check HbA1c, analogous markers of glycaemic control, auto- 
antibodies and serum lipids initially, 12 and 24 months later respectively. 
 
What is the device being used? 
We will use a continuous glucose monitor manufactured by Medtronic. We routinely 
use this device in people with diabetes, although it is currently not used to help predict 
people are at risk of developing diabetes in the future. 
 
What are the alternatives? 
At the moment, people who are found to have an abnormal glucose tolerance test are 
just given general lifestyle advice and have the test repeated every year in case they 
develop diabetes. If you decide not to take part in this research, you will be offered this 
standard follow-up. 
 
What are the possible disadvantages, side-effects and risks of taking part? 
The major disadvantage of taking part is the inconvenience of having to attend the 
Diabetes Centre, checking your blood glucose by a pin-prick 4 times a day, being 
attached to the glucose monitor for 6 days and having a blood test. Very rarely people 
are allergic to the plaster we use to fix the electrode to the skin. If you develop any 
itching or redness around the plaster, you will be asked to simply remove it. There is a 
small risk of infection (less than 1 chance in 1000) at the site of the glucose 
monitor. If this were to occur, it would be treated with antibiotics. 
 
What are the possible benefits to take part? 
Set against the disadvantages, it may be valuable to learn blood glucose testing since 
you will be asked to do this in the future should you develop diabetes. Some people also 
find that the blood glucose results help encourage them to avoid foods that clearly put 
their sugar levels up. 
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We cannot promise the study will help you personally, but the information we get from 
this study will help improve the treatment of people with abnormal glucose tolerance 
tests. In particular, it may be that the wearing of a continuous glucose monitor will help 
us predict which people are at the greatest risk of developing diabetes and this will 
allow us to use intensive lifestyle changes or drugs to reduce the risk. 
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CONSENT FORM 
 
Title of Project: Continuous glucose monitoring for the prediction of Type 2 
diabetes mellitus 
Name of Researcher: Dr John Alcolado 
 
Stage 1 [Consent to look at your results for research purposes and contact you 
again] 
1) I confirm that I have read and understand the information sheet dated 10 June 2009 
(version 2009/2) and 7 September 2011 (Version 2011/1) for the above study. I have 
had the opportunity to consider the information, ask questions and have these answered 
satisfactorily. 
                                                                                                Please initial box 
 
2) I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected. 
                                                                                                Please initial box 
 
3) I understand that the relevant sections of my medical notes and data included during the 
study, including the results of my oral glucose intolerance tests may be looked at by 
individuals involved in this research, from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
                                                                                                      Please initial box 
 
4) I agree to my GP being informed of my participation in the study.  
                                                                                                      Please initial box 
 
5) I agree to have the result of my glucose tolerance test looked at for research. If my 
results are abnormal, I agree to the researchers contacting me about my recruitment into 
the study of continuous glucose monitoring.  I understand that I am free to decide not to 
take part in the study at that stage or at any point in the future. 
                                                                                                       Please initial box 
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_______________ _________ ___________________ 
Name of patient  Date  Signature 
 
_______________ _________ ___________________ 
Name of person  Date  Signature 
obtaining consent 
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GP INFORMATION LETTER (10TH June 2009, Version 2009/1) 
 
<GP NAME> 
 
<GP ADDRESS> 
 
<DATE> 
 
Dear Dr <GP NAME> 
<PATIENT NAME, PATIENT DOB, PATIENT ADDRESS> 
 
Study Title: Continuous glucose monitoring for the prediction of Type 2 diabetes 
mellitus 
I am writing to inform you that the patient named above has consented to take part in a 
study on continuous glucose monitoring for the prediction of Type 2 diabetes mellitus. 
Your patient has recently had a glucose tolerance test performed at this hospital and was 
found to have either impaired glucose tolerance or impaired fasting glycaemia. You 
should have already received the results of this test from the laboratory, but a copy is 
enclosed for your information. The aim of the study is to see whether the results of 
continuous glucose monitoring will help predict which patients go on to develop Type 2 
diabetes mellitus. As part of this study, your patient has been taught home blood 
glucose monitoring and will wear a continuous glucose monitor for a period of 6 days. 
We will arrange a follow-up glucose tolerance testing in 12 and 24 months’ time. The 
study does not require the patient to take any trial medication.  A copy of the Patient 
Information Leaflet is enclosed for your information. 
 
If you require any further information, please do not hesitate to contact me. 
Yours sincerely, 
 
John Alcolado 
Clinical Reader in Medicine 
Consultant Physician 
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APPENDIX 2 – CGM PROFILES: LEAST VARIABILITY 
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APPENDIX 3 – CGM PROFILES: MEDIUM VARIABILITY 
  
221 
 
222 
 
223 
 
224 
 
225 
 
226 
 
227 
 
228 
 
229 
 
230 
 
231 
 
232 
 
233 
 
234 
 
235 
 
236 
 
237 
 
238 
 
239 
 
240 
 
241 
 
242 
 
243 
 
244 
 
245 
 
246 
 
247 
 
248 
 
249 
 
250 
 
251 
 
252 
 
253 
 
254 
 
255 
 
256 
 
257 
 
258 
 
259 
 
 
260 
 
APPENDIX 4 – CGM PROFILES: MOST VARIABILITY 
261 
 
262 
 
263 
 
264 
 
265 
 
266 
 
267 
 
268 
 
269 
 
270 
 
271 
 
272 
 
273 
 
274 
 
275 
 
276 
 
277 
 
278 
 
279 
 
280 
 
281 
 
282 
 
283 
 
284 
 
285 
 
286 
 
287 
 
 
 
 
